Binding molecules specific for cd73 and uses thereof

ABSTRACT

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

This application is a Continuation of U.S. Application No. 16/678,165,which is a Divisional of U.S. Application No. 16/375,051, filed Apr. 4,2019, now Pat. No. 10,556,968 issued Feb. 11, 2020, which is aDivisional of U.S. Application No. 15/903,649, filed Feb. 23, 2018, nowPat. No. 10,287,362 issued May 14, 2019, which is a Divisional of U.S.Application No. 14/936,233, filed Nov. 9, 2015, now Pat. No. 9,938,356issued Apr. 10, 2018, which claims benefit under 35 U.S.C. §119(e) ofU.S. Provisional Application No. 62/077,486, filed Nov. 10, 2014, U.S.Provisional Application No. 62/147,329, filed Apr. 14, 2015, and U.S.Provisional Application No. 62/188,999, filed Jul. 6, 2015. Each of theabove listed applications is incorporated by reference herein in itsentirety for all purposes.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically and is hereby incorporated by reference in itsentirety. Said Sequence Listing was created on Nov. 10, 2022, is namedCD73-100-US-CNT Sequence Listing ST_26.xml and is 265.4 KB in size.

BACKGROUND OF THE INVENTION

CD73 or ecto-5′-nucleotidase (5′-NT) is ubiquitously expressed in anumber of tissues. This protein is anchored to the cell membrane througha glycosylphosphatidylinositol (GPI) linkage, has ecto-enzyme activity,and plays a role in signal transduction. The primary function of CD73 isthe conversion of extracellular nucleotides (e.g., 5′-AMP), to whichcells are generally impermeable, to their corresponding nucleosides(e.g., adenosine), which can readily enter most cells. CD73 productionof adenosine by the dephosphorylation of AMP, has been shown to regulateadenosine receptor engagement in many tissues, indicating that adenosinefunctions in cytoprotection, cell growth, angiogenesis andimmunosuppression, and also plays a role in tumorigenesis.

CD73 expression on tumor cells has been reported in several types ofcancer, including colorectal cancer, pancreatic cancer, bladder cancer,leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer,thyroid cancer, esophageal cancer, prostate cancer, and breast cancer.Elevated CD73 expression has also been associated with tumorinvasiveness, metastasis, and reduced patient survival time. CD73generates an immunosuppressed environment, characterized by increasedadenosine levels, which promote the development and progression ofcancer. Notably, CD73 expression has been associated with aprometastatic phenotype in melanoma and breast cancer.

Immune-checkpoint inhibitors hold great potential as cancertherapeutics. Nevertheless, clinical benefits from immune-checkpointinhibition have been modest. One potential explanation is that tumorsuse nonoverlapping immunosuppressive mechanisms to facilitate immuneescape. Accordingly, improved compositions and methods for reducingtumor-mediated immunosuppression are urgently required.

SUMMARY OF THE INVENTION

The present invention provides isolated binding molecules orantigen-binding fragments thereof which specifically bind to CD73. Insome aspects, such CD73-binding molecules are, e.g., antibodies orantigen-binding fragments thereof. In particular embodiments, anti-CD73antibodies of the invention (e.g., MEDI9447) are useful for reducingtumor-mediated immunosuppression. Accordingly, the present inventionalso provides therapeutic combinations featuring anti-CD73 antibodies(e.g., MEDI9447) and other agents targeting additional aspects of thecancer immunity cycle (i.e. anti-PD-1 or anti-PD-L1 antibodies;anti-CTLA4 antibodies, A2aR antagonists, STAT-3 inhibitors) and methodsof using such combinations is useful for reducing tumor-mediatedimmunosuppression.

In one aspect, the invention provides an isolated binding molecule orantigen-binding fragment thereof which specifically binds to a CD73epitope, where the binding molecule specifically binds to the same CD73epitope as an antibody or antigen-binding fragment thereof having theheavy chain variable region (V_(H)) and light chain variable region(V_(L)) of an antibody selected from CD730002, CD730003, CD730004,CD730008, CD730010, CD730011, CD730021, CD730042, CD730046, CD730047, orCD730058.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73,and competitively inhibits CD73 binding by an antibody orantigen-binding fragment thereof comprising the V_(H) and V_(L) ofCD730002, CD730003, CD730004, CD730008, CD730010, CD730011, CD730021,CD730042, CD730046, CD730047, or CD730058.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73comprising an antibody V_(L), where the V_(L) has the amino acidsequence:

[FW₁]SGSLSNIGRNX₁VN[FW₂] LX₂NX₃RX₄X₅[FW₃] ATWDDSX₆X₇GWX₈[FW₄] (SEQ    ID NO: 146)     

-   where [FW₁], [FW₂], [FW₃] and [FW₄] represent V_(L) framework    regions, and where X₁ represents amino acid residues Proline (P),    Glutamic Acid (E) or Aspartic Acid (D); X₂ represents amino acid    residues Asparagine (N) or Aspartic Acid (D);-   X₃ represents amino acid residues Glutamine (Q) or Leucine (L);-   X₄ represents amino acid residues Leucine (L) or Proline (P);-   X₅ represents amino acid residues Glycine (G) or Serine (S);-   X₆ represents amino acid residues Leucine (L) or Histidine (H);-   X₇ represents amino acid residues Lysine (K), Proline (P),    Isoleucine (I) or Asparagine (N); and,-   X₈ represents amino acid residues Leucine (L) or Threonine (T).

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen binding fragment thereof according to claim6, where FW₁ comprises SEQ ID NO: 25 or 26, FW₂ comprises SEQ ID NO: 27or 28, FW₃ comprises SEQ ID NO: 29, and FW₄ comprises SEQ ID NO: 30.

In another aspect, the invention provides an isolated binding moleculeor antigen binding fragment thereof which specifically binds to CD73comprising an antibody VH, where the V_(H) has the amino acid sequence:

[FW₅]SYAX₉S [FW₆]X₁₀IX₁₁GSX₁₂GX₁₃TYYADSVKG [FW₇]LG YX₁₄X₁_(S)X₁₆DX₁₇ [FW₈]    (SEQ ID NO: 147)    

-   where [FW₅], [FW₆], [FW₇] and [FW₈] represent VH framework regions,    and where X₉ represents amino acid residues Methionine (M) or    Tyrosine (Y);-   X₁₀ represents amino acid residues Leucine (L) or Alanine (A);-   X₁₁ represents amino acid residues Tryptophan (W) or Serine (S);-   X₁₂ represents amino acid residues Tryptophan (W) or Glycine (G);-   X₁₃ represents amino acid residues Serine (S) or Arginine (R);-   X₁₄ represents amino acid residues Glycine (G) or Serine (S);-   X₁₅ represents amino acid residues Arginine (R) or Threonine (T);-   X₁₆ represents amino acid residues Valine (V) or Isoleucine (I);    and,-   X₁₇ represents amino acid residues Tyrosine (Y), Lysine (K),    Methionine (M), Leucine (L) or Glutamic acid (E).

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73comprising an antibody V_(L) and an antibody V_(H), where the V_(L)comprises the amino acid sequence:

[FW₁]SGSLSNIGRNX₁VN[FW₂]LX₂NX₃RX₄X₅[FW₃]ATWDDSX₆X₇GWX₈[FW₄] (SEQ    ID NO: 146)     

-   where [FW₁], [FW₂], [FW₃] and [FW₄] represent V_(L) framework    regions, and where X₁ represents amino acid residues Proline (P),    Glutamic Acid (E) or Aspartic Acid (D);-   X₂ represents amino acid residues Asparagine (N) or Aspartic Acid    (D);-   X₃ represents amino acid residues Glutamine (Q) or Leucine (L);-   X₄ represents amino acid residues Leucine (L) or Proline (P);-   X₅ represents amino acid residues Glycine (G) or Serine (S);-   X₆ represents amino acid residues Leucine (L) or Histidine (H);-   X₇ represents amino acid residues Lysine (K), Proline (P),    Isoleucine (I) or Asparagine (N); and,-   X₈ represents amino acid residues Leucine (L) or Threonine (T);-   and where the V_(H) comprises the amino acid sequence:

    [FW₅]SYAX₉S [FW₆]X₁₀IX₁₁GSX₁₂GX₁₃TYYADSVKG [FW₇]LGYX₁₄X₁_(S)X₁₆DX₁₇ [FW₈]     (SEQ ID NO: 147)

-   where [FW₅], [FW₆], [FW₇] and [FW₈] represent VH framework regions,    and where X₉ represents amino acid residues Methionine (M) or    Tyrosine (Y);-   X₁₀ represents amino acid residues Leucine (L) or Alanine (A);-   X₁₁ represents amino acid residues Tryptophan (W) or Serine (S);-   X₁₂ represents amino acid residues Tryptophan (W) or Glycine (G);-   X₁₃ represents amino acid residues Serine (S) or Arginine (R);-   X₁₄ represents amino acid residues Glycine (G) or Serine (S);-   X₁₅ represents amino acid residues Arginine (R) or Threonine (T);-   X₁₆ represents amino acid residues Valine (V) or Isoleucine (I);    and,-   X₁₇ represents amino acid residues Tyrosine (Y), Lysine (K),    Methionine (M), Leucine (L) or Glutamic acid (E).

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(L), where the V_(L) has a V_(L) complementaritydetermining region-2 (VL-CDR2) amino acid sequence identical to, oridentical except for four, three, two or one amino acid substitutions toSEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51 or SEQ ID NO: 52.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(L), where the V_(L) has a complementaritydetermining region-3 (VL-CDR3) amino acid sequence identical to, oridentical except for four, three, two, or one amino acid substitutionsto: SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(H), where the V_(H) has a complementaritydetermining region-1 (VH-CDR1) amino acid sequence identical to, oridentical except for four, three, two, or one amino acid substitutionsto SEQ ID NO: 35 or SEQ ID NO: 36.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(H), where the V_(H) has a complementaritydetermining region-2 (VH-CDR2) amino acid sequence identical to, oridentical except for four, three, two, or one amino acid substitutionsto: SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(H), where the V_(H) has a complementaritydetermining region-3 (VH-CDR3) amino acid sequence identical to, oridentical except for four, three, two, or one amino acid substitutionsto SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, or SEQ IDNO: 45.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(L), where the V_(L) has VL-CDR1, VL-CDR2, andVL-CDR3 amino acid sequences identical to, or identical except for four,three, two, or one amino acid substitutions in one or more of theVL-CDRs to: SEQ ID NOs: 46, 49 and 53; SEQ ID NOs: 47, 49, and 53; SEQID NOs: 47, 49, and 54; SEQ ID NOs: 46, 50, and 54; SEQ ID NOs: 46, 51,and 55; SEQ ID NOs: 48, 52, and 54; SEQ ID NOs: 46, 49, and 56; SEQ IDNOs: 47, 49, and 56; SEQ ID NOs: 46, 50, and 56; SEQ ID NOs: 46, 51, and56; or SEQ ID NOs: 48, 52, and 56, respectively.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(H), where the V_(H) has VH-CDR1, VH-CDR2, andVH-CDR3 amino acid sequences identical to, or identical except for four,three, two, or one amino acid substitutions in one or more of theVH-CDRs to: SEQ ID NOs: 35, 37 and 41; SEQ ID NOs: 36, 37, and 42; SEQID NOs: 36, 38, and 43; SEQ ID NOs: 36, 39, and 44; SEQ ID NOs: 36, 40,and 44; SEQ ID NOs: 35, 37, and 45; SEQ ID NOs: 36, 37, and 45; SEQ IDNOs: 36, 38, and 45; SEQ ID NOs: 36, 39, and 45; or SEQ ID NOs: 36, 40,and 45 respectively.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof which specifically binds to CD73 havinga V_(L) and a V_(H) having VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2,and VH-CDR3 amino acid sequences identical or identical except for four,three, two, or one amino acid substitutions in one or more CDRs to: SEQID NOs: 46, 49, 53, 35, 37, and 41; SEQ ID NOs: 47, 49, 53, 35, 37, and41; SEQ ID NOs: 47, 49, 54, 36, 37, and 42; SEQ ID NOs: 46, 50, 54, 36,38, and 43; SEQ ID NOs: 46, 51, 55, 36, 39, and 44; SEQ ID NOs: 48, 52,54, 36, 40, and 44; SEQ ID NOs: 46, 49, 56, 35, 37, and 41; SEQ ID NOs:46, 49, 53, 35, 37, and 45; SEQ ID NOs: 47, 49, 56, 36, 37, and 45; SEQID NOs: 46, 50, 56, 36, 38, and 45; SEQ ID NOs: 46, 51, 56, 36, 39, and45; SEQ ID NOs: 48, 52, 56, 36, 40, and 45; or SEQ ID NOs: 46, 49, 56,35, 37, and 45.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(L) and an antibody V_(H), where the V_(L) has anamino acid sequence at least about 90% to about 100% identical to areference amino acid sequence selected from SEQ ID NO: 57, SEQ ID NO:58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ IDNO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody V_(L) and an antibody V_(H), where the V_(H) has anamino acid sequence at least about 90% to about 100% identical to areference amino acid sequence selected from SEQ ID NO: 71, SEQ ID NO:72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ IDNO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof which specifically binds to CD73, wherethe antibody or antigen binding fragment has a V_(L) having a sequenceat least about 90% to about 100% identical to a reference amino acidsequence selected from SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64,SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO:69, and SEQ ID NO: 70, and where the antibody or antigen bindingfragment has a V_(H) having a sequence at least about 90% to about 100%identical to a reference amino acid sequence selected from SEQ ID NO:71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ IDNO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof, which has a V_(L) consistingessentially of SEQ ID NO: 57 and a V_(H) consisting essentially of SEQID NO: 71.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof, which has a V_(L) consistingessentially of SEQ ID NO: 68 and a V_(H) consisting essentially of SEQID NO: 82.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof, which has a V_(L) consisting of SEQ IDNO: 57 and a V_(H) consisting of SEQ ID NO: 71.

In another aspect, the invention provides an isolated antibody orantigen-binding fragment thereof, which has a V_(L) consisting of SEQ IDNO: 68 and a V_(H) consisting of SEQ ID NO: 82.

In another aspect, the invention provides a composition containing anisolated antibody or antigen-binding fragment thereof in accordance withthe invention, and a carrier.

In another aspect, the invention provides a nucleic acid having asequence encoding the isolated antibody or antigen-binding fragmentthereof in accordance with the invention.

In another aspect, the invention provides a composition including anucleic acid in accordance with the invention.

In another aspect, the invention provides a vector containing a nucleicacid in accordance with the invention.

In another aspect, the invention provides a host cell comprising anucleic acid sequence, composition, or the vector in accordance with theinvention.

In another aspect, the invention provides a method of making an antibodyor antigen-binding fragment thereof in accordance with the invention,involving culturing a cell containing a nucleic acid sequence,composition, or vector in accordance with the invention; and isolatingthe antibody or antigen-binding fragment thereof.

In another aspect, the invention provides a diagnostic reagentcontaining an isolated antibody or antigen binding fragment inaccordance with the invention that is labeled.

In another aspect, the invention provides a kit containing an isolatedantibody or antigen-binding fragment thereof, composition, or thediagnostic reagent in accordance with the invention.

In another aspect, the invention provides a method of inhibiting thegrowth of a cell expressing CD73 involving contacting the cell with anantibody or antigen-binding fragment thereof in accordance with theinvention.

In another aspect, the invention provides a method of treating cancer ina subject in need thereof, involving administering to the subject atherapeutically effective amount of an antibody or antigen-bindingfragment thereof in accordance with the invention.

In another aspect, the invention provides a method of treating cancer ina subject involving administering to the subject a therapeuticallyeffective amount of a first agent, which is an antibody orantigen-binding fragment in accordance with the invention, incombination with a therapeutically effective amount of a second agent,which is an anti-cancer agent other than the first agent.

In another aspect, the invention provides a method of treatmentinvolving administering an anti-CD73 antibody, or an antigen bindingfragment thereof, to a subject identified as having a tumor that hasincreased expression of CD73 relative to a reference.

In another aspect, the invention provides a method of treatmentinvolving administering an anti-CD73 antibody, or an antigen bindingfragment thereof, and an anti-PD-1, anti-PD-L1, or anti-CTLA4, or anantigen binding fragment thereof, to a subject identified as having atumor that has increased expression of CD73 compared to a reference.

In another aspect, the invention provides a method of treatmentinvolving administering MEDI9447 or Phen0203 hIgG1, or an antigenbinding fragment thereof, and pembrolizumab (Keytruda®) or nivolumab(Opdiva®), or an antigen binding fragment thereof, to a subjectidentified as having a tumor that has increased expression of CD73compared to a reference.

In another aspect, the invention provides a method of treatmentinvolving administering MEDI9447 or Phen0203 hIgG1, or an antigenbinding fragment thereof, and MEDI4736, or an antigen binding fragmentthereof, to a subject identified as having a tumor that has increasedexpression of CD73 compared to a reference.

In another aspect, the invention provides a method of treatmentinvolving administering MEDI9447 or Phen0203 hIgG1, or an antigenbinding fragment thereof, and tremelimumab, or an antigen bindingfragment thereof, to a subject identified as having a tumor that hasincreased expression of CD73 compared to a reference.

In another aspect, the invention provides a method of identifying asubject having a cancer responsive to anti-CD73 therapy, the methodinvolving detecting an increased level of CD73 expression or activity ina tumor cell or blood cell of the subject, relative to a reference,thereby identifying said cancer as responsive to anti-CD73 therapy.

In another aspect, the invention provides a method of identifying asubject having a cancer responsive to anti-CD73 therapy in combinationwith one or more of an anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy, themethod involving detecting an increased level of CD73 expression oractivity in a tumor cell or blood cell of the subject, relative to areference, thereby identifying said cancer as responsive to anti-CD73therapy in combination with one or more of an anti-PD-1, anti-PD-L1, oranti-CTLA4 therapy.

In another aspect, the invention provides a method of identifying asubject having a cancer responsive to anti-PD-1, anti-PD-L1, oranti-CTLA4 therapy, the method involving detecting a decreased level ofCD73 expression or activity in a tumor cell or blood cell of thesubject, relative to a reference, thereby identifying said cancer asresponsive to anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy.

In another aspect, the invention provides a method of inhibiting tumorgrowth in a subject, the method involving administering to a subject inneed thereof an anti-CD73 antibody, or an antigen binding fragmentthereof, and one or more of an anti-PD-1 antibody, anti-PD-L1 antibody,anti-CTLA4 antibody, or antigen binding fragment thereof.

In another aspect, the invention provides a method of increasing ananti-tumor immune response in a subject, the method involvingadministering to a subject in need thereof an anti-CD73 antibody, or anantigen binding fragment thereof, and one or more of an anti-PD-1antibody, anti-PD-L1 antibody, anti-CTLA4 antibody, or antigen bindingfragment thereof to the subject.

In another aspect, the invention provides a method of treating a tumorin a subject, the method involving administering to a subject in needthereof an anti-CD73 antibody, or an antigen binding fragment thereof,and one or more of an anti-PD-1 antibody, anti-PD-L1 antibody,anti-CTLA4 antibody, or antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of an anti-CD73 antibody, or antigenbinding fragment thereof and an anti-PD-1 antibody, or an antigenbinding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of MEDI9447, or antigen binding fragmentthereof and pembrolizumab (Keytruda®), or an antigen binding fragmentthereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of MEDI9447, or antigen binding fragmentthereof and nivolumab (Opdiva®), or an antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of Phen0203 hIgG1, or antigen bindingfragment thereof and pembrolizumab (Keytruda®), or an antigen bindingfragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of Phen0203 hIgG1, or antigen bindingfragment thereof nivolumab (Opdiva®), or an antigen binding fragmentthereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of an anti-CD73 antibody, or antigenbinding fragment thereof and an anti-PD-L1 antibody, or an antigenbinding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of MEDI9447, or antigen binding fragmentthereof and MEDI4736, or an antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of Phen0203 hIgG1, or antigen bindingfragment thereof and MEDI4736, or an antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of an anti-CD73 antibody, or antigenbinding fragment thereof and an anti-CTLA4 antibody, or an antigenbinding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of MEDI9447, or antigen binding fragmentthereof and tremelimumab, or an antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of MEDI9447, or antigen binding fragmentthereof and ipilimumab, or an antigen binding fragment thereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of Phen0203 hIgG1, or antigen bindingfragment thereof and tremelimumab, or an antigen binding fragmentthereof.

In another aspect, the invention provides a pharmaceutical formulationcontaining an effective amount of Phen0203 hIgG1, or antigen bindingfragment thereof and ipilimumab, or an antigen binding fragment thereof.

In another aspect, the invention provides a kit for increasinganti-tumor activity, the kit comprising an anti-CD73 antibody or antigenbinding fragment thereof and an anti-PD-1 antibody, or an antigenbinding fragment thereof.

In another aspect, the invention provides a kit for increasinganti-tumor activity, the kit comprising an anti-CD73 antibody or antigenbinding fragment thereof and an anti-PD-L1 antibody, or an antigenbinding fragment thereof.

In another aspect, the invention provides a kit for increasinganti-tumor activity, the kit comprising an anti-CD73 antibody or antigenbinding fragment thereof and an anti-CTLA4 antibody, or an antigenbinding fragment thereof.

In various embodiments of any aspect delineated herein, the VL and VH ofCD730002 is or includes SEQ ID NOs: 1 and 2, respectively, and the VLand VH of CD730010 are or include SEQ ID NOs: 3 and 4, respectively.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding fragment thereof includes anantibody or antigen-binding fragment thereof.

In various embodiments of any aspect delineated herein, the bindingmolecule is affinity matured.

In various embodiments of any aspect delineated herein, FW5 is orincludes SEQ ID NO: 31, FW6 is or includes SEQ ID NO: 32, FW7 is orincludes SEQ ID NO: 33 and FW8 is or includes SEQ ID NO: 34.

In various embodiments of any aspect delineated herein, FW1 is orincludes SEQ ID NO: 25 or 26, FW2 is or includes SEQ ID NO: 27 or 28,FW3 is or includes SEQ ID NO: 29, FW4 is or includes SEQ ID NO: 30, FW5is or includes SEQ ID NO: 31, FW6 is or includes SEQ ID NO: 32, FW7 isor includes SEQ ID NO: 33 and FW8 is or includes SEQ ID NO: 34.

In various embodiments of any aspect delineated herein, the VL includesa VL complementarity determining region-1 (VL-CDR1) amino acid sequenceidentical to, or identical except for four, three, two or one amino acidsubstitutions to: SEQ ID NO: 46, SEQ ID NO: 47, or SEQ ID NO: 48.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof has a VL having SEQ ID NO:57 and a VH having SEQ ID NO: 71.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof has a VL having SEQ ID NO:68 and a VH having SEQ ID NO: 82.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof includes a heavy chainconstant region or fragment thereof.

In various embodiments, the heavy chain constant region or fragmentthereof is an IgG constant region, including for example an IgG1constant region, an IgG2 constant region, an IgG3 constant region or anIgG4 constant region.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof includes a light chainconstant region selected from a human kappa constant region and a humanlambda constant region.

In various embodiments of any aspect delineated herein, the IgG constantregion has one or more amino acid substitutions relative to a wild-typeIgG constant region where the modified IgG has an increased half-lifecompared to the half-life of an IgG having the wild-type IgG constantregion.

In various embodiments of any aspect delineated herein, the IgG constantregion has one or more amino acid substitutions of amino acid residuesat positions 251-257, 285-290, 308-314, 385-389, and 428-436, where thenumbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, at least one IgGconstant region amino acid substitution is selected from:

-   (a) substitution of the amino acid at position 252 with Tyrosine    (Y), Phenylalanine (F), Tryptophan (W), or Threonine (T);-   (b) substitution of the amino acid at position 254 with Threonine    (T);-   (c) substitution of the amino acid at position 256 with Serine (S),    Arginine (R), Glutamine (Q), Glutamic acid (E), Aspartic acid (D),    or Threonine (T);-   (d) substitution of the amino acid at position 257 with Leucine (L);-   (e) substitution of the amino acid at position 309 with Proline (P);-   (f) substitution of the amino acid at position 311 with Serine (S);-   (g) substitution of the amino acid at position 428 with Threonine    (T), Leucine (L), Phenylalanine (F), or Serine (S);-   (h) substitution of the amino acid at position 433 with Arginine    (R), Serine (S), Isoleucine (I), Proline (P), or Glutamine (Q);-   (i) substitution of the amino acid at position 434 with Tryptophan    (W), Methionine (M), Serine (S), Histidine (H), Phenylalanine (F),    or Tyrosine; and,-   (j) a combination of two or more of said substitutions,

where the numbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, the human IgGconstant region has amino acid substitutions relative to a wild-typehuman IgG constant region at positions 252, 254, and 256, where

-   (a) the amino acid at position 252 is substituted with Tyrosine (Y),-   (b) the amino acid at position 254 is substituted with Threonine    (T), and-   (c) the amino acid at position 256 is substituted with Glutamic acid    (E),

where the numbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, the amino acidat position 434 is substituted with an amino acid selected fromTryptophan (W), Methionine (M), Tyrosine (Y), and Serine (S), and wherethe numbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, the amino acidat position 428 is substituted with an amino acid selected fromThreonine (T), Leucine (L), Phenylalanine (F), and Serine (S), and wherethe numbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, the amino acidat position 257 is substituted with Leucine (L), and the amino acid atKabat position 434 is substituted with Tyrosine (Y), and where thenumbering is according to the EU index as set forth in Kabat.

In various embodiments of any aspect delineated herein, the amino acidat Kabat position 428 is substituted with Leucine (L), and the aminoacid at Kabat position 434 is substituted with Serine (S).

In various embodiments of any aspect delineated herein, the human IgGconstant region, has amino acid substitutions relative to a wild-typehuman IgG constant region at positions 252, 254, and 256, where thenumbering is according to the EU index as set forth in Kabat, and where

-   (a) the amino acid at position 252 is substituted with Tyrosine (Y),-   (b) the amino acid at position 254 is substituted with Threonine    (T), and-   (c) the amino acid at position 256 is substituted with Glutamic acid    (E).

In various embodiments of any aspect delineated herein, the antibody isa fully human antibody, a humanized antibody, a chimeric antibody, amonoclonal antibody, a polyclonal antibody, a recombinant antibody, amultispecific antibody, or an antigen-binding fragment thereof.

In various embodiments of any aspect delineated herein, theantigen-binding fragment is Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, orsc(Fv)2.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof is conjugated to at leastone heterologous agent, including for example an anticancer agent.

In various embodiments of any aspect delineated herein, a composition inaccordance with the invention, further contains an anticancer agent.

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof does not induce antibodydependent cell mediated cytotoxicity (ADCC).

In various embodiments of any aspect delineated herein, the isolatedantibody or antigen-binding fragment thereof is an antagonist of CD73.

In various embodiments, the isolated antibody or antigen-bindingfragment thereof is an antagonist of CD73 in cells selected fromMB-MDA-231, 4T1, MK1, or a combination of two or more of the recitedcells.

In various embodiments of any aspect delineated herein, the CD73 ishuman CD73.

In various embodiments of any aspect delineated herein, binding of theantibody or antigen binding fragment to CD73 can reduce cellproliferation.

In various embodiments of any aspect delineated herein, the antibody orantigen binding fragment to CD73 can bind to human CD73, cynomolgusmonkey CD73, and mouse CD73.

In various embodiments of any aspect delineated herein, the cancer isselected from colorectal cancer, pancreatic cancer, bladder cancer,leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer,thyroid cancer, esophageal cancer, prostate cancer, and breast cancer.

In various embodiments of any aspect delineated herein, the cancer has aprometastatic phenotype, including melanoma or breast cancer

In various embodiments of any aspect delineated herein, the subject ishuman.

In various embodiments of any aspect delineated herein, the combinationof the first agent and the second agent has superior antitumor activity;may be additive or synergistic.

In various embodiments of any aspect delineated herein, the second agentis an antibody or antigen binding fragment thereof.

In various embodiments, the second agent specifically binds to PD-1(programmed death 1 protein), PD-L1 (programmed death 1 protein ligand1), PD-L2 (programmed death 1 protein ligand 2), or CTLA-4 (cytotoxic Tlymphocyte antigen 4 protein).

In various embodiments of any aspect delineated herein, the second agentis an anti-CTLA-4 antibody or antigen-binding fragment thereof,including for example ipilimumab, tremelimumab (ticilimumab,CP-675,206), or antigen-binding fragments thereof.

In various embodiments of any aspect delineated herein, the second agentis an anti-PD-1 antibody or antigen-binding fragment thereof, includingfor example pembrolizumab (Keytruda®, lambrolizumab, MK-3475), nivolumab(Opdiva®, BMS-936558, MDX-1106, ONO-4538), AMP-224, or antigen-bindingfragments thereof.

In various embodiments of any aspect delineated herein, the second agentis an anti-PD-L1 antibody or antigen-binding fragment thereof, includingfor example MEDI4736, BMS-936559, MPDL3280A, or antigen-bindingfragments thereof.

In various embodiments of any aspect delineated herein, the anti-CD73antibody is MEDI9447, Phen0203 hIgG1, or antigen binding fragmentsthereof.

In various embodiments of any aspect delineated herein, the subject isundergoing, has undergone, or will undergo an anti-PD-1, anti-PD-L1, oranti-CTLA4 therapy.

In various embodiments of any aspect delineated herein, the anti-PD-1,anti-PD-L1, or anti-CTLA4 therapy involves administering an anti-PD-1,anti-PD-L1, or anti-CTLA4 antibody or antigen binding fragment thereof,respectively.

In various embodiments, the anti-PD-1 antibody is pembrolizumab(Keytruda®, lambrolizumab, MK-3475), nivolumab (Opdiva®, BMS-936558,MDX-1106, ONO-4538), AMP-224, or antigen binding fragments thereof.

In various embodiments, the anti-PD-L1 antibody is MEDI4736, BMS-936559,MPDL3280A, or antigen binding fragments thereof.

In various embodiments, the anti-CTLA-4 antibody is ipilimumab,tremelimumab (ticilimumab, CP-675,206), or antigen binding fragmentsthereof.

In various embodiments of any aspect delineated herein, the tumor is acolon cancer, melanoma, breast cancer, lymphoma, non-small cell lungcarcinoma Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’slymphoma, ovarian cancer, breast cancer, head and neck cancers, orpancreatic cancer.

In various embodiments of any aspect delineated herein, CD73 expressionor activity is detected in a tumor sample, blood sample, or lymphsample.

In various embodiments of any aspect delineated herein, CD73 expressionis detected in a tumor cell or peripheral blood cell, including lymphoidor myeloid cell subsets (i.e. one or more of a B lymphocyte, CD4+,FoxP3+ lymphocyte, or myeloid-derived suppressor cell (MDSC)).

In various embodiments of any aspect delineated herein, CD73 expressionis detected by flow cytometry, immunohistochemistry (IHC) or CD73 enzymeactivity or soluble CD73 levels in samples.

In various embodiments of any aspect delineated herein, the anti-CD73antibody or antigen binding fragment thereof and the anti-PD-1,anti-PD-L1, or anti-CTLA4 antibody, or antigen binding fragment thereofare administered concurrently.

In various embodiments of any aspect delineated herein, the methodinduces or increases a tumor-specific immune response.

In various embodiments of any aspect delineated herein, the methodreduces the immunosuppressive effects of an AMP/CD73/adenosine pathway.

In various embodiments of any aspect delineated herein, the tumor is aCD73 overexpressing tumor.

In another aspect, the invention provides an isolated binding moleculeor antigen-binding fragment thereof which specifically binds to CD73having an antibody VL and an antibody VH, which specifically binds to anepitope of a CD73 protein having one or more amino acids correspondingto Val144, Lys180, and Asn185.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding further contains one or more aminoacids corresponding to Tyr135, Lys136, and Asn187.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding fragment thereof, contains the aminoacids corresponding to Tyr135, Lys136, and Asn187.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding fragment thereof, contains the aminoacids corresponding to Tyr135, Lys136, Asn187, Tyr135, Lys136, andAsn187.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding fragment thereof, binds an epitopewithin one or more of the following regions of a CD73 protein:Tyr132-Val144 and/or Lys180-Asn187.

In various embodiments of any aspect delineated herein, the isolatedbinding molecule or antigen-binding fragment thereof, contains or iswithin the amino acid sequences at Tyr132-Val144 and/or Lys180-Asn187.

In another aspect, the invention provides a conformational epitope onthe surface of a CD73 protein, having one or more amino acidscorresponding to Val144, Lys180, and Asn185, where a CD73 proteincontaining the epitope can be specifically bound by monoclonal antibodyMEDI9447 or an antigen-binding fragment, variant, analog or derivativethereof.

In various embodiments of any aspect delineated herein,theconformational epitope further contains one or more amino acidscorresponding to Tyr135, Lys136, and Asn18.

In various embodiments of any aspect delineated herein, theconformational epitope of contains the amino acids corresponding toTyr135, Lys136, and Asn187.

In various embodiments of any aspect delineated herein, theconformational epitope contains the amino acids corresponding to Tyr135,Lys136, Asn187, Tyr135, Lys136, and Asn187.

In various embodiments of any aspect delineated herein, theconformational epitope is within one or more of the following regions ofa CD73 protein: Tyr132-Val144 and/or Lys180-Asn187.

In various embodiments of any aspect delineated herein, theconformational epitope contains or is within the amino acid sequences atTyr132-Val144 and/or Lys180-Asn187.

In various embodiments of any aspect delineated herein, MEDI9447 bindsthe CD73 protein in an inactive or catalytically active state or open orclosed state.

In various embodiments of any aspect delineated herein, the CD73 proteinis human CD73.

In various embodiments of any aspect delineated herein, isolated bindingmolecule or antigen-binding fragment thereof, wherein the VL and VH arethe VL and VH of MED19447.

Compositions and articles defined by the invention were isolated orotherwise manufactured in connection with the examples provided below.Other features and advantages of the invention will be apparent from thedetailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

FIG. 1A shows the nucleotide sequence (SEQ ID NO: 22) and amino acidtranslation (SEQ ID NO: 21) of MEDI9447 VH domain with CDRs shown basedon Kabat numbering convention.

FIG. 1B shows the nucleotide sequence (SEQ ID NO: 24) and amino acidtranslation (SEQ ID NO: 23) of MEDI9447 VL domain with CDRs shown basedon Kabat numbering convention.

FIG. 1C shows an alignment of MEDI9447 VH (SEQ ID NO: 21) with closesthuman VH and JH germline sequences (SEQ ID NO: 165). CDRs based on Kabatnumbering convention are highlighted and residues different fromgermline sequences are boxed.

FIG. 1D shows an alignment of MEDI9447 VL (SEQ ID NO: 23) with closesthuman VL and JL germline sequences (SEQ ID NO: 166). CDRs based on Kabatnumbering convention are highlighted and residues different fromgermline sequences are boxed.

FIG. 2 provides two graph showing antibody-mediated internalization of acytotoxic FabZAP reagent into MDA-MB-231 cells and 4T1 cells, where theantibodies are MEDI9447 and the control antibody R347.

FIG. 3A is a graph showing inhibition of 5′ ectonucleotidase by theanti-CD73 antibody MEDI9447.

FIG. 3B is a graph showing inhibition of AMP hydrolysis by anti-CD73antibody CD370010.

FIG. 4 is a graph showing that MEDI9447 inhibited tumor growth in a CT26syngeneic tumor model. Murine CT26 tumor cells were implantedsubcutaneously on the right flank of female Balb/C mice. Tumors wereallowed to grow for 3 days and treated with MEDI9447 or an isotypecontrol twice weekly for two weeks. At Day 16, tumors were harvested forflow cytometry analysis.

FIG. 5 is a graph showing that MEDI9447 inhibited tumor-infiltratingmyeloid-derived suppressor cells (MDSCs). MEDI9447 -treated CT26tumor-bearing mice were sacrificed and tumors were harvested at studyDay 16. Tumors were disassociated into single cells, stained for CD45and MDSC markers, and analyzed by flow cytometry.

FIG. 6 includes six spider plots showing the effect of MEDI9447 mIgG1,anti-PD-1 or the combination on tumor volume. Control antibodies includerIgG2a, which is a Rat IgG2a control monoclonal rat antibody specificfor E. coli β-galactosidase (β-Gal), and Isotype control murine IgG1.Tumor volumes from each group of animals were plotted for individualanimals out to study day 40. No control group mice were tumor free bythe end of the 40 day study period. Anti-CD73 treatment alone resultedin 10% tumor free animals at the end of study. Anti-PD1 treatment alonealso resulted in 10% tumor free animals at the end of study. Remarkably,the combination of anti-CD73 and anti-PD treatment resulted in 60% tumorfree mice. None of the control group mice were tumor free by the end ofthe study.

FIG. 7 is a graph showing the effect of MEDI9447 mIgG1, anti-PD1 or thecombination on survival.

FIG. 8 is a graph showing that the combination of MEDI9447 and anti-PD-1significantly enhanced tumor growth inhibition (p<0.05) when compared toeither agent alone in colorectal carcinoma tumors. Mice were injectedsubcutaneously with syngeneic MC38-OVA colorectal carcinoma cells andtreated twice weekly with 10 mg per kg of MEDI9447 or 10 mg per kganti-PD-1 antibody alone or a combination of both antibodies. Tumorvolume was measured twice weekly.

FIG. 9 is a graph showing that anti-PD-1 induced a CD73-rich tumormicroenvironment as measured by CD73 expression on tumor cells isolatedfrom tumor-bearing mice. Mice (n=4) were injected subcutaneously withsyngeneic CT26 colorectal cells and treated twice weekly with 10 mg perkg of anti-PD-1 or an irrelevant isotype control antibody. One day afterthe first treatment tumors were isolated, cells dissociated and analyzedfor surface phenotype by flow cytometry.

FIG. 10 is a graph showing that anti-PD-1 induced a CD73-rich tumormicroenvironment as measured by CD73 expression on myeloid-derivedsuppressor cells (MDSC) isolated from tumor-bearing mice. Mice (n=4)were injected subcutaneously with syngeneic CT26 colorectal cells andtreated twice weekly with 10 mg per kg of anti-PD-1 or an irrelevantisotype control antibody. One day after the first treatment tumors wereisolated, tumor cells were isolated, peripheral whole blood cells wereharvested and analyzed for surface CD73 expression by flow cytometry.

FIG. 11 is a graph showing that anti-PD-1 induced a CD73-rich tumormicroenvironment as measured by CD73 expression on CD4+, FoxP3+lymphocytes isolated from tumor-bearing mice. Mice (n=4) were injectedsubcutaneously with syngeneic CT26 colorectal cells and treated twiceweekly with 10 mg per kg of anti-PD-1 or an irrelevant isotype controlantibody. Three days after the first treatment tumors were isolated,peripheral whole blood cells were harvested and analyzed for surfaceCD73 expression by flow cytometry

FIG. 12 is a graph showing that the combination of MEDI9447 andanti-PD-L1 significantly enhanced tumor growth inhibition (p<0.05) whencompared to either agent alone in melanoma tumors. Mice were injectedsubcutaneously with syngeneic B16F10 melanoma cells and treated twiceweekly with 10 mg per kg of MEDI9447 or 10 mg per kg anti-PD-L1 antibodyalone or a combination of both antibodies. Tumor volume was measuredtwice weekly.

FIG. 13 is a graph showing that the combination of MEDI9447 andanti-PD-L1 significantly enhanced tumor growth inhibition (p<0.01) whencompared to either agent alonein lymphoma tumors. Mice were injectedsubcutaneously with syngeneic EG7-OVA lymphoma cells and treated twiceweekly with 10 mg per kg of MEDI9447 or 10 mg per kg anti-PD-L1 antibodyalone or a combination of both antibodies. Tumor volume was measuredtwice weekly.

FIG. 14 is a graph showing that anti-PD-L1 induced a CD73-rich tumormicroenvironment as measured by surface expression of CD73 on draininglymph node B lymphocytes. Mice (n=4) were injected subcutaneously withsyngeneic CT26 colorectal cells and treated twice weekly with 10 mg perkg of anti-PD-L1 or an irrelevant isotype control antibody. One dayafter the first treatment cells were isolated from draining lymph nodesand analyzed for surface phenotype by flow cytometry.

FIG. 15 is a graph showing that anti-PD-L1 induced a CD73-rich tumormicroenvironment as measured by surface expression of CD73 on tumorinfiltrating CD4+, FoxP3+ lymphocytes. Mice (n=4) were injectedsubcutaneously with syngeneic CT26 colorectal cells and treated twiceweekly with 10 mg per kg of anti-PD-L1 or an irrelevant isotype controlantibody. Three days after the first treatment tumors were isolated,cells dissociated and analyzed for surface phenotype by flow cytometry.

FIGS. 16A and B are graphs showing that MEDI9447 alone or in combinationwith anti-PD-L1 reduced CD73 expression on tumor infiltrating lymphoidcells. Mice bearing colorectal CT26 syngeneic tumors were treated twiceweekly (Day 12 and D16) with either 30 mg/kg MEDI9447 or 30 mg/kganti-PD-L1 alone or combination of both MEDI9447 and anti-PD-L1. On Day17, tumors were harvested and analyzed for surface CD73 expression byflow cytometry. CD73 expression on tumor infiltrates (A) CD4+ FoxP3+Treg and (B) CD8+ T cells.

FIGS. 17A and B are graphs showing that MEDI9447 alone or in combinationwith anti-PD-L1 reduced CD73 activity on (A) tumor cells and (B)peripheral whole blood cells. Mice bearing colorectal CT26 syngeneictumors were treated twice weekly (Day 12 and D16) with either 30 mg/kgMEDI9447 or 30 mg/kg anti-PD-L1 alone or combination of both MEDI9447and anti-PD-L1. On Day 17, tumors and peripheral whole blood cells wereharvested and analyzed for surface CD73 expression for enzymaticactivity by using Cell-Titre Glo.

FIG. 18 are a set of graphs depicting cytokine profiles of peripheralblood mononuclear cells treated with MEDI9447 and antibodies or fusionproteins specific for CTLA4, OX40, PD-1, and PD-L1. Primary humanperipheral blood mononuclear cells were incubated for 72 hrs in a mixedleukocyte reaction with MEDI9447 and/or antibodies or fusion proteinsspecific for the indicated targets. Cytokines (IFN-γ, IL-1β, TNF-α) induplicate supernatants were quantified by ELISA. Data shown representoptimal dose combinations of anti-CD73 antibody with the 4 differentpartner agents. The anti-PD-1 and anti-CD73 combination showedsignificant (p<0.05) synergy as determined by the Bliss surface responsemethod (Zhao et al.). The cytokine profile indicates that both myeloidand lymphoid lineages were impacted. Greater than 50 donor pairs havebeen tested.

FIGS. 19A and 19B depict results of hydrogen deuterium exchange MS(HDX-MS) analysis of CD73 in complex with MEDI9447. FIG. 19A depicts ahydrogen-deuterium exchange heat map showing those regions of CD73 (SEQID NO: 167) (N- to C-terminal) that undergo decreased deuterium uptakewhen bound to MEDI9447. Relative exchange between antibody-bound andunbound CD73 is depicted as a function of exposure time with decreasedexchange in red, increased exchange in blue, and no change in white. TheN-terminal regions at positions 132-143 and 182-187 exhibited thehighest degree of differential exchange. FIG. 8B shows a crystalstructure of the CD73 monomer depicting the location of theHDX-identified binding interface (cyan) within the N-terminal domain(yellow). The CD73 linker region and C-terminal domain are representedin orange and blue, respectively.

FIGS. 20A-20E depict the results of hydrogen deuterium exchange MS(HDX-MS) analysis indicating regions of CD73 and MEDI9447 that undergodifferential hydrogen exchange in free versus bound states. FIG. 20Adepicts plots representing relative deuterium uptake (mass change indaltons) as a function of deuterium exposure time within peptidesencompassing the 132-143 region (SEQ ID NOS 168-171, respectively, inorder of appearance). FIG. 20B depicts plots representing relativedeuterium uptake (mass change in daltons) as a function of deuteriumexposure time within peptides encompassing the 182-187 region (SEQ IDNOS 172-175, respectively, in order of appearance). In FIGS. 20A and20B, uptake for CD73 alone is shown in squares and uptake for CD73 boundto MEDI9447 Fab is shown in red. The peptide sequence, position, andmass are indicted in the plot box. To narrow the region that containsthe sequence displaying a change in hydrogen exchange and would bepredicted to form the epitope, relative mass change in overlappingpeptides was compared. For example, the peptide spanning positions173-186 displayed differential exchange while there was no difference inthe peptide spanning 173-181. Thus, it was inferred that residuesupstream of 182 are not differentially labeled. FIG. 20C depicts aDynamX difference chart for MEDI9447 Fab heavy chain. FIG. 20D depicts aDynamX difference chart for MEDI9447 Fab light chain. For FIGS. 20C and20D, each data point indicates the difference in deuterium uptakebetween the CD73+Fab complex (positive values on y-axis) and Fab alone(negative values on y-axis). The vertical bar represents the sum of theuptake differences across the exposure time-points. The CDRs showinglower relative uptake when Fab was bound to CD73 are indicated. FIG. 9Edepicts a DynamX difference chart of CD73 alone (negative values ony-axis) versus CD73 bound to Fab (positive values on y-axis). Regions E1(aa 132-143) and E2 (aa 182-187) are indicated. The horizontal axiscorresponds to the analyzed peptides from the N- to C-terminus (left toright). A dotted line is overlaid on the chart showing the 1.6 dalton,98% confidence interval cut-off for statistically significant changes.

FIGS. 21A-21H depict sensor chip data showing that the MEDI9447 epitoperesides within the N-terminal domain of CD73. FIG. 21A is a graphdepicting sensor chip data for wild-type CD73 protein. Wild-type CD73protein was immobilized on a HTG sensor chip and binding of MEDI9447dilutions (5 nM to 0.3 nM) was measured by surface plasmon resonance(SPR). FIG. 21B is a graph depicting sensor chip data for N-terminaldomain-swapped CD73 protein. N-terminal domain-swapped CD73 protein wasimmobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5nM to 0.3 nM) was measured by SPR. MEDI9447 did not bind to CD73 whenthe N-terminal domain was swapped. FIG. 21C is a graph depicting sensorchip data for N-terminal and C-terminal domain-swapped CD73 protein.N-terminal and C-terminal domain-swapped CD73 protein was immobilized onan HTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM)was measured by SPR. MEDI9447 did not bind to CD73 when both N-terminaland C-terminal domains were swapped. FIG. 21D is a graph depictingsensor chip data for linker region-swapped CD73 protein. Linkerregion-swapped CD73 protein was immobilized on an HTG sensor chip andbinding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR.Swapping only the linker region did not affect binding. FIG. 21E is agraph depicting sensor chip data for C-terminal domain-swapped CD73protein. C-terminal domain-swapped CD73 protein was immobilized on anHTG sensor chip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) wasmeasured by SPR. Swapping only the C-terminal domain did not affectbinding. FIG. 21F is a graph depicting sensor chip data for interface E1(aa 132-143)-swapped CD73 protein. Interface E1 (aa 132-143) -swappedCD73 protein was immobilized on an HTG sensor chip and binding ofMEDI9447 dilutions (5 nM to 0.3 nM) was measured by SPR. FIG. 21G is agraph depicting sensor chip data for interface E2 (aa 182-187)-swappedCD73 protein. Interface E2 (aa 182-187)-swapped CD73 protein wasimmobilized on an HTG sensor chip and binding of MEDI9447 dilutions (5nM to 0.3 nM) was measured by SPR. FIG. 21H is a graph depicting sensorchip data for interface E1 (aa 132-143)- and interface E2 (aa182-187)-swapped CD73 protein. Interface E1 (aa 132-143)- and interfaceE2 (aa 182-187)-swapped CD73 protein was immobilized on an HTG sensorchip and binding of MEDI9447 dilutions (5 nM to 0.3 nM) was measured bySPR. For FIGS. 21F-21H, swapping the HDX interface E1 (aa 132-143) (FIG.21F) had a minor impact on binding as opposed to swapping HDX interfaceE2 (aa 182-187) alone (FIG. 21G) or in combination with E1 (FIG. 21H).For FIGS. 21A-21H, sensorgrams and overlaid fits are shown in matchingcolors. Kinetics measurements for each binding analysis are provided atTable 16.

FIG. 22 depicts the alignment of human (SEQ ID NO: 176) and chicken (SEQID NO: 177) CD73 protein sequences. Only the mature protein sequencesare shown. Non-conserved residues are highlighted in the chickensequence. Regions swapped between chicken and human to generate theknock-out variants are annotated (e.g. DS1a, DS1b, etc.).

FIG. 23 depict binding of MEDI9447 to CD73 variants. FIG. 23 is a tableof data showing binding of MEDI9447 to CD73 variants. K_(D) for variantshighlighted in blue are >2-fold changed from the WT or KO parentconstruct. *Kinetics measurements derived from 2:1 heterogeneous ligandfit. **Numbering corresponds to chicken sequence (129 = 133, 140 = 144,and 181 = 185 in human).

FIGS. 24A-24F depict that the MEDI9447 epitope is positioned at the apexof the N-terminal domain. FIG. 13A shows that an evaluation of MEDI9447binding to a panel of CD73 variants (see FIGS. 22 and 23 ) revealed sixpositions that constitute the interaction site. Two of the three mostimpactful residues (highlighted blocks) are located outside the HDXinterface regions (highlighted in blue). Three less important residues(pink blocks) are located within the HDX interface. FIG. 24A disclosesSEQ ID NO: 178. FIG. 24B is table showing that knocking-in N185 and V144(K180 is conserved) to a CD73 construct containing chicken N-andC-terminal domain sequence restored binding to less than 20-fold theK_(D) for wild-type CD73 (MEDI9447 dilutions from 5 nM to 0.3 nM;compare to FIG. 10B). FIG. 24C depicts a close-up of the epitoperesidues located within the N-terminal domain of CD73. The mostimportant residues for binding are shown highlighted and less impactfulpositions (Y135, K136, and N187) are in pink. The HDX interface isoverlaid in blue. FIG. 24D depicts a surface representation showing thatthe epitope forms a near contiguous binding surface. FIG. 24E depicts acrystal structure of the open conformation of CD73 showing the positionof the epitope at the apical, lateral surface of the N-terminal domain.FIG. 24F shows that the location of the epitope is distant from thesubstrate binding site (adenosine depicted in spheres) and the zinc ion(grey sphere) coordination site (side chains in cyan). In all crystalstructures, the CD73 N-terminal domain, linker region, and C-terminaldomain are depicted in yellow, orange, and blue, respectively.

FIGS. 25A-25C show that MEDI9447 is a non-competitive inhibitor of CD73hydrolysis of AMP. FIG. 25A is a graph depicting the kinetics of CD73phosphohydrolysis of AMP measured in the presence of MEDI9447 or anisotype matched control mAb. FIG. 25B is a graph showing that MEDI9447acts as a non-competitive inhibitor in that it equivalently inhibitshydrolysis regardless of substrate concentration. In contrast, APCP, aknown competitive inhibitor of CD73, increases K_(m) but did notV_(max). FIG. 25C is a graph depicting dose response of MEDI9447 IgG,Fab, or control IgG on the inhibition of CD73 hydrolysis of AMP.MEDI9447 IgG reached maximal inhibition at a 1:1 molar stoichiometrywith CD73 dimer (arrow). At high concentrations, where MEDI9447 IgG isin excess (>10 nM), a loss of inhibition or “hook effect” was observed.MEDI9447 Fab and control IgG did not inhibit CD73. All experiments wereperformed using the CellTiterGlo assay as described herein (RLU,relative light units) .

FIGS. 26A-26C show that anti-CD73 mAb (clone 0069) binding is dependenton CD73 N- and C-terminal domain residues. FIG. 26A is a graph showingsensor chip data for histidine tagged CD73. Histidine tagged CD73 wasimmobilized on a HIS2 biosensor and binding by mAb A was measured bybio-layer interferometry (BLI). Binding of mAb A to WT CD7 (bluesensorgram), N-terminal domain swap knockout CD73 (KO_1-291, greensensorgram) and C-terminal domain swap knockout CD7 (KO_311-523 cyansensorgram) show that mAb binding is impacted by residues in both the N-and C-terminal domain. FIG. 26B Crystal structure of open and closedCD73 showing position of mAb A binding hot spot highlighted (aa 114-134and 153-170), which is positioned near the N- and C-terminal domaininterface (N-terminal domain in yellow, linker in orange, and C-terminaldomain in blue). Mapping was based on binding data from FIGS. 26A and26C. FIG. 26C shows binding sensorgrams of mAb A to different domainswap knockout variants of CD73. Swapping sub-regions DS2c (aa 114-134)or DS3a (aa 153-170) knocked out binding. All binding analysis wasperformed on an Octet QK384 instrument as described herein.

FIGS. 27A-27C show that MEDI9447 inhibited the transition of CD73 to theconformationally active structure. FIG. 27A is a graph showing biosensordata for wild type CD73. Wild type CD73 was immobilized on a HIS2biosensor and binding of MEDI9447 (blue sensorgram) and anti-CD73 mAb A(brown sensorgram) was measured by BLI on an Octet QK384. When CD73 waspre-incubated with Zn²⁺ and APCP, MEDI9447 retained binding (blacksensorgram) but mAb A binding was lost (orange sensorgram). FIG. 27B isa graph showing that although Zn²⁺ and APCP pre-incubation with CD73caused a loss in mAb A binding (orange sensorgram), pre-incubation withMEDI9447 before addition of Zn²⁺ and APCP restored binding (purplesensorgram). Binding of mAb A to CD73 alone and CD73 pre-incubated withMEDI9447 (but not Zn²⁺ and APCP) are shown in the blue and brownsensorgrams, respectively. FIG. 27C shows a proposed model depicting howMEDI9447 prevents CD73 from adopting the fully closed, activeconformation induced by Zn²⁺ and APCP. MEDI9947 may restrict transitionto an intermediate state with lower affinity for mAb A.

FIGS. 28A and 28B show binding of MEDI9447 or mAb A to CD73 underdifferent conditions measured by BLI as described herein, unlessotherwise noted below. FIG. 28A is a graph depicting binding ofanti-CD73 mAb A to histidine-tagged wild-type CD73 immobilized on a HIS2biosensor. After a 100 sec baseline, captured CD73 was incubated withZn²⁺, APCP, and/or EDTA for 900 sec, and then the biosensor wasincubated in 30 nM mAb A for 600 sec to measure binding. mAb A bound toCD73 (blue sensorgram) but not CD73 pre-incubated with Zn²⁺ and APCP(purple sensorgram). mAb A maintained binding to CD73 pre-incubated withAPCP and EDTA (green sensorgram) or Zn²⁺, APCP, and EDTA (goldsensorgram). The chelating effect of EDTA shows that the divalent cationwas required for loss of mAb A binding when CD73 was incubated with Zn²⁺and APCP. FIG. 28B is a graph showing that MEDI9447 Fab or control IgGdid not rescue binding of mAb A to CD73 pre-incubated with Zn²⁺ andAPCP. The assay was performed as in FIG. 27B. MEDI9447 Fab orisotype-matched control IgG were pre-incubated with CD73 before additionof Zn²⁺ and APCP. mAb A immobilized on the biosensor bound to CD73 alone(blue sensorgram), CD73 pre-incubated with either MEDI9447 Fab (lightblue sensorgram) or control IgG (black sensorgram), but not CD73incubated with Zn²⁺ and APCP (brown sensorgram), or either Fab (goldsensorgram) or control IgG (purple sensorgram) pre-incubated with CD73prior to addition of Zn²⁺ and APCP.

FIGS. 29A and 29B show that anti-CD73 mAb B binding is dependent onresidues in sub-regions DS2b (aa 92-134) or DS2c (aa 114-134). FIG. 29Ais a table showing SEC-MALS data corresponding to FIGS. 30A-30C. Foreach mixture of CD73 and either MEDI9447 or mAb B, the corresponding SECretention time, Mw, and polydispersity of the formed complexes areshown. FIG. 29B depicts the determination of the binding hot spot of mAbB on CD73. mAb B binding to CD73 variants immobilized on HIS2 biosensorswas measured by BLI as described for mAb A (clone 0069) in FIGS. 26A-26Caccording to the methods herein. Binding sensorgrams showed thatswapping either sub-region DS2b (aa 92-134) or DS2c (aa 114-134) knockedout binding by mAb B.

FIGS. 30A-30C show that MEDI9447 forms inter-dimer bridges betweensoluble CD73 molecules. CD73 was incubated with varying amounts ofMEDI9447 or anti-CD73 mAb B and analyzed by SEC-MALS. Shown are SEC UVchromatograms with protein retention time on the x-axis and molar massdetermined by MALS on the y-axis. FIG. 30A is a chromatogram showingthat at a 1:1 molar ratio (green trace), MEDI9447 formed complexes withCD73 of ~1.7 (^) and ~6.6 (+) megadaltons. Comparably sized complexeswere formed at lower ratios of MEDI9447:CD73 (0.5:1 in blue, 0.1:1 inmagenta). MEDI9447 and CD73 alone are represented by the black and redUV traces, respectively. FIG. 30B is a top-down view of the crystalstructure of CD73 dimer showing the mAb B binding hot spot (purple) andMEDI9447 epitope (magenta and pink). mAb B binds to a site close to thecentral groove between the dimers in the open conformation. FIG. 30C isa chromatogram showing that when CD73 is bound to mAb B a singlepredominant complex of ~270-290 kD (peak at ~7.2 min) was formed. UVtraces shown represent 1:1 mAb B:CD73 (red), 0.5:1 (blue), and 0.1:1(green). mAb A and CD73 alone are in magenta and black, respectively.

FIGS. 31A-31D depict that surface-bound CD73 was inhibited by IgG andFab formats of MEDI9447. FIG. 31A is a graph depicting inhibition of AMPhydrolysis of immobilized CD73 by MEDI9447 IgG, Fab or controlantibodies. CD73 was immobilized via a C-terminal histidine tag to anickel-coated microtiter plate and inhibition of AMP hydrolysis byMEDI9447 IgG, Fab or control antibodies was measured using the MalachiteGreen assay as described herein. MEDI9447 IgG, but not control IgG,inhibited CD73 hydrolysis of AMP in a dose-dependent manner. MEDI9447Fab also inhibited CD73 activity, but to a much lower extent. FIG. 31Bdepicts complexes comprising MEDI9447 Fab (green) bound to anti-Fdantibody (xFd, red). When MEDI9447 Fab (green) was bound to one arm ofan anti-Fd antibody (xFd, red) and the other arm bound to a non-specificpolyclonal Fab (pFab, orange) inhibition increased to that comparablewith MEDI9447 IgG (Fab+xFd+pFab vs. MEDI9447 IgG and MEDI9947IgG+xFd+pFab) (see FIG. 31A). FIG. 31C a graph depicting inhibition ofAMP hydrolysis of GPI-anchored CD73 by MEDI9447 IgG, Fab or controlantibodies. Enzyme activity of endogenously expressed CD73 in MDA-MB-231cells was measured by CellTiterGlo assay. Similar to immobilizedrecombinant CD73, MEDI9447 IgG inhibits AMP hydrolysis to a greaterdegree than the Fab, but increasing the effective size of the MEDI9447Fab by forming a complex with an anti-Fd antibody enhances inhibition.FIG. 31D is a graph depicting inhibition of AMP hydrolysis of solubleCD73 (sCD73) by MEDI9447 IgG, Fab or control antibodies. To test whetherthe xFd+MEDI9447 can inhibit soluble CD73, AMP hydrolysis was measuredusing the Malachite Green assay. MEDI9447 Fab either alone or bound to asingle xFd arm did not inhibit soluble CD73 activity. In contrast,binding MEDI9947 Fab to both xFd arms (MEDI9447 Fab + xFd) conferredbivalency resulting in CD73 inhibition.

FIG. 32 is a graph showing that MEDI94447 IgG and Fab inhibited CD73hydrolysis of AMP. CD73 activity was measured in the presence ofincreasing concentrations of antibody using the Malachite Green assay,as described herein. MEDI9447 IgG inhibited CD73 hydrolytic activity ina dose-dependent manner and no hook effect, or loss of inhibition, wasobserved. MEDI9447 Fab also inhibited CD73 function, but to a lowerlevel of maximal inhibition. The experiment was performed twice withcomparable results. Data from only one experiment are shown.

FIG. 33 depicts a model showing that inhibition of CD73 hydrolyticactivity by MEDI9447 occurs through a dual mechanism. MEDI9447IgG(green) inhibits soluble CD73 by forming inter-dimer bridges thatprevent the conformational transition to the closed state. Monovalentlybound IgG or Fab does not inhibit soluble CD73. When CD73 issurface-bound, inhibition can occur through bridging of adjacent CD73dimers, or steric blocking from monovalently bound IgG or Fab/xFd (red)complex.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides isolated binding molecules orantigen-binding fragments thereof which specifically bind to CD73. Insome aspects, such molecules are antibodies and antigen-bindingfragments thereof that specifically bind to CD73. Relatedpolynucleotides, vectors, pharmaceutical compositions comprising theanti-CD73 antibodies or antigen-binding fragments thereof, are alsoprovided. Also provided are methods of making as well as methods ofusing the anti-CD73 antibodies and antigen-binding fragments disclosedherein, for example, diagnostic methods and methods of treating cancerin a subject (as direct therapy, adjuvant therapy, or in combinationtherapy). The invention also provides antibody-drug conjugates derivedfrom the CD73 binding molecules disclosed herein. Further, the inventionprovides therapeutic combinations featuring anti-CD73 antibodies (e.g.,MEDI9447) and one or more of agents targeting additional aspects of thecancer immunity cycle such as anti-PD-1 antibodies, anti-PD-L1antibodies (e.g., MEDI4736), anti-CTLA4 antibodies; and methods of usingsuch combinations for reducing tumor-mediated immunosuppression.

In order that the present disclosure can be more readily understood,certain terms are first defined. Additional definitions are set forththroughout the detailed description.

I. Definitions

Before describing the present invention in detail, it is to beunderstood that this invention is not limited to specific compositionsor process steps, as such can vary. As used in this specification andthe appended claims, the singular forms “a”, “an” and “the” includeplural referents unless the context clearly dictates otherwise. Theterms “a” (or “an”), as well as the terms “one or more,” and “at leastone” can be used interchangeably herein.

Furthermore, “and/or” where used herein is to be taken as specificdisclosure of each of the two specified features or components with orwithout the other. Thus, the term and/or″ as used in a phrase such as “Aand/or B” herein is intended to include “A and B,” “A or B,” “A”(alone), and “B” (alone). Likewise, the term “and/or” as used in aphrase such as “A, B, and/or C” is intended to encompass each of thefollowing aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; Aand C; A and B; B and C; A (alone); B (alone); and C (alone).

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this disclosure is related. For example, the ConciseDictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed.,2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed.,1999, Academic Press; and the Oxford Dictionary Of Biochemistry AndMolecular Biology, Revised, 2000, Oxford University Press, provide oneof skill with a general dictionary of many of the terms used in thisdisclosure.

Units, prefixes, and symbols are denoted in their Système Internationalde Unites (SI) accepted form. Numeric ranges are inclusive of thenumbers defining the range. Unless otherwise indicated, amino acidsequences are written left to right in amino to carboxy orientation. Theheadings provided herein are not limitations of the various aspects,which can be had by reference to the specification as a whole.Accordingly, the terms defined immediately below are more fully definedby reference to the specification in its entirety.

It is understood that wherever aspects are described herein with thelanguage “comprising,” otherwise analogous aspects described in terms of“consisting of” and/or “consisting essentially of” are also provided.

Amino acids are referred to herein by either their commonly known threeletter symbols or by the one-letter symbols recommended by the IUPAC-IUBBiochemical Nomenclature Commission. Nucleotides, likewise, are referredto by their commonly accepted single-letter codes.

The term “CD73 polypeptide” as used herein refers to the CD73 (Clusterof Differentiation 73) protein, also referred to as 5′-nucleotidase(5′-NT) or ecto-5′-nucleotidase in the literature, which is encoded bythe NT5E gene. See, e.g., Misumi et al. Eur. J. Biochem. 191(3): 563-9(1990). The respective sequences of the human and murine forms of CD73are available at the Uniprot database under accession numbers P21589 andQ61503, respectively. In defining any CD73 antibody epitopes, the aminoacid numbering used represents the amino acid residue of the mature CD73protein which does not contain the signal sequence residues.Accordingly, an antibody binding amino acids Val144, Lys180, and Asn185,for example, refers to the amino acid positions after cleavage of thesignal sequence, ie., the amino acid in the mature protein.

An exemplary CD73 polypeptide is provided below: >sp|P21589|5NTD_HUMAN5′-nucleotidase OS=Homo sapiens GN=NT5E PE=1 SV=1

MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFSTGSHCHGSFSLIFLSLWAVIFVLYQ (SEQ ID NO: 148)

Soluble and membrane-bound forms of CD73 have been identified. SeeKlemens et al, Biochem. Biophys. Res. Commun. 172(3):1371-7 (1990). Inaddition, several different isoenzymes have been identified. See Rosi etal. Life Sci. 62(25):2257-66 (1998). The full-length CD73 proteincomprises 574 amino acids. The mature CD73 protein is produced afterremoval of a signal sequence (positions 1 to 26) and the C-terminalregion of the propeptide (positions 550-574). In addition, amino acids404 to 453 are removed in isoform 2 of CD73 after alternative splicing.Natural variants are also known, for example, variant C358Y, variantT376A, and variant M379T. See Misumi et al., Eur. J. Biochem.191:563-569 (1990); Otsuki et al. DNA Res. 12:117-126 (2005); Mungall etal. Nature 425:805-811 (2003); Hansen et al. Gene 167:307-312 (1995);Klemens et al. Biochem. Biophys. Res. Commun. 172:1371-1377 (1990);Knapp et al. Structure 20:2161-2173 (2012); or St. Hilaire et al. N.Engl. J. Med. 364:432-442 (2011), all of which are herein incorporatedby reference in their entireties.

Typical diseases leading to a change in the patient’s CD73 level intissue fluids, especially in serum are: tissue trauma; reperfusioninjuries resulting from myocardial infarction or stroke, organtransplantations or other surgical operations; cancer or cancermetastasis; or inflammatory conditions resulting from the aforesaidtraumas or reperfusion injuries or from chronic conditions includingallergic conditions, autoimmune diseases, and inflammatory diseases. Asexamples of such chronic conditions can be mentioned arthritis, allergicconditions such as asthma, inflammatory conditions such as inflammatorybowel disease or an inflammatory condition of the skin, psoriasis,Parkinson’s disease, Alzheimer’s disease, autoimmune diseases, type I ortype II diabetes, atherosclerosis, multiple sclerosis, Crohn’s disease,or rejection reactions due to organ transplantations. Particularly, theinflammatory diseases systemic inflammatory response syndrome (SIRS),acute lung injury (ALI), multi-organ failure (MOF), ischemia reperfusioninjury (IRI) and adverse drug reaction (ADRS) lead to alterations oftissue fluid CD73 protein. Accordingly, the CD73-binding moleculesdisclosed herein can be used for example to treat or diagnose cancer(e.g., colon cancer, melanoma, breast cancer, lymphoma, non-small celllung carcinoma Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’slymphoma, ovarian cancer, breast cancer, head and neck cancers, andpancreatic cancer). In addition, the measurement of the levels of CD73in a sample from a patient (e.g., a tissue fluid) using the CD73-bindingmolecules disclosed herein can be used for monitoring the development ofthe above described diseases, for assessing the efficacy of therapies,to elect patients for treatment with a particular therapy, or to takemedical decisions, for example, commencing, ending, interrupting, ormodifying a certain treatment.

The terms “inhibit,” “block,” “suppress,” and grammatical variantsthereof are used interchangeably herein and refer to any statisticallysignificant decrease in biological activity, including full blocking ofthe activity. For example, “inhibition” can refer to a decrease of about10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% in biologicalactivity. Accordingly, when the terms “inhibition” or “suppression” areapplied to describe, e.g., an effect on the enzymatic activity of CD73,the term refers to the ability of an anti-CD73 antibody or antigenbinding fragment thereof to statistically significantly decrease the5′-nucleotidase activity of CD73 (catabolizing the hydrolysis ofadenosine monophosphate, AMP, to adenosine), relative to theCD73-mediated 5′-nucleotidase activity in an untreated (control) cell.The cell which expresses CD73 can be a naturally occurring cell or cellline (e.g., a cancer cell) or can be recombinantly produced byintroducing a nucleic acid encoding CD73 into a host cell. In someaspects, an anti-CD73 antibody or antigen binding fragment thereof canstatistically significantly decrease the 5′-nucleotidase activity of asoluble form of CD73 in a biological fluid. In one aspect, the anti-CD73binding molecule, e.g., an antibody or antigen binding fragment thereofinhibits CD73-mediated 5′-nucleotidase activity by at least 10%, atleast 15%, or at least 20%, at least 25%, or at least 30%, at least 35%,or at least 40%, at least 45%, or at least 50%, at least 55%, or atleast 60%, at least 65%, or at least 70%, at least 75%, or at least 80%,at least 85%, or at least 90%, at least 95%, or about 100%, asdetermined, for example, by the methods described in the Examples infra,and/or methods known in the art.

The term “suppress CD73 activity,” as used herein, refer to the abilityof anti-CD73 binding molecule, e.g., an antibody or antigen-bindingfragment thereof to statistically significantly decrease CD73-dependent5′-nucleotidase activity in a cell expressing CD73 or a samplecontaining CD73. In some aspects, the suppression of CD73 activity canbe a decrease of at least 10%, or at least 15%, or at least 20%, or atleast 25%, or at least 30%, or at least 35%, or at least 40%, or atleast 45%, or at least 50%, or at least 55%, or at least 60%, or atleast 65%, or at least 70%, or at least 75%, or at least 80%, or atleast 85%, or at least 90%, or at least 95%, or about 100% when cells ora sample are contacted with an anti-CD73 binding molecule, e.g., anantibody or antigen-binding fragment thereof of the present disclosure,relative to the CD73 activity measured in the absence of the anti-CD73binding molecule, e.g., an antibody or antigen-binding fragment thereof(control conditions).

The terms “antibody” or “immunoglobulin,” as used interchangeablyherein, include whole antibodies and any antigen binding fragment orsingle chains thereof.

A typical antibody comprises at least two heavy (H) chains and two light(L) chains interconnected by disulfide bonds. Each heavy chain iscomprised of a heavy chain variable region (abbreviated herein as VH orV_(H)) and a heavy chain constant region. The heavy chain constantregion is comprised of three domains, CH1, CH2, and CH3. Each lightchain is comprised of a light chain variable region (abbreviated hereinas VL or V_(L)) and a light chain constant region. The light chainconstant region is comprised of one domain, CL. The VH and VL regionscan be further subdivided into regions of hypervariability, termedComplementarity Determining Regions (CDR), interspersed with regionsthat are more conserved, termed framework regions (FW). Each VH and VLis composed of three CDRs and four FWs, arranged from amino-terminus tocarboxy-terminus in the following order: FW1, CDR1, FW2, CDR2, FW3,CDR3, FW4. The variable regions of the heavy and light chains contain abinding domain that interacts with an antigen. The constant regions ofthe antibodies can mediate the binding of the immunoglobulin to hosttissues or factors, including various cells of the immune system (e.g.,effector cells) and the first component (C1q) of the classicalcomplement system. Exemplary antibodies of the present disclosureinclude anti-CD73 antibodies (original and germlined), affinityoptimized clones, optimized antibodies lacking ADCC, conjugatedantibodies (e.g., ADC), and other optimized antibodies (e.g., serumhalf-life-optimized antibodies including, for example, YTE mutations,see Dall’Acqua et al., J. Biol. Chem. 281:23514-24 (2006) and U.S. Pat.No. 7,083,784, which are hereby incorporated by reference in theirentireties).

The term “germlining” means that amino acids at specific positions in anantibody are mutated back to those in the germ line.

The term “antibody” means an immunoglobulin molecule that recognizes andspecifically binds to a target, such as a protein, polypeptide, peptide,carbohydrate, polynucleotide, lipid, or combinations of the foregoingthrough at least one antigen recognition site within the variable regionof the immunoglobulin molecule. As used herein, the term “antibody”encompasses intact polyclonal antibodies, intact monoclonal antibodies,antibody fragments (such as Fab, Fab′, F(ab′)2, and Fv fragments),single chain Fv (scFv) mutants, multispecific antibodies such asbispecific antibodies generated from at least two intact antibodies,chimeric antibodies, humanized antibodies, human antibodies, fusionproteins comprising an antigen determination portion of an antibody, andany other modified immunoglobulin molecule comprising an antigenrecognition site so long as the antibodies exhibit the desiredbiological activity.

An antibody can be of any the five major classes of immunoglobulins:IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g.IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), based on the identity of theirheavy-chain constant domains referred to as alpha, delta, epsilon,gamma, and mu, respectively. The different classes of immunoglobulinshave different and well known subunit structures and three-dimensionalconfigurations. Antibodies can be naked or conjugated to other moleculessuch as toxins, radioisotopes, etc. to form ADCs.

A “blocking” antibody or an “antagonist” antibody is one which inhibitsor reduces biological activity of the antigen it binds, such as CD73. Ina certain aspect blocking antibodies or antagonist antibodiessubstantially or completely inhibit the biological activity of theantigen. Desirably, the biological activity is reduced by at least 10%,at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, atleast 40%, at least 45%, at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%,at least 85%, atleast 90%, at least 95%, or even 100%.

The terms “CD73 antibody,” “antibody that binds to CD73” or “anti-CD73”refers to an antibody or antigen binding fragment thereof that iscapable of binding CD73 with sufficient affinity such that the moleculeis useful as a therapeutic agent or diagnostic reagent in targetingCD73. The extent of binding of an anti-CD73 antibody to an unrelated,non-CD73 protein is less than about 10% of the binding of the antibodyto CD73 as measured, e.g., by a radioimmunoassay (RIA), BIACORE™ (usingrecombinant CD73 as the analyte and antibody as the ligand, or viceversa), or other binding assays known in the art. In certain aspects, anantibody that binds to CD73 has a dissociation constant (K_(D)) of ≤1µM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤10 pM, ≤1 pM, or ≤0.1 pM. The term“anti-CD73” also broadly encompasses molecules comprising, e.g., theCDRs of the antibodies disclosed herein incorporated into a scaffold.Thus, the phrase “isolated binding molecule or antigen binding fragmentthereof which specifically binds to CD73” would refer not only toantibodies and antigen-binding fragments thereof, but also would referto a molecule comprising, for example, one or more scaffolds (such as afibronectin III domain from fibronectin or tenascin-3) incorporating theCDRs of the antibodies disclosed herein. See, for example, U.S. Pat.Publ. No. 20150098955, which is herein incorporated by reference in itsentirety.

In one embodiment, an anti-CD73 antibody refers to an antibody inIgG1-TM format such that the IgG1 Fc domain comprises mutations L234,L235E and P331, binds soluble and cell-surface displayed CD73, andinhibits CD73 enzymatic activity. FIGS. 1A-1D provide the nucleotide andamino acid sequences of MEDI9447 VH and VL domains.

By “CTLA4 polypeptide” is meant a polypeptide having at least 85% aminoacid sequence identity to GenBank AccessionAAL07473.1 or a fragmentthereof having T cell inhibitory activity. The sequence of AAL07473.1 isprovided below: CTLA4 polypeptide sequence [Homo sapiens]gi|15778586|gb|AAL07473.1|AF414120_1

MACLGFQRHKAQLNLATRTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDFLLWILAAVSSGLFFYSFLLTAVSLSKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN (SEQ ID NO: 149)

By “CTLA4 nucleic acid molecule” is meant a polynucleotide encoding aCTLA4 polypeptide. An exemplary CTLA4 nucleic acid molecule sequence isprovided at GenBank Accession No. AAL07473.

By “anti-CTLA4 antibody” is meant an antibody that selectively binds aCTLA4 polypeptide. Exemplary anti-CTLA4 antibodies are described forexample at U.S. Pat. Nos. 6,682,736; 7,109,003; 7,123,281; 7,411,057;7,824,679; 8,143,379; 7,807,797; and 8,491,895 (Tremelimumab is 11.2.1,therein), which are herein incorporated by reference. Tremelimumab is anexemplary anti-CTLA4 antibody. Tremelimumab sequences are provided in asequence listing herein below (SEQ ID NOs: 130-137).

By “PD-1 polypeptide” is meant a polypeptide or fragment thereof havingat least about 85% amino acid identity to NCBI Accession No. NP_005009and having PD-L1 and/or PD-L2 binding activity. The sequence ofNP_005009 is provided below. PD-1 polypeptide sequence NCBI ACCESSIONNO. NP_005009

mqipqapwpv vwavlqlgwr pgwfldspdr pwnpptfspa llvvtegdna tftcsfsntsesfvlnwyrm spsnqtdkla afpedrsqpg qdcrfrvtql pngrdfhmsv vrarrndsgtylcgaislap kaqikeslra elrvterrae vptahpspsp rpagqfqtlv vgvvggllgslvllvwvlav icsraargti garrtgqplk edpsavpvfs vdygeldfqw rektpeppvpcvpeqteyat ivfpsgmgts sparrgsadg prsaqplrpe dghcswpl (SEQ ID NO: 150)

By “PD-1 nucleic acid molecule” is meant a polynucleotide encoding aPD-1 polypeptide. An exemplary PD-1 nucleic acid molecule sequence isprovided at NCBI Accession No. NM_005018.

By “anti-PD-1 antibody” is meant an antibody or antigen binding fragmentthereof that selectively binds a PD-1 polypeptide. Exemplary anti-PD-1antibodies include for example pembrolizumab (KEYTRUDA®, lambrolizumab,MK-3475), nivolumab (OPDIVA®, BMS-936558, MDX-1106, ONO-4538), orAMP-224.

By “PD-L1 polypeptide” is meant a polypeptide or fragment thereof havingat least about 85%, 95% or 100% amino acid identity to NCBI AccessionNo. NP_001254635 and having PD-1 and CD80 binding activity. The sequenceof NP_001254635 is provided below. PD-L1 polypeptide sequence NCBIACCESSION NO. NP_001254635

mrifavfifm tywhllnapy nkinqrilvv dpvtsehelt cqaegypkae viwtssdhqvlsgkttttns kreeklfnvt stlrintttn eifyctfrrl dpeenhtael vipelplahppnerthlvil gaillclgva ltfifrlrkg rmmdvkkcgi qdtnskkqsd thleet (SEQ ID NO:151)

By “PD-L1 nucleic acid molecule” is meant a polynucleotide encoding aPD-L1 polypeptide. An exemplary PD-L1 nucleic acid molecule sequence isprovided at NCBI Accession No. NM _001267706.

By “anti-PD-L1 antibody” is meant an antibody or antigen bindingfragment thereof that selectively binds a PD-L1 polypeptide. Exemplaryanti-PD-L1 antibodies are described for example at US20130034559 /US8779108 and US20140356353, which is herein incorporated by reference.MEDI4736 is an exemplary PD-L1 antibody. Sequences of MEDI4736 areprovided in a sequence listing herein below (SEQ ID NOs: 138-145).

The term “antigen binding fragment” refers to a molecule comprising aportion of an intact antibody, and in particular refers to a moleculecomprising the antigenic determining variable regions of an intactantibody. It is known in the art that the antigen binding function of anantibody can be performed by fragments of a full-length antibody.Examples of antibody fragments include, but are not limited to Fab,Fab′, F(ab′)2, and Fv fragments, linear antibodies, single chainantibodies, and multispecific antibodies formed from antibody fragments.

A “monoclonal antibody” refers to a homogeneous antibody populationinvolved in the highly specific recognition and binding of a singleantigenic determinant, or epitope. This is in contrast to polyclonalantibodies that typically include different antibodies directed againstdifferent antigenic determinants.

The term “monoclonal antibody” encompasses both intact and full-lengthmonoclonal antibodies as well as antibody fragments (such as Fab, Fab′,F(ab′)2, Fv), single chain variable fragments (scFv), fusion proteinscomprising an antibody portion, and any other modified immunoglobulinmolecule comprising an antigen recognition site. Furthermore,“monoclonal antibody” refers to such antibodies made in any number ofways including, but not limited to, by hybridoma, phage selection,recombinant expression, and transgenic animals (e.g., expression of ahuman antibody in a transgenic mouse).

The term “humanized antibody” refers to an antibody derived from anon-human (e.g., murine) immunoglobulin, which has been engineered tocontain minimal non-human (e.g., murine) sequences. Typically, humanizedantibodies are human immunoglobulins in which residues from the CDRs arereplaced by residues from the CDR of a non-human species (e.g., mouse,rat, rabbit, or hamster) that have the desired specificity, affinity,and capability (Jones et al., 1986, Nature, 321:522-525; Riechmann etal., 1988, Nature, 332:323-327; Verhoeyen et al., 1988, Science,239:1534-1536). In some instances, the framework (FW) amino acidresidues of a human immunoglobulin are replaced with the correspondingresidues in an antibody from a non-human species that has the desiredspecificity, and/or affinity, and/or capability.

The humanized antibody can be further modified by the substitution ofadditional residues either in the Fv framework region and/or within thereplaced non-human residues to refine and optimize antibody specificity,affinity, and/or capability. In general, the humanized antibody willcomprise substantially all of at least one, and typically two or three,variable domains containing all or substantially all of the CDR regionsthat correspond to the non-human immunoglobulin, whereas all orsubstantially all of the FR regions are those of a human immunoglobulinconsensus sequence. The humanized antibody can also comprise at least aportion of an immunoglobulin constant region or domain (Fc), typicallythat of a human immunoglobulin. Examples of methods used to generatehumanized antibodies are described in U.S. Pat. Nos. 5,225,539 or5,639,641.

A “variable region” of an antibody refers to the variable region of theantibody light chain or the variable region of the antibody heavy chain,either alone or in combination. The variable regions of the heavy andlight chain each consist of four FW regions connected by three CDRregions. The CDRs in each chain are held together in close proximity bythe FW regions and, with the CDRs from the other chain, contribute tothe formation of the antigen-binding site of antibodies. There are atleast two techniques for determining CDRs: (1) an approach based oncross-species sequence variability (i.e., Kabat et al. Sequences ofProteins of Immunological Interest, (5th ed., 1991, National Institutesof Health, Bethesda Md.)); and (2) an approach based on crystallographicstudies of antigen-antibody complexes (Al-lazikani et al. (1997) J.Molec. Biol. 273:927-948)). In addition, combinations of these twoapproaches are sometimes used in the art to determine CDRs.

The Kabat numbering system is generally used when referring to a residuein the variable domain (approximately residues 1-107 of the light chainand residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences ofImmunological Interest, 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, Md. (1991)).

The phrases “amino acid position numbering as in Kabat,” “Kabatposition,” and grammatical variants thereof refer to the numberingsystem used for heavy chain variable domains or light chain variabledomains of the compilation of antibodies in Kabat et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991). Using thisnumbering system, the actual linear amino acid sequence can containfewer or additional amino acids corresponding to a shortening of, orinsertion into, a FW or CDR of the variable domain. For example, a heavychain variable domain can include a single amino acid insert (residue52a according to Kabat) after residue 52 of H2 and inserted residues(e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavychain FW residue 82.

TABLE 1 Loop Kabat AbM Chothia L1 L24-L34 L24-L34 L24-L34 L2 L50-L56L50-L56 L50-L56 L3 L89-L97 L89-L97 L89-L97 H1 H31-H35B H26-H35BH26-H32...34 (Kabat Numbering) H1 H31-H35 H26-H35 H26-H32 (ChothiaNumbering) H2 H50-H65 H50-H58 H52-H56 H3 H95-H102 H95-H102 H95-H102

The Kabat numbering of residues can be determined for a given antibodyby alignment at regions of homology of the sequence of the antibody witha “standard” Kabat numbered sequence. Chothia refers instead to thelocation of the structural loops (Chothia and Lesk, J. Mol. Biol.196:901-917 (1987)). The end of the Chothia CDR-H1 loop when numberedusing the Kabat numbering convention varies between H32 and H34depending on the length of the loop (this is because the Kabat numberingscheme places the insertions at H35A and H35B; if neither 35A nor 35B ispresent, the loop ends at 32; if only 35A is present, the loop ends at33; if both 35A and 35B are present, the loop ends at 34). The AbMhypervariable regions represent a compromise between the Kabat CDRs andChothia structural loops, and are used by Oxford Molecular’s AbMantibody modeling software.

IMGT (ImMunoGeneTics) also provides a numbering system for theimmunoglobulin variable regions, including the CDRs. See e.g., Lefranc,M.P. et al., Dev. Comp. Immunol. 27: 55-77(2003), which is hereinincorporated by reference. The IMGT numbering system was based on analignment of more than 5,000 sequences, structural data, andcharacterization of hypervariable loops and allows for easy comparisonof the variable and CDR regions for all species. According to the IMGTnumbering schema VH-CDR1 is at positions 26 to 35, VH-CDR2 is atpositions 51 to 57, VH-CDR3 is at positions 93 to 102, VL-CDR1 is atpositions 27 to 32, VL-CDR2 is at positions 50 to 52, and VL-CDR3 is atpositions 89 to 97.

The EU index or EU numbering system is based on the sequential numberingof the first human IgG sequenced (the EU antibody). Because the mostcommon reference for this convention is the Kabat sequence manual (Kabatet al., 1991), the EU index is sometimes erroneously used synonymouslywith the Kabat index. The EU index does not provide insertions anddeletions, and thus in some cases comparisons of IgG positions acrossIgG subclass and species can be unclear, particularly in the hingeregions. Nonetheless, the convention has sufficed at enablingstraightforward comparison between Fc regions in numerous Fc structurefunction studies. Accordingly, the numbering scheme used forsubstitutions and insertions in Fc regions in this specification is theEU index as in Kabat. In contrast, the numbering scheme used for thevariable regions (VH and VL) in this specification is the regular Kabatnumbering.

As used throughout the specification the VH CDRs sequences describedcorrespond to the classical Kabat numbering locations, namely KabatVH-CDR1 is at positions 31-35, VH-CDR2 is a positions 50-65, and VH-CDR3is at positions 95-102. VL-CDR1, VL-CDR2 and VL-CDR3 also correspond toclassical Kabat numbering locations, namely positions 24-34, 50-56 and89-97, respectively.

As used herein the Fc region includes the polypeptides comprising theconstant region of an antibody excluding the first constant regionimmunoglobulin domain. Thus, Fc refers to the last two constant regionimmunoglobulin domains of IgA, IgD, and IgG, and the last three constantregion immunoglobulin domains of IgE and IgM, and the flexible hingeN-terminal to these domains. For IgA and IgM Fc can include the J chain.For IgG, Fc comprises immunoglobulin domains Cgamma2 and Cgamma3 (Cγ2and Cγ3) and the hinge between Cgamma1 (Cγ1) and Cgamma2 (Cγ2).

Although the boundaries of the Fc region can vary, the human IgG heavychain Fc region is usually defined to comprise residues C226 or P230 toits carboxyl-terminus, wherein the numbering is according to the EUindex as set forth in Kabat (Kabat et al., Sequences of Proteins ofImmunological Interest, 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, Md. (1991)). Fc can refer to this regionin isolation, or this region in the context of an antibody, antibodyfragment, or Fc fusion protein. Polymorphisms have been observed at anumber of different Fc positions, including but not limited to positions270, 272, 312, 315, 356, and 358 as numbered by the EU index, and thusslight differences between the presented sequence and sequences in theprior art can exist.

The term “human antibody” means an antibody produced by a human or anantibody having an amino acid sequence corresponding to an antibodyproduced by a human made using any technique known in the art (e.g.,recombinant expression in cultures cells, or expression in transgenicanimals). Thus, the term human antibody also encompasses an antibodyhaving an amino acid sequence corresponding to an antibody originallyproduced by a human (or an engineered variant or derivative thereof) butexpressed in a non-human system (e.g., produced by chemical synthesis;recombinantly expressed in microbial, mammal, or insect cells; orexpressed in an animal subject). Accordingly, an antibody obtained froma human subject or from human cells (e.g., hybridoma or cell lineexpressing a recombinant antibody or fragment thereof) and subsequentlyexpressed in an animal, e.g., mice, is considered a human antibody. Thisdefinition of a human antibody includes intact or full-lengthantibodies, fragments thereof, and/or antibodies comprising at least onehuman heavy and/or light chain polypeptide such as, for example, anantibody comprising murine light chain and human heavy chainpolypeptides.

The term “chimeric antibodies” refers to antibodies wherein the aminoacid sequence of the immunoglobulin molecule is derived from two or moreanimal species. Typically, the variable region of both light and heavychains corresponds to the variable region of antibodies derived from onespecies of mammals (e.g., mouse, rat, rabbit, etc.) with the desiredspecificity, and/or affinity, and/or capability while the constantregions are homologous to the sequences in antibodies derived fromanother specie (usually human) to avoid eliciting an immune response inthat species.

The term “epitope” as used herein refers to an antigenic proteindeterminant capable of binding to a CD73 antibody or CD73 bindingmolecule disclosed herein. Epitopes usually consist of chemically activesurface groupings of molecules such as amino acids or sugar side chainsand usually have specific three dimensional structural characteristics,as well as specific charge characteristics. The part of an antibody orbinding molecule that recognizes the epitope is called a paratope. Theepitopes of protein antigens are divided into two categories,conformational epitopes and linear epitopes, based on their structureand interaction with the paratope. A conformational epitope is composedof discontinuous sections of the antigen’s amino acid sequence. Theseepitopes interact with the paratope based on the 3-D surface featuresand shape or tertiary structure of the antigen. By contrast, linearepitopes interact with the paratope based on their primary structure. Alinear epitope is formed by a continuous sequence of amino acids fromthe antigen.

The term “antibody binding site” refers to a region in the antigen(e.g., CD73) comprising a continuous or discontinuous site (i.e., anepitope) to which a complementary antibody specifically binds. Thus, theantibody binding site can contain additional areas in the antigen whichare beyond the epitope and which can determine properties such asbinding affinity and/or stability, or affect properties such as antigenenzymatic activity or dimerization. Accordingly, even if two antibodiesbind to the same epitope within an antigen, if the antibody moleculesestablish distinct intermolecular contacts with amino acids outside ofthe epitope, such antibodies are considered to bind to distinct antibodybinding sites.

“Binding affinity” generally refers to the strength of the sum total ofnoncovalent interactions between a single binding site of a molecule(e.g., an antibody) and its binding partner (e.g., an antigen). Unlessindicated otherwise, as used herein, “binding affinity” refers tointrinsic binding affinity which reflects a 1:1 interaction betweenmembers of a binding pair (e.g., antibody and antigen). The affinity ofa molecule X for its partner Y can generally be represented by thedissociation constant (K_(D)). Affinity can be measured by commonmethods known in the art, including those described herein. Low-affinityantibodies generally bind antigen slowly and tend to dissociate readily,whereas high-affinity antibodies generally bind antigen faster and tendto remain bound longer. A variety of methods of measuring bindingaffinity are known in the art, any of which can be used for purposes ofthe present disclosure.

“Potency” is normally expressed as an IC₅₀ value, in nM unless otherwisestated. IC₅₀ is the median inhibitory concentration of anantigen-binding molecule. In functional assays, IC₅₀ is theconcentration that reduces a biological response by 50% of its maximum.In ligand-binding studies, IC₅₀ is the concentration that reducesreceptor binding by 50% of maximal specific binding level. IC₅₀ can becalculated by any number of means known in the art. Improvement inpotency can be determined by measuring, e.g., against a parent antibody(for example, the parent antibody prior to germlining or the parentantibody prior to affinity optimization).

The fold improvement in potency for the antibodies or polypeptides ofthe present disclosure as compared to a parent antibody can be at leastabout 2-fold, at least about 4-fold, at least about 6-fold, at leastabout 8-fold, at least about 10-fold, at least about 15-fold, at leastabout 20-fold, at least about 25-fold, at least about 30-fold, at leastabout 40-fold, at least about 50-fold, at least about 60-fold, at leastabout 70-fold, at least about 80-fold, at least about 90-fold, at leastabout 100-fold, at least about 110-fold, at least about 120-fold, atleast about 130-fold, at least about 140-fold, at least about 150-fold,at least about 160-fold, at least about 170-fold, or at least about180-fold or more.

“Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to aform of cytotoxicity in which secreted immunoglobulins bound onto Fcreceptors (FcRs) present on certain cytotoxic cells (e.g., NaturalKiller (NK) cells, neutrophils, and macrophages) enable these cytotoxiceffector cells to bind specifically to an antigen-bearing target celland subsequently kill the target cell with cytotoxins. Specifichigh-affinity IgG antibodies directed to the surface of target cells“arm” the cytotoxic cells and are absolutely required for such killing.Lysis of the target cell is extracellular, requires direct cell-to-cellcontact, and does not involve complement. It is contemplated that, inaddition to antibodies, other proteins comprising Fc regions,specifically Fc fusion proteins, having the capacity to bindspecifically to an antigen-bearing target cell will be able to effectcell-mediated cytotoxicity. For simplicity, the cell-mediatedcytotoxicity resulting from the activity of an Fc fusion protein is alsoreferred to herein as ADCC activity.

A polypeptide, antibody, polynucleotide, vector, cell, or compositionwhich is “isolated” is a polypeptide, antibody, polynucleotide, vector,cell, or composition which is in a form not found in nature. Isolatedpolypeptides, antibodies, polynucleotides, vectors, cells orcompositions include those which have been purified to a degree thatthey are no longer in a form in which they are found in nature. In someaspects, an antibody, polynucleotide, vector, cell, or composition whichis isolated is substantially pure.

The term “subject” refers to any animal (e.g., a mammal), including, butnot limited to humans, non-human primates, rodents, and the like, whichis to be the recipient of a particular treatment. Typically, the terms“subject” and “patient” are used interchangeably herein in reference toa human subject.

The term “pharmaceutical composition” refers to a preparation which isin such form as to permit the biological activity of the activeingredient (e.g., an anti-CD73 binding molecule disclosed herein) to beeffective, and which contains no additional components which areunacceptably toxic to a subject to which the composition would beadministered. Such composition can be sterile.

An “effective amount” of an anti-CD73 binding molecule as disclosedherein is an amount sufficient to carry out a specifically statedpurpose. An “effective amount” can be determined empirically and in aroutine manner, in relation to the stated purpose.

The term “therapeutically effective amount” refers to an amount of ananti-CD73 binding molecule disclosed herein or other drug effective to“treat” a disease or disorder in a subject or mammal.

The word “label” when used herein refers to a detectable compound orcomposition which is fused (e.g., genetically fused) or conjugated(e.g., chemically conjugated) directly or indirectly to an anti-CD73binding molecule disclosed herein so as to generate a “labeled”anti-CD73 binding molecule . The label can be detectable by itself(e.g., radioisotope labels or fluorescent labels) or, in the case of anenzymatic label, can catalyze chemical alteration of a substratecompound or composition which is detectable.

Terms such as “derivatizable group” and “derivatizable functional group”are used interchangeably and refer to a functional group that is capableof reacting to permit the formation of a covalent bond between ananti-CD73 binding molecule disclosed herein (e.g., a CD73 antibody) andanother substance. In some aspects, such substance is a therapeuticagent (e.g., a cytotoxin), a detectable label, a polymer (e.g., PEG),etc. Exemplary derivatizable groups include thiol, hydroxyl, amino,carboxy, and amide, as well as modified forms thereof, such as activatedor protected forms.

Terms such as “treating” or “treatment” or “to treat” or “alleviating”or “to alleviate” refer to both (1) therapeutic measures that cure, slowdown, lessen symptoms of, and/or halt progression of a diagnosedpathologic condition or disorder and (2) prophylactic or preventativemeasures that prevent and/or slow the development of a targetedpathologic condition or disorder. Thus, those in need of treatmentinclude those already with the disorder; those prone to have thedisorder; and those in whom the disorder is to be prevented. In certainaspects, a subject is successfully “treated” for cancer according to themethods of the present disclosure if the patient shows, e.g., total,partial, or transient remission of a certain type of cancer.

The terms “cancer”, “tumor”, “cancerous”, and “malignant” refer to ordescribe the physiological condition in mammals that is typicallycharacterized by unregulated cell growth. Examples of cancers includebut are not limited to, carcinoma including adenocarcinomas, lymphomas,blastomas, melanomas, sarcomas, and leukemias. More particular examplesof such cancers include squamous cell cancer, small-cell lung cancer,non-small cell lung cancer, gastrointestinal cancer, Hodgkin’s andnon-Hodgkin’s lymphoma, pancreatic cancer, glioblastoma, glioma,cervical cancer, ovarian cancer, liver cancer such as hepatic carcinomaand hepatoma, bladder cancer, breast cancer (including hormonallymediated breast cancer, see, e.g., Innes et al. (2006) Br. J. Cancer94:1057-1065), colon cancer, colorectal cancer, endometrial carcinoma,myeloma (such as multiple myeloma), salivary gland carcinoma, kidneycancer such as renal cell carcinoma and Wilms’ tumors, basal cellcarcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer,testicular cancer, esophageal cancer, various types of head and neckcancer and cancers of mucinous origins, such as, mucinous ovariancancer, cholangiocarcinoma (liver) and renal papillary carcinoma. Insome aspects, the term cancer as used herein specifically refers tocancer expressing CD73. In some specific aspects, the term cancer refersto cancers expressing low levels of CD73.In some aspects, the termcancer as used herein specifically refers to cancer expressing CD73(e.g., colon cancer, breast cancer, lymphoma, non-small cell carcinoma).

“Polynucleotide,” or “nucleic acid,” as used interchangeably herein,refer to polymers of nucleotides of any length, and include DNA and RNA.The nucleotides can be deoxyribonucleotides, ribonucleotides, modifiednucleotides or bases, and/or their analogs, or any substrate that can beincorporated into a polymer by DNA or RNA polymerase. A polynucleotidecan comprise modified nucleotides, such as methylated nucleotides andtheir analogs. The preceding description applies to all polynucleotidesreferred to herein, including RNA and DNA.

The term “vector” means a construct, which is capable of delivering, andin some aspects, expressing, one or more gene(s) or sequence(s) ofinterest in a host cell. Examples of vectors include, but are notlimited to, viral vectors, naked DNA or RNA expression vectors, plasmid,cosmid or phage vectors, DNA or RNA expression vectors associated withcationic condensing agents, DNA or RNA expression vectors encapsulatedin liposomes, and certain eukaryotic cells, such as producer cells.

The terms “polypeptide,” “peptide,” and “protein” are usedinterchangeably herein to refer to polymers of amino acids of anylength. The polymer can be linear or branched, it can comprise modifiedamino acids, and it can be interrupted by non-amino acids. The termsalso encompass an amino acid polymer that has been modified naturally orby intervention; for example, disulfide bond formation, glycosylation,lipidation, acetylation, phosphorylation, or any other manipulation ormodification, such as conjugation with a labeling component. Alsoincluded within the definition are, for example, polypeptides containingone or more analogs of an amino acid (including, for example, unnaturalamino acids, etc.), as well as other modifications known in the art. Itis understood that, because the polypeptides of the instant disclosureare based upon antibodies, in certain aspects, the polypeptides canoccur as single chains or associated chains.

A “recombinant” polypeptide or protein refers to a polypeptide orprotein produced via recombinant DNA technology. Recombinantly producedpolypeptides and proteins expressed in engineered host cells areconsidered isolated, as are native or recombinant polypeptides whichhave been separated, fractionated, or partially or substantiallypurified by any suitable technique. The polypeptides disclosed hereincan be recombinantly produced using methods known in the art.Alternatively, the proteins and peptides disclosed herein can bechemically synthesized.

The term “amino acid substitution” refers to replacing an amino acidresidue present in a parent sequence with another amino acid residue. Anamino acid can be substituted in a parent sequence, for example, viachemical peptide synthesis or through recombinant methods known in theart. Accordingly, references to a “substitution at position X” or“substitution at position X” refer to the substitution of an amino acidpresent at position X with an alternative amino acid residue. In someaspects, substitution patterns can described according to the schemaAXY, wherein A is the single letter code corresponding to the amino acidnaturally present at position X, and Y is the substituting amino acidresidue. In other aspects, substitution patterns can described accordingto the schema XY, wherein Y is the single letter code corresponding tothe amino acid residue substituting the amino acid naturally present atposition X.

A “conservative amino acid substitution” is one in which the amino acidresidue is replaced with an amino acid residue having a similar sidechain. Families of amino acid residues having similar side chains havebeen defined in the art, including basic side chains (e.g., lysine,arginine, histidine), acidic side chains (e.g., aspartic acid, glutamicacid), uncharged polar side chains (e.g., glycine, asparagine,glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains(e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,methionine, tryptophan), beta-branched side chains (e.g., threonine,valine, isoleucine) and aromatic side chains (e.g., tyrosine,phenylalanine, tryptophan, histidine). Thus, if an amino acid in apolypeptide is replaced with another amino acid from the same side chainfamily, the substitution is considered to be conservative. In anotheraspect, a string of amino acids can be conservatively replaced with astructurally similar string that differs in order and/or composition ofside chain family members.

Non-conservative substitutions include those in which (i) a residuehaving an electropositive side chain (e.g., Arg, His or Lys) issubstituted for, or by, an electronegative residue (e.g., Glu or Asp),(ii) a hydrophilic residue (e.g., Ser or Thr) is substituted for, or by,a hydrophobic residue (e.g., Ala, Leu, Ile, Phe or Val), (iii) acysteine or proline is substituted for, or by, any other residue, or(iv) a residue having a bulky hydrophobic or aromatic side chain (e.g.,Val, His, Ile or Trp) is substituted for, or by, one having a smallerside chain (e.g., Ala, Ser) or no side chain (e.g., Gly).

Other substitutions can be readily identified by workers of ordinaryskill. For example, for the amino acid alanine, a substitution can betaken from any one of D-alanine, glycine, beta-alanine, L-cysteine andD-cysteine. For lysine, a replacement can be any one of D-lysine,arginine, D-arginine, homo-arginine, methionine, D-methionine, omithine,or D-ornithine. Generally, substitutions in functionally importantregions that can be expected to induce changes in the properties ofisolated polypeptides are those in which (i) a polar residue, e.g.,serine or threonine, is substituted for (or by) a hydrophobic residue,e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteineresidue is substituted for (or by) any other residue; (iii) a residuehaving an electropositive side chain, e.g., lysine, arginine orhistidine, is substituted for (or by) a residue having anelectronegative side chain, e.g., glutamic acid or aspartic acid; or(iv) a residue having a bulky side chain, e.g., phenylalanine, issubstituted for (or by) one not having such a side chain, e.g., glycine.The likelihood that one of the foregoing non-conservative substitutionscan alter functional properties of the protein is also correlated to theposition of the substitution with respect to functionally importantregions of the protein: some non-conservative substitutions canaccordingly have little or no effect on biological properties.

The term “amino acid insertion” refers to introducing a new amino acidresidue between two amino acid residues present in the parent sequence.An amino acid can be inserted in a parent sequence, for example, viachemical peptide synthesis or through recombinant methods known in theart. Accordingly as used herein, the phrases “insertion betweenpositions X and Y” or “insertion between Kabat positions X and Y,”wherein X and Y correspond to amino acid positions (e.g., a cysteineamino acid insertion between positions 239 and 240), refers to theinsertion of an amino acid between the X and Y positions, and also tothe insertion in a nucleic acid sequence of a codon encoding an aminoacid between the codons encoding the amino acids at positions X and Y.Insertion patterns can be described according to the schema AXins,wherein A is the single letter code corresponding to the amino acidbeing inserted, and X is the position preceding the insertion.

The term “percent sequence identity” between two polypeptide orpolynucleotide sequences refers to the number of identical matchedpositions shared by the sequences over a comparison window, taking intoaccount additions or deletions (i.e., gaps) that must be introduced foroptimal alignment of the two sequences. A matched position is anyposition where an identical nucleotide or amino acid is presented inboth the target and reference sequence. Gaps presented in the targetsequence are not counted since gaps are not nucleotides or amino acids.Likewise, gaps presented in the reference sequence are not counted sincetarget sequence nucleotides or amino acids are counted, not nucleotidesor amino acids from the reference sequence.

The percentage of sequence identity is calculated by determining thenumber of positions at which the identical amino-acid residue or nucleicacid base occurs in both sequences to yield the number of matchedpositions, dividing the number of matched positions by the total numberof positions in the window of comparison and multiplying the result by100 to yield the percentage of sequence identity. The comparison ofsequences and determination of percent sequence identity between twosequences can be accomplished using readily available software both foronline use and for download. Suitable software programs are availablefrom various sources, and for alignment of both protein and nucleotidesequences. One suitable program to determine percent sequence identityis bl2seq, part of the BLAST suite of program available from the U.S.government’s National Center for Biotechnology Information BLAST website (blast.ncbi.nlm.nih.gov). Bl2seq performs a comparison between twosequences using either the BLASTN or BLASTP algorithm. BLASTN is used tocompare nucleic acid sequences, while BLASTP is used to compare aminoacid sequences. Other suitable programs are, e.g., Needle, Stretcher,Water, or Matcher, part of the EMBOSS suite of bioinformatics programsand also available from the European Bioinformatics Institute (EBI) atwww.ebi.ac.uk/Tools/psa.

Different regions within a single polynucleotide or polypeptide targetsequence that aligns with a polynucleotide or polypeptide referencesequence can each have their own percent sequence identity. It is notedthat the percent sequence identity value is rounded to the nearesttenth. For example, 80.11, 80.12, 80.13, and 80.14 are rounded down to80.1, while 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded up to80.2. It also is noted that the length value will always be an integer.

In certain aspects, the percentage identity “X” of a first amino acidsequence to a second sequence amino acid is calculated as 100 x (Y/Z),where Y is the number of amino acid residues scored as identical matchesin the alignment of the first and second sequences (as aligned by visualinspection or a particular sequence alignment program) and Z is thetotal number of residues in the second sequence. If the length of afirst sequence is longer than the second sequence, the percent identityof the first sequence to the second sequence will be higher than thepercent identity of the second sequence to the first sequence.

One skilled in the art will appreciate that the generation of a sequencealignment for the calculation of a percent sequence identity is notlimited to binary sequence-sequence comparisons exclusively driven byprimary sequence data. Sequence alignments can be derived from multiplesequence alignments. One suitable program to generate multiple sequencealignments is ClustalW2, available from www.clustal.org. Anothersuitable program is MUSCLE, available from www.drive5.com/muscle/.ClustalW2 and MUSCLE are alternatively available, e.g., from the EBI.

It will also be appreciated that sequence alignments can be generated byintegrating sequence data with data from heterogeneous sources such asstructural data (e.g., crystallographic protein structures), functionaldata (e.g., location of mutations), or phylogenetic data. A suitableprogram that integrates heterogeneous data to generate a multiplesequence alignment is T-Coffee, available at www.tcoffee.org, andalternatively available, e.g., from the EBI. It will also be appreciatedthat the final alignment used to calculate percent sequence identity canbe curated either automatically or manually.

The term “consensus sequence,” as used herein with respect to lightchain (VL) and heavy chain (VH) variable regions, refers to a compositeor genericized VL or VH sequence defined based on information as towhich amino acid residues within the VL or VH chain are amenable tomodification without detriment to antigen binding. Thus, in a “consensussequence” for a VL or VH chain, certain amino acid positions areoccupied by one of multiple possible amino acid residues at thatposition. For example, if an arginine (R) or a serine (S) occur at aparticular position, then that particular position within the consensussequence can be either arginine or serine (R or S). Consensus sequencesfor VH and VL chain can be defined, for example, by in vitro affinitymaturation (e.g., randomizing every amino acid position in a certain CDRusing degenerate coding primers), by scanning mutagenesis (e.g., alaninescanning mutagenesis) of amino acid residues within the antibody CDRs,or any other methods known in the art, followed by evaluation of thebinding of the mutants to the antigen to determine whether the mutatedamino acid position affects antigen binding. In some aspects, mutationsare introduced in the CDR regions. In other aspects, mutations areintroduced in framework regions. In some other aspects, mutations areintroduced in CDR and framework regions.

II. CD73-Binding Molecules

The present disclosure provides CD73 binding molecules, e.g., antibodiesand antigen-binding fragments thereof that specifically bind CD73, forexample, human CD73. The full-length amino acid (aa) and nucleotide (nt)sequences for CD73 are known in the art (see, e.g., UniProt Acc. No.P21589 for human CD73, or UniProt Acc. No. Q61503 for mouse CD73). Insome aspects, the anti-CD73 binding molecules are human antibodies (forexample, a clone 10.3 antibody, a clone 2C5 antibody, MEDI9447). Incertain aspects, the CD73 binding molecules are antibodies orantigen-binding fragments thereof.

In some aspects, CD73 binding molecules, e.g., antibodies orantigen-binding fragments thereof comprise a Fab, a Fab′, a F(ab′)₂, aFd, a single chain Fv or scFv, a disulfide linked Fv, a V-NAR domain, anIgNar, an intrabody, an IgG CH2, a minibody, a F(ab′)₃ a tetrabody, atriabody, a diabody, a single-domain antibody, DVD-Ig, Fcab, mAb², a(scFv)₂, or a scFv-Fc. In some aspects, the antibody is of the IgG type,for example of the IgG1 type.

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof comprises a heavy chain constant region or fragment thereof. Insome specific aspects, the heavy chain constant region is an IgGconstant region. The IgG constant region can comprise a light chainconstant region selected from the group consisting of a kappa constantregion and a lambda constant region.

In certain aspects, anti-CD73 antibodies or antigen-binding fragmentsthereof disclosed herein are modified compared to a parent antibody,e.g., the CD730010 antibody or the CD730002 antibody. In some aspects,the parent antibody is CD730010. In other aspects, the parent antibodyis CD730002. In other aspects, the parent antibody is CD730004,CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068,or CD730069. The modifications can include mutations in the CDR regionsand/or in the FW regions as compared to the parent antibody, e.g.,CD730010 or CD730002.

The phrase “CD730002 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:1 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 2.

The phrase “CD730004 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO: 104 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 103.

The phrase “CD730008 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO: 106 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 107.

The phrase “CD730010 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:3 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 4.

The phrase “CD730011 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:5 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 6.

The phrase “CD730021 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:7 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 8.

The phrase “CD730042 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:9 and two VHdomains comprising the amino acid sequence of SEQ ID NO: 10.

The phrase “CD730046 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:11 and two VHdomains comprising the amino acid sequence of SEQ ID NO:12.

The phrase “CD730047 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:13 and two VHdomains comprising the amino acid sequence of SEQ ID NO:14.

The phrase “CD730068 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:108 and two VHdomains comprising the amino acid sequence of SEQ ID NO:107.

The phrase “CD730069 antibody” refers to an IgG1 comprising two VLdomains comprising the amino acid sequence of SEQ ID NO:110 and two VHdomains comprising the amino acid sequence of SEQ ID NO:109.

(I) CD730010-Derived Anti-CD73 Antibodies

In certain aspects, an anti-CD73 antibody of the present disclosurecomprises modifications to CDR1 and/or CDR2 and/or CDR3 of the lightchain of the CD730010 antibody, including, but not limited to:

-   1) a light chain CDR1 comprising the consensus sequence    SGSLSNIGRNX₁VN (SEQ ID NO: 152), wherein X₁ represents amino acid    residues Proline (P), Glutamic Acid (E) or Aspartic Acid (D);    and/or,-   2) a light chain CDR2 comprising the consensus sequence LX₂NX₃RX₄X₅    (SEQ ID NO: 153), wherein X₂ represents amino acid residues    Asparagine (N) or Aspartic Acid (D), X₃ represents amino acid    residues Glutamine (Q) or Leucine (L), X₄ represents amino acid    residues Leucine (L) or Proline (P), and X₅ represents amino acid    residues Glycine (G) or Serine (S); and/or,-   3) a light chain CDR3 comprising the consensus sequence    ATWDDSX₆X₇GWX₈ (SEQ ID NO: 154), wherein X₆ represents amino acid    residues Leucine (L) or Histidine (H), X₇ represents amino acid    residues Lysine (K), Proline (P), Isoleucine (I) or Asparagine (N),    and X₈ represents amino acid residues Leucine (L) or Threonine (T).

In certain aspects, an anti-CD73 antibody of the present disclosurecomprises modifications to CDR1 and/or CDR2 and/or CDR3 of the heavychain of the CD730010 antibody, including, but not limited to:

-   1) a heavy chain CDR1 comprising the consensus sequence SYAX₉S (SEQ    ID NO: 155), wherein X₉ represents amino acid residues    Methionine (M) or Tyrosine (Y); and/or,-   2) a heavy chain CDR2 comprising the consensus sequence    X₁₀IX₁₁GSX₁₂GX₁₃TYYADSVKG (SEQ ID NO: 156), wherein X₁₀ represents    amino acid residues Leucine (L) or Alanine (A), X₁₁ represents amino    acid residues Tryptophan (W) or Serine (S), X₁₂ represents amino    acid residues Tryptophan (W) or Glycine (G), and X₁₃ represents    amino acid residues Serine (S) or Arginine (R); and/or,-   3) a heavy chain CDR3 comprising the consensus sequence    LGYX₁₄X₁₅X₁₆DX₁₇ (SEQ ID NO: 157), wherein X₁₄ represents amino acid    residues Glycine (G) or Serine (S), X₁₅ represents amino acid    residues Arginine (R) or Threonine (T), X₁₆ represents amino acid    residues Valine (V) or Isoleucine (I), and X₁₇ represents amino acid    residues Tyrosine (Y), Lysine (K), Methionine (M), Leucine (L) or    Glutamic acid (E).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VL region comprising the consensus amino acidsequence:

[FW₁]SGSLSNIGRNX₁VN[FW₂] LX₂NX₃RX₄X₅[FW₃] ATWDDSXn₆X₇GWX₈[FW₄] (SEQ    ID NO: 146)

-   wherein [FW₁], [FW₂], [FW₃] and [FW₄] represent the amino acid    residues of VL framework region 1 (SEQ ID NO: 25 or 26), VL    framework region 2 (SEQ ID NO: 27 or 28), VL framework region 3 (SEQ    ID NO: 29) and VL framework region 4 (SEQ ID NO: 30), respectively,    and wherein-   X₁ represents amino acid residues Proline (P), Glutamic Acid (E) or    Aspartic Acid (D);-   X₂ represents amino acid residues Asparagine (N) or Aspartic Acid    (D);-   X₃ represents amino acid residues Glutamine (Q) or Leucine (L);-   X₄ represents amino acid residues Leucine (L) or Proline (P);-   X₅ represents amino acid residues Glycine (G) or Serine (S);-   X₆ represents amino acid residues Leucine (L) or Histidine (H);-   X₇ represents amino acid residues Lysine (K), Proline (P),    Isoleucine (I) or Asparagine (N); and,-   X₈ represents amino acid residues Leucine (L) or Threonine (T).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VH region which comprises the consensus amino acidsequence:

 [FW₅]SYAX₉S [FW₆]X₁₀IX₁₁GSX₁₂GX₁₃TYYADSVKG [FW₇]LGYX₁₄X₁₅X₁₆DX₁₇ [FW₈](SEQ ID NO: 147)

-   wherein [FW₅], [FW₆], [FW₇] and [FW₈] represent the amino acid    residues of VH framework region 1 (SEQ ID NO: 31), VH framework    region 2 (SEQ ID NO: 32), VH framework region 3 (SEQ ID NO: 33) and    VH framework region 4 (SEQ ID NO: 34), respectively, and wherein-   X₉ represents amino acid residues Methionine (M) or Tyrosine (Y);-   X₁₀ represents amino acid residues Leucine (L) or Alanine (A);-   X₁₁ represents amino acid residues Tryptophan (W) or Serine (S);-   X₁₂ represents amino acid residues Tryptophan (W) or Glycine (G);-   X₁₃ represents amino acid residues Serine (S) or Arginine (R);-   X₁₄ represents amino acid residues Glycine (G) or Serine (S);-   X₁₅ represents amino acid residues Arginine (R) or Threonine (T);-   X₁₆ represents amino acid residues Valine (V) or Isoleucine (I)-   X₁₇ represents amino acid residues Tyrosine (Y), Lysine (K),    Methionine (M), Leucine (L) or Glutamic acid (E).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VL region comprising the consensus amino acidsequence:

[FW₁]SGSLSNIGRNX₁VN[FW₂] LX₂NX₃RX₄X₅[FW₃] ATWDDSX₆X₇GWX₈[FW₄] (SEQ    ID NO: 146)

-   wherein [FW₁], [FW₂], [FW₃] and [FW₄] represent the amino acid    residues of VL framework region 1 (SEQ ID NO: 25 or 26), VL    framework region 2 (SEQ ID NO: 27 or 28), VL framework region 3 (SEQ    ID NO: 29) and VL framework region 4 (SEQ ID NO: 30), respectively,    and wherein-   X₁ represents amino acid residues Proline (P), Glutamic Acid (E) or    Aspartic Acid (D);-   X₂ represents amino acid residues Asparagine (N) or Aspartic Acid    (D);-   X₃ represents amino acid residues Glutamine (Q) or Leucine (L);-   X₄ represents amino acid residues Leucine (L) or Proline (P);-   X₅ represents amino acid residues Glycine (G) or Serine (S);-   X₆ represents amino acid residues Leucine (L) or Histidine (H);-   X₇ represents amino acid residues Lysine (K), Proline (P),    Isoleucine (I) or Asparagine (N); and,-   X₈ represents amino acid residues Leucine (L) or Threonine (T);-   and wherein the anti-CD73 antibody or antigen binding fragment    thereof further comprises a VH region which comprises the consensus    amino acid sequence:

 [FW₅]SYAX₉S [FW₆]X₁₀IX₁₁GSX₁₂GX₁₃TYYADSVKG [FW₇]LGYX₁₄X₁₅X₁₆DX₁₇ [FW₈](SEQ ID NO: 147)

-   wherein [FW₅], [FW₆], [FW₇] and [FW₈] represent the amino acid    residues of VH framework region 1 (SEQ ID NO: 31), VH framework    region 2 (SEQ ID NO: 32), VH framework region 3 (SEQ ID NO: 33) and    VH framework region 4 (SEQ ID NO: 34), respectively, and wherein X₉    represents amino acid residues Methionine (M) or Tyrosine (Y);-   X₁₀ represents amino acid residues Leucine (L) or Alanine (A);-   X₁₁ represents amino acid residues Tryptophan (W) or Serine (S);-   X₁₂ represents amino acid residues Tryptophan (W) or Glycine (G);-   X₁₃ represents amino acid residues Serine (S) or Arginine (R);-   X₁₄ represents amino acid residues Glycine (G) or Serine (S);-   X₁₅ represents amino acid residues Arginine (R) or Threonine (T);-   X₁₆ represents amino acid residues Valine (V) or Isoleucine (I)-   X₁₇ represents amino acid residues Tyrosine (Y), Lysine (K),    Methionine (M), Leucine (L) or Glutamic acid (E).

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 46, 47, and 48. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR1 comprising a sequence selected from the group consisting of SEQID NOs: 46, 47, and 48.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 49, 50, 51, and 52. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 49, 50, 51 and 52.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR3 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 53, 54, 55, and 56. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR3 comprising a sequence selected from the group consisting of SEQID NOs: 53, 54, 55, and 56.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35 and 36. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR1 comprising a sequence selected from the group consisting of SEQID NOs: 35 and 36.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 37, 38, 39, and 40. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 37, 38, 39, and 40.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR3 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 41, 42, 43, 44, and 45. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR3 comprising a sequence selected from the group consisting of SEQID NOs: 41, 42, 43, 44, and 45.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 46, 47, and 48, except for one, two,three or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment comprises a VL-CDR1 comprising asequence selected from the group consisting of SEQ ID NOs: 46, 47, and48, except for one, two, three or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 49, 50, 51, and 52, except for one, two,three, or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VL-CDR2comprising a sequence selected from the group consisting of SEQ ID NOs:49, 50, 51, and 52, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR3 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 53, 54, 55, and 56, except for one, two,three, or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VL-CDR3comprising a sequence selected from the group consisting of SEQ ID NOs:53, 54, 55, and 56, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35 and 36, except for one, two, three,or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VH-CDR1comprising a sequence selected from the group consisting of SEQ ID NOs:35 and 36, except for one, two, three or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 37, 38, 39, and 40, except for one, two,three, or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VH-CDR2comprising a sequence selected from the group consisting of SEQ ID NOs:37, 38, 39, and 40, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR3 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 41, 42, 43, 44, and 45, except for one,two, three, or four amino acid substitutions. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR3 comprising sequence selected from the group consisting of SEQ IDNOs: 41, 42, 43, 44, and 45, except for one, two, three or four aminoacid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 46, 47 and 48; a VL-CDR2 consisting of asequence selected from the group consisting of SEQ ID NOs: 49, 50, 51,and 52; and a VL-CDR3 consisting of a sequence selected from the groupconsisting of SEQ ID NOs: 53, 54, 55, and 56. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR1 comprising a sequence selected from the group consisting of SEQID NOs: 46, 47 and 48; a VL-CDR2 comprising a sequence selected from thegroup consisting of SEQ ID NOs: 49, 50, 51, and 52; and a VL-CDR3comprising a sequence selected from the group consisting of SEQ ID NOs:53, 54, 55, and 56.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35 and 36; a VH-CDR2 consisting of asequence selected from the group consisting of SEQ ID NOs: 37, 38, 39,and 40; and a VH-CDR3 consisting of a sequence selected from the groupconsisting of SEQ ID NOs: 41, 42, 43, 44, and 45. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR1 comprising a sequence selected from the group consisting of SEQID NOs: 35 and 36; a VH-CDR2 comprising a sequence selected from thegroup consisting of SEQ ID NOs: 37, 38, 39, and 40; a VH-CDR3 comprisinga sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43,44, and 45.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 46, 47 and 48 except for one, two, threeor four amino acid substitutions; a VL-CDR2 consisting of a sequenceselected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52except for one, two, three or four amino acid substitutions; and aVL-CDR3 consisting of a sequence selected from the group consisting ofSEQ ID NOs: 53, 54, 55, and 56 except for one, two, three or four aminoacid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 comprising a sequence selected from thegroup consisting of SEQ ID NOs: 46, 47 and 48 except for one, two,three, or four amino acid substitutions; a VL-CDR2 comprising a sequenceselected from the group consisting of SEQ ID NOs: 49, 50, 51, and 52except for one, two, three, or four amino acid substitutions; and aVL-CDR3 comprising a sequence selected from the group consisting of SEQID NOs: 53, 54, 55, and 56 except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35 and 36 except for one, two, three, orfour amino acid substitutions; a VH-CDR2 consisting of a sequenceselected from the group consisting of SEQ ID NOs: 37, 38, 39, and 40except for one, two, three, or four amino acid substitutions; and aVH-CDR3 consisting of a sequence selected from the group consisting ofSEQ ID NOs: 41, 42, 43, 44, and 45 except for one, two, three or fouramino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 comprising a sequence selected from thegroup consisting of SEQ ID NOs: 35 and 36 except for one, two, three, orfour amino acid substitutions; a VH-CDR2 comprising a sequence selectedfrom the group consisting of SEQ ID NOs: 37, 38, 39, and 40 except forone, two, three, or four amino acid substitutions; a VH-CDR3 comprisinga sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43,44, and 45 except for one, two, three or four amino acid substitutions.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises modifications to CDR1, and/or CDR2, and/or CDR3 of theheavy and/or light chain, and further comprises modifications to FW1,and/or FW2, and/or FW3, and/or FW4 of the heavy and/or light chain.

In some aspects, FW₁ comprises SEQ ID NO: 25 or 26, FW₂ comprises SEQ IDNO: 27 or 28, FW₃ comprises SEQ ID NO: 29, FW₄ comprises SEQ ID NO: 30,FW₅ comprises SEQ ID NO: 31, FW₆ comprises SEQ ID NO: 32, FW₇ comprisesSEQ ID NO: 33, and FW₈ comprises SEQ ID NO: 34.

In some aspects, FW₁ comprises SEQ ID NO: 25 or 26, except for one, two,three, or four amino acid substitutions; FW₂ comprises SEQ ID NO: 27 or28, except for one, two, three, or four amino acid substitutions; FW₃comprises SEQ ID NO: 29, except for one, two, three, or four amino acidsubstitutions; FW₄ comprises SEQ ID NO: 30, except for one, two, three,or four amino acid substitutions; FW₅ comprises SEQ ID NO: 31, exceptfor one, two, three, or four amino acid substitutions; FW₆ comprises SEQID NO: 32, except for one, two, three, or four amino acid substitutions;FW₇ comprises SEQ ID NO: 33, except for one, two, three, or four aminoacid substitutions; and FW₈ comprises SEQ ID NO: 34.

In certain aspects, the anti-CD733 antibody or antigen-binding fragmentthereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3,VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical oridentical except for one, two, three or four amino acid substitutions inone or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1,VH-CDR2, and VH-CDR3 are:

-   SEQ ID NOs: 46, 49, 53, 35, 37, and 41; or,-   SEQ ID NOs: 47, 49, 53, 35, 37 and 41; or,-   SEQ ID NOs: 47, 49, 54, 36, 37 and 42; or,-   SEQ ID NOs: 46, 50, 54, 36, 38 and 43; or,-   SEQ ID NOs: 46, 51, 55, 36, 39 and 44; or,-   SEQ ID NOs: 48, 52, 54, 36, 40 and 44; or,-   SEQ ID NOs: 46, 49, 56, 35, 37 and 41; or,-   SEQ ID NOs: 46, 49, 53, 35, 37 and 45; or,-   SEQ ID NOs: 47, 49, 56, 36, 37 and 45; or,-   SEQ ID NOs: 46, 50, 56, 36, 38 and 45; or,-   SEQ ID NOs: 46, 51, 56, 36, 39 and 45; or,-   SEQ ID NOs: 48, 52, 56, 36, 40 and 45; or-   SEQ ID NOs: 46, 49, 56, 35, 37 and 45, respectively.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VLcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from thegroup consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ IDNO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69,and SEQ ID NO: 70.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VHcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from thegroup consisting of SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ IDNO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQID NO: 79, SEQ ID NO: 80, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82,SEQ ID NO: 83 and SEQ ID NO: 84.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL comprising a sequence at least about 80%, about85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%,or about 100% identical to a reference amino acid sequence selected fromthe group consisting of SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64,SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO:69, and SEQ ID NO: 70, and further comprises a VH comprising a sequenceat least about 80%, about 85%, about 90%, about 95%, about 96%, about97%, about 98%, about 99%, or about 100% identical to a reference aminoacid sequence selected from the group consisting of SEQ ID NO: 71, SEQID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76,SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO:81, SEQ ID NO: 82, SEQ ID NO: 83 and SEQ ID NO: 84.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL comprising the sequence of SEQ ID NO: 68 and a VHcomprising the sequence of SEQ ID NO:82. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VL consistingof the sequence of SEQ ID NO:68 and a VH consisting of the sequence ofSEQ ID NO:82.

The “clone 10.3 antibody” (also designated “73combo3” or “MEDI9447”) isan IgG1 comprising two CD730010-derived light chains (VL) of SEQ ID NO:68 (comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences ofSEQ ID NO: 46, 51 and 56, respectively), and two CD730010-derived heavychains (VH) of SEQ ID NO: 82 (comprising three CDRs, CDR1, CDR2, andCDR3, with the sequences of SEQ ID NO: 36, 39, and 45, respectively).

In certain aspects, an anti-CD73 antibody or antigen-binding fragmentthereof disclosed herein binds CD73 with substantially the same orbetter affinity as a 10.3 antibody comprising the 10.3 heavy chain VH ofSEQ ID NO: 82 and the 10.3 light chain VL of SEQ ID NO: 68.

(Ii) CD730002-Derived Anti-CD73 Antibodies

In certain aspects, the anti-CD73 antibody of the present disclosurecomprises modifications to CDR1 and/or CDR2 and/or CDR3 of the lightchain of the CD730002 antibody, including, but not limited to:

-   1) a light chain CDR1 comprising the sequence SGDKVGDKYAS (SEQ ID    NO: 97); and/or,-   2) a light chain CDR2 comprising the consensus sequence    EDX₁₈KX₁₉X₂₀S (SEQ ID NO: 158), wherein X₁₈ represents amino acid    residues Serine (S) or Threonine (T), X₁₉ represents amino acid    residues Arginine (R) or Tyrosine (Y), and X₂₀ represents amino acid    residues Histidine (H), Proline (P) or Leucine (L); and/or,-   3) a light chain CDR3 comprising the sequence QAWDTSFWV (SEQ ID NO:    100).

In certain aspects, the anti-CD73 antibody of the present disclosurecomprises modifications to CDR1 and/or CDR2 and/or CDR3 of the heavychain of CD730002, including, but not limited to:

-   1) a heavy chain CDR1 comprising the sequence SX₂₁A X₂₂S (SEQ ID NO:    159), wherein X₂₁ represents amino acid residues Tyrosine (Y) or    Valine (V), and X₂₂ represents amino acid residues Methionine (M) or    Arginine (R); and/or,-   2) a heavy chain CDR2 comprising the sequence AISGSGGSX₂₃YY    X₂₄DSVKX₂₅ (SEQ ID NO: 160), wherein X₂₃ represents amino acid    residues Threonine (T) or Proline (P); X₂₄ represents amino acid    residues Alanine (A) or G (Glycine); and X₂₅ represents amino acid    residues Glycine (G) or Arginine (R); and/or,-   3) a heavy chain CDR3 comprising the sequence DKGYYWYM (SEQ ID NO:    161).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VL region comprising the consensus amino acidsequence:

[FW₉]SGDKVGDKYAS[FW₁₀]EDX₁₈KX₁₉X₂₀S[FW₁₁]QAWDTSFWV[FW₁₂] (SEQ ID NO: 162)

wherein [FW₉], [FW₁₀], [FW₁₁] and [FW₁₂] represent the amino acidresidues of VL framework region 1 (SEQ ID NO: 90 or 91), VL frameworkregion 2 (SEQ ID NO: 92), VL framework region 3 (SEQ ID NO: 93, 94 or122) and VL framework region 4 (SEQ ID NO: 30), respectively; andwherein X₁₈ represents amino acid residues Proline (P) or Leucine (L);X₁₉ represents amino acid residues Arginine (R) or Tyrosine (Y); and X₂₀represents amino acid residues Histidine (H), Proline (P) or Leucine(L).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VH region which comprises the consensus amino acidsequence:

[FW₁₃] SX₂₁A X₂₂S[FW₁₄]AISGSGGSX₂₃YY X₂₄DSVKX₂₅[FW₁₅]DKGYYWYM[FW₁₆] (SEQID NO: 163)

wherein [FW₁₃], [FW₁₄], [FW₁₅] and [FW₁₆] represent the amino acidresidues of VH framework region 1 (SEQ ID NO: 31), VH framework region 2(SEQ ID NO: 32), VH framework region 3 (SEQ ID NO: 33) and VH frameworkregion 4 (SEQ ID NO: 89), respectively; and wherein X₂₁ represents aminoacid residues Tyrosine (Y) or Valine (V); X₂₂ represents amino acidresidues Methionine (M) or Arginine (R); X₂₃ represents amino acidresidues Threonine (T) or Proline (P); X₂₄ represents amino acidresidues Alanine (A) or G (Glycine); and X₂₅ represents amino acidresidues Glycine (G) or Arginine (R).

In one aspect, the anti-CD73 antibody or antigen binding fragmentthereof comprises a VL region comprising the consensus amino acidsequence:

[FW₉]SGDKVGDKYAS[FW₁₀]EDX₁₈KX₁₉X₂₀S[FW₁₁]QAWDTSFWV[FW₁₂] (SEQ ID NO: 162)

wherein [FW₉], [FW₁₀], [FW₁₁] and [FW₁₂] represent the amino acidresidues of VL framework region 1 (SEQ ID NO: 90 or 91), VL frameworkregion 2 (SEQ ID NO: 92), VL framework region 3 (SEQ ID NO: 93, 94 or122) and VL framework region 4 (SEQ ID NO: 30), respectively; andwherein X₁₈ represents amino acid residues Proline (P) or Leucine (L);X₁₉ represents amino acid residues Arginine (R) or Tyrosine (Y); and X₂₀represents amino acid residues Histidine (H), Proline (P) or Leucine(L), and wherein the anti-CD73 antibody or antigen binding fragmentthereof further comprises a VH region which comprises the consensusamino acid sequence:

[FW₁₃] SX₂₁A X₂₂S[FW₁₄]AISGSGGSX₂₃YY X₂₄DSVKX₂₅[FW₁₅]DKGYY-WYM[FW₁₆] (SEQID NO: 163)

wherein [FW₁₃], [FW₁₄], [FW₁₅] and [FW₁₆] represent the amino acidresidues of VH framework region 1 (SEQ ID NO: 31), VH framework region 2(SEQ ID NO: 32), VH framework region 3 (SEQ ID NO: 33) and VH frameworkregion 4 (SEQ ID NO: 89), respectively; and wherein X₂₁ represents aminoacid residues Tyrosine (Y) or Valine (V); X₂₂ represents amino acidresidues Methionine (M) or Arginine (R); X₂₃ represents amino acidresidues Threonine (T) or Proline (P); X₂₄ represents amino acidresidues Alanine (A) or G (Glycine); and X₂₅ represents amino acidresidues Glycine (G) or Arginine (R).

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence consisting of SEQID NO: 97. In some aspects, the anti-CD73 antibody or antigen-bindingfragment thereof comprises a VL-CDR1 comprising a sequence consisting ofSEQ ID NO: 97.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 98, 99, 127, 128, and 129. In someaspects, the anti-CD73 antibody or antigen-binding fragment thereofcomprises a VL-CDR2 comprising a sequence selected from the groupconsisting of SEQ ID NOs: 98, 99, 127, 128 and 129.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR3 consisting of a sequence consisting of SEQID NO: 100. In some aspects, the anti-CD73 antibody or antigen-bindingfragment thereof comprises a VL-CDR3 comprising a sequence consisting ofSEQ ID NO: 100.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence of a sequenceselected from the group consisting of SEQ ID NOs: 35, 123 and 124. Insome aspects, the anti-CD73 antibody or antigen-binding fragment thereofcomprises a VH-CDR1 comprising a sequence selected from the groupconsisting of SEQ ID NOs: 35, 123 and 124.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 37, 95, 125 and 126. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 37, 95, 125, and 126.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR3 consisting of a sequence consisting of SEQID NO: 96. In some aspects, the anti-CD73 antibody or antigen-bindingfragment thereof comprises a VH-CDR3 comprising a sequence consisting ofSEQ ID NO: 96.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence consisting of SEQID NO: 97, except for one, two, three, or four amino acid substitutions.In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 comprising a sequence consisting of SEQ IDNO: 97, except for one, two, three or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 98, 99, 127, 128, and 129, except forone, two, three, or four amino acid substitutions. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 98, 99, 127, 128, and 129, except for one, two, three, or fouramino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR3 consisting of a sequence consisting of SEQID NO: 100, except for one, two, three, or four amino acidsubstitutions. In some aspects, the anti-CD73 antibody orantigen-binding fragment thereof comprises a VL-CDR3 comprising asequence consisting of SEQ ID NO: 100, except for one, two, three, orfour amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35, 123 and 124, except for one, two,three, or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VH-CDR1comprising a sequence selected from the group consisting of SEQ ID NOs:35, 123 and 124, except for one, two, three, or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR2 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 37, 95, 125 and 126, except for one,two, three, or four amino acid substitutions. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 37, 95, 125 and 126, except for one, two, three, or four aminoacid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR3 consisting of a sequence consisting of SEQID NO: 96, except for one, two, three, or four amino acid substitutions.In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR3 comprising a sequence consisting of SEQ IDNO: 96, except for one, two, three, or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence consisting of SEQID NO: 97; a VL-CDR2 consisting of a sequence selected from the groupconsisting of SEQ ID NOs: 98, 99, 127, 128, and 129; and a VL-CDR3consisting of a sequence consisting of SEQ ID NO: 100. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR1 comprising a sequence consisting of SEQ ID NO: 97; a VL-CDR2comprising a sequence selected from the group consisting of SEQ ID NOs:98, 99, 127, 128, and 129; and a VL-CDR3 comprising a sequenceconsisting of SEQ ID NO: 100.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35, 123, and 124; a VH-CDR2 consistingof a sequence selected from the group consisting of SEQ ID NOs: 37, 95,125, and 126; and a VH-CDR3 consisting of a sequence consisting of SEQID NOs: 96. In some aspects, the anti-CD73 antibody or antigen-bindingfragment thereof comprises a VH-CDR1 comprising a sequence selected fromthe group consisting of SEQ ID NOs: 35, 123, and 124; a VH-CDR2comprising a sequence selected from the group consisting of SEQ ID NOs:37, 95, 125, and 126; a VH-CDR3 comprising a sequence consisting of SEQID NO: 96.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 consisting of a sequence consisting of SEQID NO: 97, except for one, two, three, or four amino acid substitutions;a VL-CDR2 consisting of a sequence selected from the group consisting ofSEQ ID NOs: 98, 99, 127, 128, and 129, except for one, two, three orfour amino acid substitutions; and a VL-CDR3 consisting of a sequenceconsisting of SEQ ID NO: 100, except for one, two, three, or four aminoacid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 comprising a sequence consisting of SEQ IDNOs: 97, except for one, two, three or four amino acid substitutions; aVL-CDR2 comprising a sequence selected from the group consisting of SEQID NOs: 98, 99, 127, 128, and 129, except for one, two, three or fouramino acid substitutions; and a VL-CDR3 comprising a sequence consistingof SEQ ID NO: 100, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 consisting of a sequence selected from thegroup consisting of SEQ ID NOs: 35, 123, and 124, except for one, two,three or four amino acid substitutions; a VH-CDR2 consisting of asequence selected from the group consisting of SEQ ID NOs: 37, 95, 125,and 126, except for one, two, three, or four amino acid substitutions;and a VH-CDR3 consisting of a sequence consisting of SEQ ID NO: 96,except for one, two, three or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 comprising a sequence selected from thegroup consisting of SEQ ID NOs: 35, 123, and 124, except for one, two,three, or four amino acid substitutions; a VH-CDR2 comprising a sequenceselected from the group consisting of SEQ ID NOs: 37, 95, 125, and 126,except for one, two, three, or four amino acid substitutions; a VH-CDR3comprising a sequence consisting of SEQ ID NO: 96, except for one, two,three or four amino acid substitutions.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises modifications to CDR1, and/or CDR2, and/or CDR3 of theheavy and/or light chain, and further comprises modifications to FW1,and/or FW2, and/or FW3, and/or FW4 of the heavy and/or light chain.

In some aspects, FW₉ comprises SEQ ID NO: 90 or 91, FW₁₀ comprises SEQID NO: 92, FW₁₁ comprises SEQ ID NO: 93, 94, or 122, FW₁₂ comprises SEQID NO: 30, FW₁₃ comprises SEQ ID NO: 31, FW₁₄ comprises SEQ ID NO: 32,FW₁₅ comprises SEQ ID NO: 33, and FW₁₆ comprises SEQ ID NO: 89.

In some aspects, FW₉ comprises SEQ ID NO: 90 or 91, except for one, two,three, or four amino acid substitutions, FW₁₀ comprises SEQ ID NO: 92,except for one, two, three, or four amino acid substitutions, FW₁₁comprises SEQ ID NO: 93, 94, or 122, except for one, two, three, or fouramino acid substitutions, FW₁₂ comprises SEQ ID NO: 30, except for one,two, three, or four amino acid substitutions, FW₁₃ comprises SEQ ID NO:31, except for one, two, three, or four amino acid substitutions, FW₁₄comprises SEQ ID NO: 32, except for one, two, three, or four amino acidsubstitutions, FW₁₅ comprises SEQ ID NO: 33, except for one, two, threeor four amino acid substitutions, and FW₁₆ comprises SEQ ID NO: 89.

In certain aspects, the anti-CD733 antibody or antigen-binding fragmentthereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3,VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical oridentical except for one, two, three, or four amino acid substitutionsin one or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1,VH-CDR2, and VH-CDR3 are:

-   SEQ ID NOs: 97, 98, 100, 35, 37, and 96; or,-   SEQ ID NOs: 97, 99, 100, 35, 95 and 96; or,-   SEQ ID NOs: 97, 98, 100, 35, 37, and 96; or,-   SEQ ID NOs: 97, 99, 100, 123, 37, and 96; or,-   SEQ ID NOs: 97, 99, 100, 124, 37, and 96; or,-   SEQ ID NOs: 97, 99, 100, 35, 125, and 96; or,-   SEQ ID NOs: 97, 99, 100, 35, 126, and 96; or,-   SEQ ID NOs: 97, 99, 100, 35, 95, and 96; or,-   SEQ ID NOs: 97, 127, 100, 35, 95, and 96; or,-   SEQ ID NOs: 97, 128, 100, 35, 95, and 96; or,-   SEQ ID NOs: 97, 129, 100, 35, 95, and 96; or,-   SEQ ID NOs: 97, 99, 100, 35, 95, and 96; respectively.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VLcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from thegroup consisting of SEQ ID NOs: 86, 88, 112, 118, 119, 120, and 121.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VHcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from thegroup consisting of SEQ ID NOs: 85, 87, 111, 113, 114, 115, 116, and117.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL comprising a sequence at least about 80%, about85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%,or about 100% identical to a reference amino acid sequence selected fromthe group consisting of SEQ ID NOs: 86, 88, 112, 118, 119, 120, and 121;and further comprises a VH comprising a sequence at least about 80%,about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about99%, or about 100% identical to a reference amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 85, 87, 111, 113, 114, 115,116, and 117.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL comprising the sequence of SEQ ID NO: 88; and aVH comprising the sequence of SEQ ID NO:87. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises a VLconsisting of the sequence of SEQ ID NO:87, and a VH consisting of thesequence of SEQ ID NO:87.

The “clone 2C5 antibody” is an IgG1 comprising two CD730002-derivedlight chains (VL) of SEQ ID NO: 88 (comprising three CDRs, CDR1, CDR2,and CDR3, with the sequences of SEQ ID NO: 97, 99, and 100,respectively), and CD7300002-derived heavy chains (VH) of SEQ ID NO: 87(comprising three CDRs, CDR1, CDR2, and CDR3, with the sequences of SEQID NO: 35, 95, and 96, respectively).

In certain aspects, an anti-CD73 antibody or antigen-binding fragmentthereof disclosed herein binds CD73 with substantially the same orbetter affinity as a 2C5 antibody comprising the 2C5 heavy chain VH ofSEQ ID NO: 87 and the 2C5 light chain VL of SEQ ID NO: 88.

(Iii) Anti-CD73 Antibodies With Parent Antibodies Other Than CD730002 orCD730010

In other aspects, the parent antibody of an anti-CD73 antibody orantigen-binding fragment disclosed herein is CD730004 (i.e., ananti-CD73 antibody comprising a VL of SEQ ID NO: 104 and a VH of SEQ IDNO:103), CD730008 (i.e., an anti-CD73 antibody comprising a VL of SEQ IDNO: 106 and a VH of SEQ ID NO:107), CD7300011 (i.e., an anti-CD73antibody comprising a VL of SEQ ID NO: 5 and a VH of SEQ ID NO:6),CD730021 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 7and a VH of SEQ ID NO:8), CD730042 (i.e., an anti-CD73 antibodycomprising a VL of SEQ ID NO: 9 and a VH of SEQ ID NO:10), CD730046(i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO: 11 and a VHof SEQ ID NO:12), CD730047 (i.e., an anti-CD73 antibody comprising a VLof SEQ ID NO: 13 and a VH of SEQ ID NO:14), CD730068 (i.e., an anti-CD73antibody comprising a VL of SEQ ID NO: 108 and a VH of SEQ ID NO:107),or CD730069 (i.e., an anti-CD73 antibody comprising a VL of SEQ ID NO:110 and a VH of SEQ ID NO:109). The modifications to the parentantibodies can include mutations in the CDR regions and/or in the FWregions as compared to the parent antibody, e.g., CD730004.

In certain aspects, the anti-CD73 antibody comprises modifications toCDR1 and/or CDR2 and/or CDR3 of the light chain of CD730004, CD730008,CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, orCD730069.

In certain aspects, the anti-CD73 antibody comprises modifications toCDR1 and/or CDR2 and/or CDR3 of the heavy chain of CD730004, CD730008,CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, orCD730069.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069. In someaspects, the anti-CD73 antibody or antigen-binding fragment thereofcomprises a VL-CDR2 from CD730004, CD730008, CD7300011, CD730021,CD730042, CD730046, CD730047, CD730068, or CD730069. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069. In someaspects, the anti-CD73 antibody or antigen-binding fragment thereofcomprises a VH-CDR2 from CD730004, CD730008, CD7300011, CD730021,CD730042, CD730046, CD730047, CD730068, or CD730069. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR3 from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069 except forone, two, three, or four amino acid substitutions. In some aspects, theanti-CD73 antibody or antigen-binding fragment thereof comprises aVL-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069, except for one, two, three,or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VL-CDR3 fromCD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047,CD730068, or CD730069, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, exceptfor one, two, three, or four amino acid substitutions. In some aspects,the anti-CD73 antibody or antigen-binding fragment thereof comprises aVH-CDR2 from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069, except for one, two, three,or four amino acid substitutions. In some aspects, the anti-CD73antibody or antigen-binding fragment thereof comprises a VH-CDR3 fromCD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047,CD730068, or CD730069, except for one, two, three or four amino acidsubstitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; a VL-CDR2from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046,CD730047, CD730068, or CD730069; and a VL-CDR3 from CD730004, CD730008,CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, orCD730069.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069; a VH-CDR2from CD730004, CD730008, CD7300011, CD730021, CD730042, CD730046,CD730047, CD730068, or CD730069; and a VH-CDR3 from CD730004, CD730008,CD7300011, CD730021, CD730042, CD730046, CD730047, CD730068, orCD730069.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, exceptfor one, two, three or four amino acid substitutions; a VL-CDR2 fromCD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047,CD730068, or CD730069, except for one, two, three or four amino acidsubstitutions; and a VL-CDR3 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, exceptfor one, two, three or four amino acid substitutions.

In some aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VH-CDR1 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, exceptfor one, two, three or four amino acid substitutions; a VH-CDR2 fromCD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047,CD730068, or CD730069, except for one, two, three or four amino acidsubstitutions; and a VH-CDR3 from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069, exceptfor one, two, three or four amino acid substitutions.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises modifications to CDR1, and/or CDR2, and/or CDR3 of theheavy and/or light chain from CD730004, CD730008, CD7300011, CD730021,CD730042, CD730046, CD730047, CD730068, or CD730069, and furthercomprises modifications to FW1, and/or FW2, and/or FW3, and/or FW4 ofthe heavy and/or light chain from CD730004, CD730008, CD7300011,CD730021, CD730042, CD730046, CD730047, CD730068, or CD730069.

In certain aspects, the anti-CD733 antibody or antigen-binding fragmentthereof comprises a VL and a VH comprising VL-CDR1, VL-CRD2, VL-CDR3,VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences identical oridentical except for one, two, three, or four amino acid substitutionsin one or more CDRs, wherein such VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1,VH-CDR2, and VH-CDR3 are from CD730004, CD730008, CD7300011, CD730021,CD730042, CD730046, CD730047, CD730068, or CD730069.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VLcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from VLsequences from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises an antibody VL and an antibody VH, wherein the VHcomprises an amino acid sequence at least about 80%, about 85%, about90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about100% identical to a reference amino acid sequence selected from VHsequences from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069.

In other aspects, the anti-CD73 antibody or antigen-binding fragmentthereof comprises a VL comprising a sequence at least about 80%, about85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%,or about 100% identical to a reference amino acid sequence selected fromVL sequences from CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069, and further comprises a VHcomprising a sequence at least about 80%, about 85%, about 90%, about95%, about 96%, about 97%, about 98%, about 99%, or about 100% identicalto a reference amino acid sequence selected from VH sequences fromCD730004, CD730008, CD7300011, CD730021, CD730042, CD730046, CD730047,CD730068, or CD730069.

In certain aspects, the anti-CD73 antibody or antigen-binding fragmentthereof disclosed herein binds CD73 with substantially the same orbetter affinity as a CD730004, CD730008, CD7300011, CD730021, CD730042,CD730046, CD730047, CD730068, or CD730069 antibody.

(Iv) Mixed and Matched Anti-CD73 Antibodies

The VH and VL sequences from the anti-CD73 binding molecules disclosedherein (e.g., CD730002, CD730004, CD730008, CD730010, CD730011, CD73021,CD730042, CD730046, CD730047, CD730068, or CD730069) or VH and VL ofvariants of such sequences (e.g., clone 10 GL9, clone 10 P32E, clone 10C1, clone 10 C2, clone 10 D3, clone 10 G10, clone 10 HPT, clone 10 GRVE,clone 10 combo1, clone 10 combo2, clone 10 combo3, clone 10 combo5, orclone combo6) can be “mixed and matched” to create other anti-CD73binding molecules.

In certain aspects, the VH sequences of the 10.3 antibody and the 2C5antibody are mixed and matched. In another aspect, the VL sequences ofthe 10.03 antibody and the 2C5 antibody can be mixed and matched.Additionally or alternatively, the VL and/or VH sequences of clone 10(CD730010) variants disclosed herein can be mixed and matched.Additionally or alternatively, the VL and/or VH sequences of clone 2(CD730002) variants disclosed herein can be mixed and matched.Additionally or alternatively, the VL and/or VH sequences of clone 10(CD730010) and clone 2 (CD730002) variants disclosed herein can be mixedand matched.

In some aspects, VL and/or VH mixing and matching can take place betweensequences derived from antibodies grouped in the same epitope bin (seeExample 2). As used herein, the term “epitope bin” refers to thegrouping of antibodies or antigen-binding fragments thereof that bindthe same epitope or an overlapping epitope, or compete with each otherfor binding with the same epitope or overlapping epitope. E.g.,sequences from CD730003, CD730010, CD730021, CD730042, CD730046, andCD730047, all of them antibodies belonging to “Epitope Bin B” can bemixed in matched. In other aspects, the VL and/or VH mixing and matchingcan take place between sequences derived from anti-CD73 antibodiesgrouped in different epitope bins. Accordingly, sequences fromantibodies belonging to “Epitope Bin B” can be mixed and matched withsequences from anti-CD73 antibodies in “Epitope Bin A” (CD730002,CD730004, CD730008, and CD730011) or “Epitope Bin C” (CD730068 andCD730069).

(V) Mutant Anti-CD73 Antibodies

In certain aspects, an anti-CD73 antibody (for example, MEDI9447, aclone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof disclosed herein comprises mutations that improve the binding tohuman FcRn and improve the half-life of the anti-CD73 antibody orantigen-binding fragment thereof. In some aspects, such mutations are amethionine (M) to tyrosine (Y) mutation in position 252, a serine (S) tothreonine (T) mutation in position 254, and a threonine (T) to glutamicacid (E) mutation in position 256, numbered according to the EU index asin Kabat (Kabat, et al. (1991) Sequences of Proteins of ImmunologicalInterest, U.S. Public Health Service, National Institutes of Health,Washington, D.C.), introduced into the constant domain of an IgG1. SeeU.S. Pat. No. 7,658,921, which is incorporated by reference herein. Thistype of mutant IgG, referred to as a “YTE mutant” has been shown displayapproximately four-times increased half-life as compared to wild-typeversions of the same antibody (Dall’Acqua et al., J. Biol. Chem.281:23514-24 (2006)). In some aspects, an anti-CD73 antibody orantigen-binding fragment thereof comprising an IgG constant domaincomprises one or more amino acid substitutions of amino acid residues atpositions 251-257, 285-290, 308-314, 385-389, and 428-436, numberedaccording to the EU index as in Kabat, wherein such mutations increasethe serum half-life of the anti-CD73 antibody or antigen-bindingfragment thereof.

In some aspects, a YTE mutant further comprises a substitution atposition 434 of the IgG constant domain, numbered according to the EUindex as in Kabat, with an amino acid selected from the group consistingof tryptophan (W), methionine (M), tyrosine (Y), and serine (S). Inother aspects, a YTE mutant further comprises a substitution at position434 of the IgG constant domain, numbered according to the EU index as inKabat, with an amino acid selected from the group consisting oftryptophan (W), methionine (M), tyrosine (Y), and serine (S), andsubstitution at position 428 of the IgG constant domain, numberedaccording to the EU index as in Kabat, with an amino acid selected fromthe group consisting of threonine (T), leucine (L), phenylalanine (F),and serine (S).

In yet other aspect, a YTE mutant further comprises a substitution atposition 434 of the IgG constant domain, numbered according to the EUindex as in Kabat, with tyrosine (Y), and a substitution at position 257of the IgG constant domain, numbered according to the EU index as inKabat, with leucine (L). In some aspects, a YTE mutant further comprisesa substitution at position 434 of the IgG constant domain, numberedaccording to the EU index as in Kabat, with serine (S), and asubstitution at position 428 of the IgG constant domain, numberedaccording to the EU index as in Kabat, with leucine (L).

In a specific aspect, the anti-CD73 antibody (for example, MEDI9447, aclone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof disclosed herein comprises an IgG1 constant domain comprising amethionine (M) to tyrosine (Y) mutation in position 252, a serine (S) tothreonine (T) mutation in position 254, and a threonine (T) to glutamicacid (E) mutation in position 256 of the IgG1 constant domain, numberedaccording to the EU index as in Kabat.

In certain aspects, the anti-CD73 antibody (for example, MEDI9447, aclone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof disclosed herein comprises at least one IgG constant domainamino acid substitution selected from the group consisting of:

-   (a) substitution of the amino acid at position 252 with tyrosine    (Y), phenylalanine (F), tryptophan (W), or threonine (T);-   (b) substitution of the amino acid at position 254 with threonine    (T);-   (c) substitution of the amino acid at position 256 with serine (S),    arginine (R), glutamine (Q), glutamic acid (E), aspartic acid (D),    or threonine (T);-   (d) substitution of the amino acid at position 257 with leucine (L);-   (e) substitution of the amino acid at position 309 with proline (P);-   (f) substitution of the amino acid at position 311 with serine (S);-   (g) substitution of the amino acid at position 428 with threonine    (T), leucine (L), phenylalanine (F), or serine (S);-   (h) substitution of the amino acid at position 433 with arginine    (R), serine (S), isoleucine (I), proline (P), or glutamine (Q);-   (i) substitution of the amino acid at position 434 with tryptophan    (W), methionine (M), serine (S), histidine (H), phenylalanine (F),    or tyrosine; and,-   (j) a combination of two or more of said substitutions,

wherein the positions are numbered according to the EU index as inKabat, and wherein the modified IgG has an increased serum half-lifecompared to the serum half-life of an IgG having the wild-type IgGconstant domain.

In some aspects, the VH and/or VL amino acid sequence of an anti-CD73antibody (for example, MEDI9447, a clone 10.3 antibody or a clone 2C5antibody) or antigen-binding fragment thereof disclosed herein can be85%, 90%, 95%, 96%, 97%, 98% or 99% similar to the VH and VL sequencesset forth above, and comprise 1, 2, 3, 4, 5 or more conservativesubstitutions. A CD73 antibody having VH and VL regions having high(i.e., 80% or greater) sequence similarity or sequence identity to theVH regions of SEQ ID NOs: 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81,82, 83, 84, 85, 87, 111, 113, 114, 115, 116, or 117, and/or VL regionsof SEQ ID NOs: 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,86, 88, 112, 118, 119, 120, or 121 respectively, can be obtained bymutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of nucleicacid molecules encoding SEQ ID NOs: 57, 58, 59, 60, 61, 62, 63, 64, 65,66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83,84, 85, 86, 87, 88, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, or121, followed by testing of the encoded altered antibody for retainedfunction using the functional assays described herein.

In some aspects, the Fc domain of an anti-CD73 antibody disclosed hereinor the Fc domain of a fusion protein comprising a CD73-binding fragmentof an antibody disclosed herein has reduced binding to an Fc receptor toreduce cytotoxicity, e.g., via ADCC. In some aspects, the Fc domain ofthe antibody or Fc fusion protein has increased binding to an Fcreceptor to increase cytotoxicity, e.g., via ADCC. In some aspects, theFc domain of the antibody or Fc fusion protein comprises a non-naturallyoccurring ADCC reducing amino acid residue at one or more positionsselected from the group consisting of 234, 235, 236, 237, 238, 239, 240,241, 243, 244, 245, 247, 251, 252, 254, 255, 256, 262, 263, 264, 265,266, 267, 269, 279, 280, 284, 292, 296, 297, 298, 299, 305, 313, 316,325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 339, 341, 343, 370,373, 378, 392, 416, 419, 421, 440, and 443 as numbered by the EU indexas set forth in Kabat. Numerous specific mutations capable of reducingthe ADCC activity of an antibody are known in the art and include, forexample 234F, 235E, 235F, 235Q (or 235Y), 239A, 332Q, 331S andcombinations thereof. For example, see the mutations described in U.S.Pat. Nos. 5,624,821, 5,648,260, 7,597,889, 8,961,967, 7,371,826,7,785,791, 7,790,858, U.S. Pat. Publication No. 20140378663,20130071390, 20110212087, 20150118227, 20060194290, 20060194291,20080274105, 20080274506, US20130089541, and US20130108623, which areherein incorporated by reference in their entireties. Antibodies withreduced ADCC effector function also include those with substitution ofone or more of Fc region residues 238, 265, 269, 270, 297, 327, and 329(see, e.g., U.S. Pat. No. 6,737,056). Such Fc mutants also include Fcmutants with substitutions at two or more of amino acid positions 265,269, 270, 297 and 327, including Fc mutant with substitution of residues265 and 297 to alanine (see, e.g., U.S. Pat. No. 7,332,581). Optionally,mutations which reduce both ADCC and CDC can be incorporated. In someaspects, anti-CD73 antibodies disclosed herein or antigen-bindingfragment thereof comprising mutations that reduce or abolish ADCC and/orCDC can be used to generate antibody drug conjugates (ADC).

In one aspect, the present disclosure provides an anti-CD73 antibody,wherein the antibody is an IgG1, IgG2 or IgG3 and comprises at least onemodification at one or more positions selected from the group consistingof 234, 235, and 331 as numbered by the EU index as set forth in Kabat.In still another specific aspect, the Fc region is an IgG1, IgG2 or IgG3Fc region and the non-naturally occurring amino acids are selected fromthe group consisting of 234F, 235E, 235F, 235Q (or 235Y), 239A, 332Q,331S, 332Q as numbered by the EU index as set forth in Kabat.

In another aspect, the present disclosure provides an anti-CD73antibody, wherein the antibody is an IgG4 and comprises at least onemodification at one or more positions selected from the group consistingof 228 and 235 as numbered by the EU index as set forth in Kabat. Instill another specific aspect, the Fc region is an IgG4 Fc region andthe non-naturally occurring amino acids are selected from the groupconsisting of 228P, 235E and 235Y as numbered by the EU index as setforth in Kabat. In specific aspects, the present disclosure provides ananti-CD73 antibody, wherein the antibody is an IgG1, IgG2, or IgG3 andcomprises modifications at positions (i) 234F, 235E, and 331S; (ii)234F, 235F, and 331S; (iii) 234F, 235Q, and 322Q. In another specificaspect, the present disclosure provides an anti-CD73 antibody, whereinthe antibody is an IgG4 and comprises modifications 228P and 235E.

III. Epitope-Competing CD73-Binding Molecules

In another aspect, the present disclosure provides CD73-bindingmolecules that bind to the same epitope as do the various anti-CD73antibodies described herein, for example, molecules that bind to thesame epitope as MEDI9447, a clone 10.3 antibody or to the same epitopeas a clone 2C5 antibody.

Such antibodies can be identified based on their ability tocross-compete (e.g., to competitively inhibit the binding of, in astatistically significant manner) with the anti-CD73 antibodiesdisclosed herein, such as the CD730010 antibody, CD730002 antibody,CD730004 antibody, and antigen-binding fragments thereof, in standardCD73 binding assays (e.g., flow cytometry assays, surface plasmonresonance, or solution assays).

Accordingly, in one aspect, the present disclosure provides anti-CD73antibodies and antigen-binding fragments thereof, e.g., human monoclonalantibodies, that compete for binding to CD73 with another anti-CD73antibody or antigen-binding fragment thereof, such as the CD730010antibody, CD730002 antibody, CD730004 antibody, variants thereof (e.g.,MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody), orantigen-binding fragments thereof. The ability of a test antibody toinhibit the binding of, e.g., the CD730010 antibody (or a clone 10.3antibody or an antigen-binding fragment thereof), or the CD730002antibody (or clone 2C5 antibody or an antigen-binding fragment thereof)demonstrates that the test antibody can compete with that antibody forbinding to CD73; such antibody can, according to nonlimiting theory,bind to the same or a related (e.g., a structurally similar or spatiallyproximal) epitope on CD73 as the anti-CD73 antibody or antigen-bindingfragment thereof with which it competes. In one aspect, the anti-CD73antibody or antigen-binding fragment thereof that binds to the sameepitope on CD73 as, e.g., the CD730010 antibody (or a clone 10.3antibody or an antigen-binding fragment thereof), or the CD730002antibody (or clone 2C5 antibody or an antigen-binding fragment thereof),is a human monoclonal antibody.

As described herein, the epitope of MEDI9447, a monoclonal antibody thatdirectly inhibits the enzymatic activity of CD73 was identified toelucidate the mechanism of action of MEDI9447. The epitope resideswithin the apical surface of the N-terminal domain of CD73, a regiondistal from substrate binding and active site residues. Structural andmechanistic studies revealed that MEDI9447 antagonizes CD73 through adual mechanism that prevents CD73 from adopting a catalytically activeconformation. These results provide the first report of a finely mappedepitope that can be targeted for selective, potent, and non-competitiveinhibition of CD73 as a means to modulate adenosine signaling in thetumor microenvironment.

Using hydrogen-deuterium exchange (HDX) mass spectrometry (MS) andmutagenesis strategies, we defined the epitope of MEDI9447 and examinedpotential effects of antibody binding on global CD73 structure. Theantibody binds to a site in the N-terminal domain of CD73 that enablesnon-competitive inhibition of AMP hydrolysis. In various aspects, theepitope comprises one or more CD73 amino acid residues corresponding toV144, K180, and N185. In various aspects, the epitope additionallycomprises one or more CD73 amino acid residues corresponding to Y135,K136, and N187 of CD73. Remarkably, the epitope is positioned such thatantibody binding impedes the conversion of CD73 from the open conformerto the catalytically active, closed conformer. Furthermore, our studiesshow that MEDI9447 can inhibit both anchored and soluble CD73 through adual mechanism of inhibition that is mediated by the valency of antibodyinteraction with CD73.

IV. Functional Characteristics of Anti-CD73 Antibodies

The affinity or avidity of an antibody for an antigen can be determinedexperimentally using any suitable method well known in the art, e.g.,flow cytometry, enzyme-linked immunosorbent assay (ELISA), orradioimmunoassay (RIA), or kinetics (e.g., BIACORE™ analysis). Directbinding assays as well as competitive binding assay formats can bereadily employed. (See, for example, Berzofsky et al., “Antibody-AntigenInteractions,” In Fundamental Immunology, Paul, W. E., Ed., Raven Press:New York, N.Y. (1984); Kuby, Immunology, W. H. Freeman and Company: NewYork, N.Y. (1992); and methods described herein. The measured affinityof a particular antibody-antigen interaction can vary if measured underdifferent conditions (e.g., salt concentration, pH, temperature). Thus,measurements of affinity and other antigen-binding parameters (e.g.,K_(D) or Kd, K_(on), K_(off)) are made with standardized solutions ofantibody and antigen, and a standardized buffer, as known in the art andsuch as the buffer described herein.

It also known in the art that affinities measured using surface plasmonresonance analysis (e.g., BIACORE™) can vary depending on which one ofthe reactants is bound to the chip. In this respect, affinity can bemeasured using a format in which the targeting antibody (e.g., a clone10.3 antibody or a clone 2C5 antibody) is immobilized onto the chip(referred to as an “IgG down” format) or using a format in which thetarget protein (e.g., CD73) is immobilized onto the chip (referred toas, e.g., a “CD73 down” format).

In one aspect of the present disclosure, the anti-CD73 antibody (forexample, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or anantigen-binding fragment thereof specifically binds CD73 and/orantigenic fragments thereof with a dissociation constant or k_(d)(k_(off)/k_(on)) of less than 10⁻⁶ M, or of less than 10⁻⁷ M, or of lessthan 10⁻⁸ M, or of less than 10⁻⁹ M, or of less than 10⁻¹⁰ M, or of lessthan 10⁻¹¹ M, or of less than 10⁻¹² M, or of less than 10⁻¹³ M.

In another aspect, the anti-CD73 antibody (for example, MEDI9447, aclone 10.3 antibody or a clone 2C5 antibody) or an antigen-bindingfragment thereof binds to CD73 and/or antigenic fragments thereof with aK_(off) of less than 1×10⁻³ s⁻¹, or less than 2×10⁻³ s⁻¹. In otheraspects, an anti-CD73 antibody or an antigen-binding fragment thereofbinds to CD73 and antigenic fragments thereof with a K_(off) of lessthan 10⁻³ s⁻¹, less than 5×10⁻³ s⁻¹, less than 10⁻⁴ s⁻¹, less than5×10⁻⁴ s⁻¹, less than 10⁻⁵ s⁻¹, less than 5×10⁻⁵ s⁻¹, less than 10⁻⁶s⁻¹, less than 5×10⁻⁶ s⁻¹, less than less than 5×10⁻⁷ s⁻¹, less than10⁻⁸ s⁻¹, less than 5×10⁻⁸ s⁻¹, less than 10⁻⁹ s⁻¹, less than 5×10⁻⁹s⁻¹, or less than 10⁻¹⁰ s⁻¹.

In another aspect, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or an antigen-binding fragment thereofbinds to CD73 and/or antigenic fragments thereof with an associationrate constant or k_(on) rate of at least 10⁵ M⁻¹ s⁻¹, at least 5×10⁵ M⁻¹s-¹, at least 10⁶ M⁻¹ s⁻¹, at least 5×10⁶ M⁻¹ s⁻¹, at least 10⁷ M⁻¹ s⁻¹,at least 5×10⁷ M⁻¹ s⁻¹, or at least 10⁸ M⁻¹ s⁻¹, or at least 10⁹ M⁻¹s⁻¹.

In some aspects, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or an antigen-binding fragment thereofbinds to CD73 on the surface of MB-MDA-231 cells with a K_(D) of atleast about 60 pM, at least about 70 pM, at least about 80 pM, at leastabout 90 pM, at least about 100 pM, at least about 110 pM, at leastabout 120 pM, at least about 130 pM, at least about 140 pM, at leastabout 150 pM, at least about 160 pM, or at least about 170 pM, asmeasured by flow cytometry. In one specific aspect, the anti-CD73antibody is a clone 10.3 antibody and it binds to CD73 on the surface ofMB-MDA-231 cells with a K_(D) of about 150 pM as measured by flowcytometry. In another specific aspect, the anti-CD73 antibody is a clone2C5 antibody and it binds to CD73 on the surface of MB-MDA-231 cellswith a K_(D) of about 80 pM as measured by flow cytometry.

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof binds to CD73 binds on the surface of murine 3T1 cells with aK_(D) of a of at least about 40 pM, at least about 50 pM, at least about60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM,at least about 100 pM, at least about 120 pM, or at least about 130 pM,as measured by flow cytometry. In one specific aspect, the anti-CD73antibody is a clone 10.3 antibody and it binds to CD73 on the surface ofmurine 3T1 cells with a K_(D) of about 110 pM as measured by flowcytometry. In another specific aspect, the anti-CD73 antibody is a clone2C5 antibody and it binds to CD73 on the surface of murine 3T1 cellswith a K_(D) of about 55 pM as measured by flow cytometry.

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof binds to CD73 on the surface of cynomolgus MK-1 cells with aK_(D) of a of at least about 40 pM, at least about 50 pM, at least about60 pM, at least about 70 pM, at least about 80 pM, at least about 90 pM,or at least about 100 pM, as measured by flow cytometry. In one specificaspect, the anti-CD73 antibody is a clone 10.3 antibody and it binds toCD73 on the surface of cynomolgus MK-1 cells with a K_(D) of about 80 pMas measured by flow cytometry. In another specific aspect, the anti-CD73antibody is a clone 2C5 antibody and it binds to CD73 on the surface ofcynomolgus MK-1 cells with a K_(D) of about 60 pM as measured by flowcytometry.

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof binds to human CD73 with a K_(D) of a of at least about 3 pM, atleast about 4 pM, at least about 5 pM, at least about 6 pM, at leastabout 7 pM, at least about 8 pM, at least about 9 pM, or at least about10 pM, as measured by surface plasmon resonance (PROTEON®). In onespecific aspect, the anti-CD73 antibody is a clone 10.3 antibody and itbinds to human CD73 with a K_(D) of about 4 pM as measured by surfaceplasmon resonance (PROTEON®). In another specific aspect, the anti-CD73antibody is a clone 2C5 antibody and it binds to human CD73 with a K_(D)of about 9 pM as measured by surface plasmon resonance (PROTEON®).

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof disclosed herein binds to murine CD73 with a K_(D) of a of atleast about 1 pM, at least about 2 pM, at least about 3 pM, at leastabout 4 pM, at least about 5 pM, at least about 6 pM, at least about 7pM, at least about 8 pM, at least about 9 pM, at least about 10 pM, atleast about 11 pM, at least about 12 pM, at least about 13 pM, at leastabout 14 pM, at least about 15 pM, at least about 16 pM, at least about17 pM, at least about 18 pM, at least about 19 pM, at least about 20 pM,at least about 21 pM, at least about 22 pM, at least about 23 pM, atleast about 24 pM, or at least about 25 pM, as measured by surfaceplasmon resonance (PROTEON®). In one specific aspect, the anti-CD73antibody is a clone 10.3 antibody and it binds to murine CD73 with aK_(D) of about 1 pM as measured by surface plasmon resonance (PROTEON®).In another specific aspect, the anti-CD73 antibody is a clone 2C5antibody and it binds to murine CD73 with a K_(D) of about 22 pM asmeasured by surface plasmon resonance (PROTEON®).

In some aspects, an anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof binds to cynomolgus CD73 with a K_(D) of a of at least about 3pM, at least about 4 pM, at least about 5 pM, at least about 6 pM, atleast about 7 pM, at least about 8 pM, at least about 9 pM, or at leastabout 10 pM, as measured by surface plasmon resonance (PROTEON®). In onespecific aspect, the anti-CD73 antibody is a clone 10.3 antibody and itbinds to cynomolgus CD73 with a K_(D) of about 7 pM as measured by SPR(Proteon). In another specific aspect, the anti-CD73 antibody is a clone2C5 antibody and it binds to cynomolgus CD73 with a K_(D) of about 9 pMas measured by surface plasmon resonance (PROTEON®).

In some aspects, the anti-CD73 antibody (for example, MEDI9447, a clone10.3 antibody or a clone 2C5 antibody) or an antigen-binding fragmentthereof binds to human CD73 with a K_(D) of a of at least about 40 pM,at least about 50 pM, at least about 60 pM, at least about 70 pM, atleast about 80 pM, at least about 90 pM, at least about 100 pM, or atleast about 110 pM, as measured by solution binding. In one specificaspect, the anti-CD73 antibody is a clone 10.3 antibody and it binds tohuman CD73 with a K_(D) of about 80 pM as measured by solution binding.In another specific aspect, the anti-CD73 antibody is a clone 2C5antibody and it binds to human CD73 with a K_(D) of about 80 pM asmeasured by solution binding.

In some aspects, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or an antigen-binding fragment thereofbinds to murine CD73 with a K_(D) of a of at least about 100 pM, atleast about 200 pM, at least about 300 pM, at least about 400 pM, atleast about 500 pM, at least about 600 pM, at least about 700 pM, atleast about 800 pM, at least about 900 pM, at least about 1000 pM, atleast about 1100 pM, at least about 1200 pM, at least about 1300 pM, atleast about 1400 pM, at least about 1500 pM, at least about 1600 pM, atleast about, or at least about 1700 pM, as measured by solution binding.In one specific aspect, the anti-CD73 antibody is a clone 10.3 antibodyand it binds to murine CD73 with a K_(D) of about 130 pM as measured bysolution binding. In another specific aspect, the anti-CD73 antibody isa clone 2C5 antibody and it binds to murine CD73 with a K_(D) of about1500 pM as measured by solution binding.

In some aspects, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or an antigen-binding fragment thereofbinds to cynomolgus CD73 with a K_(D) of a of at least about 60 pM, atleast about 70 pM, at least about 80 pM, at least about 90 pM, at leastabout 100 pM, at least about 110 pM, or at least about 120 pM, asmeasured by solution binding. In one specific aspect, the anti-CD73antibody is a clone 10.3 antibody and it binds to cynomolgus CD73 with aK_(D) of about 90 pM as measured by solution binding. In anotherspecific aspect, the anti-CD73 antibody is a clone 2C5 antibody and itbinds to cynomolgus CD73 with a K_(D) of about 100 pM as measured bysolution binding. In particular aspect, MEDI9447 binds CD73 with a K_(D)of about 1 × 10⁻¹², 5 × 10⁻¹², 10 × 10⁻¹², 100 × 10⁻¹², or 150 × 10⁻¹².

In some aspects, a CD73-binding molecule disclosed herein, e.g., ananti-CD73 antibody (for example, MEDI9447, a clone 10.3 antibody or aclone 2C5 antibody) or an antigen-binding fragment thereof can relieveAMP-mediated suppression of T cell division. In other aspects, aCD73-binding molecule disclosed herein, e.g., an anti-CD73 antibody (forexample, MEDI9447, a clone 10.3 antibody or a clone 2C5 antibody) or anantigen-binding fragment thereof can rescue ATP-induced T_(eff)suppression by T_(reg).

In some aspects, a CD73-binding molecule disclosed herein, e.g., ananti-CD73 antibody or antigen-binding fragment thereof (for example, aclone 10.3 antibody or a clone 2C5 antibody) can significantly inhibitsyngeneic tumor growth. In one aspect, the tumor is a non small celllung, ovarian, breast, head and neck, pancreatic, colorectal cancertumor, melanoma tumor, lymphoma tumor. In one aspect, the tumor is aCT26 mouse syngeneic CRC tumor, B16F10 melanoma tumor, EG7-OVA lymphomatumor, or a LL2 (Lewis Lung) tumor.. In some aspects, a CD73-bindingmolecule, e.g., an anti-CD73 antibody or antigen-binding fragmentthereof disclosed herein (for example, a clone 10.3 antibody or a clone2C5 antibody) can significantly inhibit tumor growth, wherein the tumoris unresponsive to therapy with anti-PD-1 and/or anti-PD-L1 and/oranti-PD-L2 and/or anti-CTLA-4 antibodies. In some aspects, aCD73-binding molecule disclosed herein, e.g., an anti-CD73 antibody orantigen binding fragment thereof (for example, a clone 10.3 antibody ora clone 2C5 antibody) can significantly inhibit tumor growth whenadministered at a concentration of about 1 mg/kg, about 2 mg/kg, about 3mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about8 mg/kg, about 9 mg/kg, or about 10 mg/kg.PD1.

In some aspects, a CD73-binding molecule disclosed herein, e.g., ananti-CD73 antibody or antigen-binding fragment thereof (for example, aclone 10.3 antibody or a clone 2C5 antibody) can be internalized afterbinding to cells. In some aspects, the CD73-binding molecule is anantibody drug conjugate (ADC).

V. Preparation of Anti-CD73 Antibodies and Antigen-Binding Fragments

Monoclonal anti-CD73 antibodies (e.g., MEDI9447, a clone 10.3 antibodyor a clone 2C5 antibody) and antigen-binding fragments thereof can beprepared using hybridoma methods, such as those described by Kohler andMilstein (1975) Nature 256:495. Using the hybridoma method, a mouse,hamster, or other appropriate host animal, is immunized as describedabove to elicit the production by lymphocytes of antibodies that willspecifically bind to an immunizing antigen. Lymphocytes can also beimmunized in vitro. Following immunization, the lymphocytes are isolatedand fused with a suitable myeloma cell line using, for example,polyethylene glycol, to form hybridoma cells that can then be selectedaway from unfused lymphocytes and myeloma cells. Hybridomas that producemonoclonal antibodies directed specifically against a chosen antigen asdetermined by immunoprecipitation, immunoblotting, or by an in vitrobinding assay (e.g. radioimmunoassay (RIA); enzyme-linked immunosorbentassay (ELISA)) can then be propagated either in in vitro culture usingstandard methods (Goding, Monoclonal Antibodies: Principles andPractice, Academic Press, 1986) or in vivo as ascites tumors in ananimal. The monoclonal antibodies can then be purified from the culturemedium or ascites fluid as described for polyclonal antibodies above.

Alternatively anti-CD73 monoclonal antibodies (for example, MEDI9447, aclone 10.3 antibody or a clone 2C5 antibody) and antigen-bindingfragments thereof can also be made using recombinant DNA methods asdescribed, for example, in U.S. Pat. No. 4,816,567. The polynucleotidesencoding a monoclonal antibody are isolated from mature B-cells orhybridoma cell, such as by RT-PCR using oligonucleotide primers thatspecifically amplify the genes encoding the heavy and light chains ofthe antibody, and their sequence is determined using conventionalprocedures. The isolated polynucleotides encoding the heavy and lightchains are then cloned into suitable expression vectors, which whentransfected into host cells such as E. coli cells, simian COS cells,Chinese hamster ovary (CHO) cells, or myeloma cells that do nototherwise produce immunoglobulin protein, monoclonal antibodies aregenerated by the host cells. Also, recombinant anti-CD73 monoclonalantibodies or antigen-binding fragments thereof of the desired speciescan be isolated from phage display libraries expressing CDRs of thedesired species as described (McCafferty et al., 1990, Nature,348:552-554; Clarkson et al., 1991, Nature, 352:624-628; and Marks etal., 1991, J. Mol. Biol., 222:581-597).

The polynucleotide(s) encoding an anti-CD73 antibody (for example, aclone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof can further be modified in a number of different manners usingrecombinant DNA technology to generate alternative antibodies. In someaspects, the constant domains of the light and heavy chains of, forexample, a mouse monoclonal antibody can be substituted (1) for thoseregions of, for example, a human antibody to generate a chimericantibody or (2) for a non-immunoglobulin polypeptide to generate afusion antibody. In some aspects, the constant regions are truncated orremoved to generate the desired antibody fragment of a monoclonalantibody. Site-directed or high-density mutagenesis of the variableregion can be used to optimize specificity, affinity, etc. of amonoclonal antibody.

In certain aspects, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or antigen-binding fragment thereof isa human antibody or antigen-binding fragment thereof. Human antibodiescan be directly prepared using various techniques known in the art.Immortalized human B lymphocytes immunized in vitro or isolated from animmunized individual that produce an antibody directed against a targetantigen can be generated (See, e.g., Cole et al., Monoclonal Antibodiesand Cancer Therapy, Alan R. Liss, p. 77 (1985); Boemer et al., 1991, J.Immunol., 147 (1):86-95; and U.S. Pat. 5,750,373).

Also, the anti-CD73 human antibody (for example, a clone 10.3 antibodyor a clone 2C5 antibody) or antigen-binding fragment thereof can beselected from a phage library, where that phage library expresses humanantibodies, as described, for example, in Vaughan et al., 1996, Nat.Biotech., 14:309-314, Sheets et al., 1998, Proc. Nat′l. Acad. Sci.,95:6157-6162, Hoogenboom and Winter, 1991, J. Mol. Biol., 227:381, andMarks et al., 1991, J. Mol. Biol., 222:581). Techniques for thegeneration and use of antibody phage libraries are also described inU.S. Pat. Nos. 5,969,108, 6,172,197, 5,885,793, 6,521,404; 6,544,731;6,555,313; 6,582,915; 6,593,081; 6,300,064; 6,653,068; 6,706,484; and7,264,963; and Rothe et al., 2007, J. Mol. Bio.,doi:10.1016/j.jmb.2007.12.018 (each of which is incorporated byreference in its entirety).

Affinity maturation strategies and chain shuffling strategies (Marks etal., 1992, Bio/Technology 10:779-783, incorporated by reference in itsentirety) are known in the art and can be employed to generate highaffinity human antibodies or antigen-binding fragments thereof.

In some aspects, the anti-CD73 monoclonal antibody (for example, a clone10.3 antibody or a clone 2C5 antibody) can be a humanized antibody.Methods for engineering, humanizing or resurfacing non-human or humanantibodies can also be used and are well known in the art. A humanized,resurfaced or similarly engineered antibody can have one or more aminoacid residues from a source that is non-human, e.g., but not limited to,mouse, rat, rabbit, non-human primate or other mammal. These non-humanamino acid residues are replaced by residues that are often referred toas “import” residues, which are typically taken from an “import”variable, constant or other domain of a known human sequence. Suchimported sequences can be used to reduce immunogenicity or reduce,enhance or modify binding, affinity, on-rate, off-rate, avidity,specificity, half-life, or any other suitable characteristic, as knownin the art. In general, the CDR residues are directly and mostsubstantially involved in influencing CD73 binding. Accordingly, part orall of the non-human or human CDR sequences are maintained while thenon-human sequences of the variable and constant regions can be replacedwith human or other amino acids.

Antibodies can also optionally be humanized, resurfaced, engineered orhuman antibodies engineered with retention of high affinity for the CD73antigen and other favorable biological properties. To achieve this goal,humanized (or human) or engineered anti-CD73 antibodies and resurfacedantibodies can be optionally prepared by a process of analysis of theparental sequences and various conceptual humanized and engineeredproducts using three-dimensional models of the parental, engineered, andhumanized sequences. Three-dimensional immunoglobulin models arecommonly available and are familiar to those skilled in the art.Computer programs are available which illustrate and display probablethree-dimensional conformational structures of selected candidateimmunoglobulin sequences. Inspection of these displays permits analysisof the likely role of the residues in the functioning of the candidateimmunoglobulin sequence, i.e., the analysis of residues that influencethe ability of the candidate immunoglobulin to bind its antigen, such asCD73. In this way, framework (FW) residues can be selected and combinedfrom the consensus and import sequences so that the desired antibodycharacteristic, such as increased affinity for the target antigen(s), isachieved.

Humanization, resurfacing or engineering of anti-CD73 antibodies (forexample, a clone 10.3 antibody or a clone 2C5 antibody) orantigen-binding fragments thereof can be performed using any knownmethod, such as but not limited to those described in, Jones et al.,Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988);Verhoeyen et al., Science 239:1534 (1988)), Sims et al., J. Immunol.151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carteret al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al., J.Immunol. 151:2623 (1993), U.S. Pat. Nos. 5,639,641, 5,723,323;5,976,862; 5,824,514; 5,817,483; 5,814,476; 5,763,192; 5,723,323;5,766,886; 5,714,352; 5,9,55,358; 6,204,023; 6,180,370; 6,331,431;5,693,762; 5,530,101; 5,585,089; 5,225,539; 4,816,567; 5,969,108;7,635,666; 7,723,270; 7,557,189; 7,538,195; and 7,342,110; InternationalApplication Nos. PCT/US98/16280; PCT/US91/05939; PCT/US94/01234;PCT/GB92/01755; International Patent Application Publication Nos.WO90/14443; WO90/14424; WO90/14430; and European Patent Publication No.EP 229246; each of which is entirely incorporated herein by reference,including the references cited therein.

Anti-CD73 humanized antibodies and antigen-binding fragments thereof canalso be made in transgenic mice containing human immunoglobulin locithat are capable upon immunization of producing the full repertoire ofhuman antibodies in the absence of endogenous immunoglobulin production.This approach is described in U.S. Pat. Nos. 5,545,807; 5,545,806;5,569,825; 5,625,126; 5,633,425; and 5,661,016.

In certain aspects an anti-CD73 antibody fragment (for example, afragment from a clone 10.3 antibody or from a clone 2C5 antibody) isprovided. Various techniques are known for the production of antibodyfragments. Traditionally, these fragments are derived via proteolyticdigestion of intact antibodies (for example Morimoto et al., 1993,Journal of Biochemical and Biophysical Methods 24:107-117; Brennan etal., 1985, Science, 229:81). In certain aspects, anti-CD73 antibodyfragments are produced recombinantly. Fab, Fv, and scFv antibodyfragments can all be expressed in and secreted from E. coli or otherhost cells, thus allowing the production of large amounts of thesefragments. Such anti-CD73 antibody fragments can also be isolated fromthe antibody phage libraries discussed above. The anti-CD73 antibodyfragments can also be linear antibodies as described in U.S. Pat. No.5,641,870. Other techniques for the production of antibody fragments,e.g., chemical synthesis, will be apparent to the skilled practitioner.

According to the present disclosure, techniques can be adapted for theproduction of single-chain antibodies specific to CD73 (see, e.g., U.S.Pat. No. 4,946,778). In addition, methods can be adapted for theconstruction of Fab expression libraries (see, e.g., Huse et al.,Science 246:1275-1281 (1989)) to allow rapid and effectiveidentification of monoclonal Fab fragments with the desired specificityfor CD73, or derivatives, fragments, analogs or homologs thereof.Antibody fragments can be produced by techniques in the art including,but not limited to: (a) a F(ab′)2 fragment produced by pepsin digestionof an antibody molecule; (b) a Fab fragment generated by reducing thedisulfide bridges of an F(ab′)2 fragment, (c) a Fab fragment generatedby the treatment of the antibody molecule with papain and a reducingagent, and (d) Fv fragments.

An anti-CD733 antibody (for example, a clone 10.3 antibody or a clone2C5 antibody) or an antigen-binding fragment thereof disclosed hereincan be modified in order to increase its serum half-life. This can beachieved, for example, by incorporation of a salvage receptor bindingepitope into the antibody or antibody fragment by mutation of theappropriate region in the antibody or antibody fragment or byincorporating the epitope into a peptide tag that is then fused to theantibody or antibody fragment at either end or in the middle (e.g., byDNA or peptide synthesis), or by YTE mutation. Other methods to increasethe serum half-life of an antibody or antigen-binding fragment thereof,e.g., conjugation to a heterologous molecule such as PEG are known inthe art.

Heteroconjugate anti-CD73 antibodies (for example, a clone 10.3 antibodyor a clone 2C5 antibody) and antigen-binding fragments thereof are alsowithin the scope of the present disclosure. Heteroconjugate antibodiesare composed of two covalently joined antibodies. Such antibodies have,for example, been proposed to target immune cells to unwanted cells(see, e.g., U.S. Pat. No. 4,676,980). It is contemplated that theheteroconjugate anti-CD73 antibodies (for example, a clone 10.3 antibodyor a clone 2C5 antibody) and antigen-binding fragments thereof can beprepared in vitro using known methods in synthetic protein chemistry,including those involving crosslinking agents. For example, immunotoxinscan be constructed using a disulfide exchange reaction or by forming athioether bond. Examples of suitable reagents for this purpose includeiminothiolate and methyl-4-mercaptobutyrimidate.

In certain aspects, the CD73-binding molecules disclosed herein, e.g.,antibodies (for example, a clone 10.3 antibody or a clone 2C5 antibody)or antigen binding fragments thereof can be combined with othertherapeutic agents (e.g., in a combination therapy) or they can be fused(e.g., genetically fused, to form a fusion protein) or conjugated (e.g.,chemically or enzymatically conjugated) to at least one heterologousmoiety. Thus, the CD73-binding molecules disclosed herein they can befused or conjugated to other therapeutic agents or toxins to formimmunoconjugates and/or fusion proteins. The present disclosure alsoprovides antibody-drug conjugates (ADC) comprising at least one of theCD73-binding molecules disclosed herein which has been derivatized orlinked (e.g., chemically or recombinantly) to another molecule (e.g., apeptide, small drug molecule, detectable molecule, etc.). In general,anti-CD73 antibodies or portions thereof are derivatized such that theirCD73 binding is not affected adversely by the derivatization orlabeling. Accordingly, the anti-CD73 antibodies and antibody portions ofthe instant disclosure are intended to include both intact and modifiedforms of the anti-CD73 binding molecules described herein. For example,an anti-CD73 binding molecule disclosed herein or Cd73-binding portionthereof can be functionally linked (by chemical coupling, geneticfusion, noncovalent association, or otherwise) to one or more othermolecular entities, such as a cytotoxic agent, a pharmaceutical agent, adetection agent, and/or a protein or peptide that can mediateassociation of the anti-CD73 binding molecule with another molecule(such as a streptavidin core region or a polyhistidine tag).

One type of derivatized molecule can be produced by crosslinking two ormore molecular entities, e.g., an anti-CD73 binding molecule disclosedherein and a therapeutic agent (e.g., a cytotoxin such as tubulysin orMEDI 1508). Suitable crosslinkers include those that areheterobifunctional, i.e., having two distinctly reactive groupsseparated by an appropriate spacer (e.g.,m-maleimidobenzoyl-N-hydroxysuccinimidc ester); or homobifunctional(e.g., disuccinimidyl suberate). Such crosslinkers are available, forexample, from Pierce Chemical Company, Rockford, II. Additionalbifunctional coupling agents include N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, iminothiolane (IT), bifunctional derivativesof imidoesters (such as dimethyl adipimidate HCL), active esters (suchas disuccinimidyl suberate), aldehydes (such as glutaraldehyde),bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine),bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene).

Another type of derivatized molecule can be produced by incorporating adetectable label. Useful detection agents include fluorescent compounds(e.g., fluorescein, fluorescein isothiocyanate, rhodamine,5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrin, lanthanidephosphors and the like), enzymes that are useful for detection (e.g.,horseradish peroxidase, β-galactosidase, luciferase, alkalinephosphatase, glucose oxidase and the like), epitopes recognized by asecondary reporter (e.g., leucine zipper pair sequences, binding sitesfor secondary antibodies, metal binding domains, epitope tags, etc.). Insome aspects, detectable labels can be attached by at least one spacerarm. Spacer arms can be of various lengths to reduce potential sterichindrance.

Anti-CD73 binding molecules disclosed herein can also be labeled with aradiolabeled amino acid. The radiolabel can be used for both diagnosticand therapeutic purposes. For instance, the radiolabel can be used todetect CD73-expressing cells by X-ray or other diagnostic techniquessuch as positron emission tomography (PET).

Further, the radiolabel can be used therapeutically as a toxin forCD73-expressing cells, such as those which cause unwanted immuneresponse. Examples of labels for polypeptides include, but are notlimited to, the following radioisotopes or radionuclides: ³H, ¹⁴C, ¹⁵N,³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I and ¹³¹I. In some aspects, the anti-CD73binding molecule can be labeled with a paramagnetic, radioactive, orfluorogenic ion that is detectable upon imaging. In some aspects, theparamagnetic ion is chromium (III), manganese (II), iron (III), iron(II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium(III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III),dysprosium (III), holmium (III) or erbium (III). In other aspects, theradioactive ion is iodine-123, technetium-99, indium-111, rhenium-188,rhenium-186, copper-67, iodine-131, yttrium-90, iodine-125,astatine-211, and gallium-67. In other aspects, the anti-Cd73 bindingmolecule is labeled with an X-ray imaging agent such as lanthanum (III),gold (III), lead (II), and bismuth (III). An anti-CD73 binding moleculesdisclosed herein can also be derivatized with a chemical group, forexample a polymer such as polyethylene glycol (PEG), a methyl group, anethyl group, or a carbohydrate group. These groups are useful to improvethe biological characteristics of the antibody, e.g., to increase serumhalf-life or to increase tissue binding.

The term “cytotoxic agent” as used herein is defined broadly and refersto a substance that inhibits or prevents the function of cells and/orcauses destruction of cells (cell death), and/or exertsanti-neoplastic/anti-proliferative effects. For example, the cytotoxicagent can prevent directly or indirectly the development, maturation, orspread of neoplastic tumor cells. The term includes also such agentsthat cause a cytostatic effect only and not a mere cytotoxic effect. Theterm includes chemotherapeutic agents as specified below, as well asother CD73 antagonists, anti-angiogenic agents, tyrosine kinaseinhibitors, protein kinase A inhibitors, members of the cytokine family,radioactive isotopes, and toxins such as enzymatically active toxins ofbacterial, fungal, plant or animal origin.

The term “chemotherapeutic agent” is a subset of the term “cytotoxicagent” comprising natural or synthetic chemical compounds. Examples ofchemotherapeutic or agents include alkylating agents, for example,nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and othercompounds with an alkylating action such as nitrosoureas, cisplatin anddacarbazine; antimetabolites, for example, folic acid, purine orpyrimidine antagonists; mitotic inhibitors, for example, Vinca alkaloidsand derivatives of podophyllotoxin; cytotoxic antibiotics andcamptothecin derivatives. Other chemotherapeutic agents are amifostine(ETHYOL®), cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine(nitrogen mustard), streptozocin, cyclophosphamide, carrnustine (BCNU),lomustine (CCNU), doxorubicin (ADRIAMYCIN®), doxorubicin lipo (DOXIL®),gemcitabine (GEMZAR®), daunorubicin, daunorubicin lipo (DAUNOXOME®),procarbazine, mitomycin, cytarabine, etoposide, methotrexate,5-fluorouracil (5-FU), vinblastine, vincristine, bleomycin, paclitaxel(TAXOL®), docetaxel (TAXOTERE®), aldesleukin, asparaginase, busulfan,carboplatin, cladribine, camptothecin, CPT-11,10-hydroxy-7-ethyl-camptothecin (SN38), gefitinib (IRESSA®),dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide,idarubicin, mesna, interferon alpha, interferon beta, irinotecan,mitoxantrone, topotecan, leuprolide, megestrol, melphalan,mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin,pipobroman, plicamycin, streptozocin, tamoxifen, teniposide,testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine,chlorambucil aromatase inhibitors, and combinations thereof.

For the purposes of the present disclosure, it should be appreciatedthat modified anti-CD73 antibodies or antigen-binding fragments thereofcan comprise any type of variable region that provides for theassociation of the antibody or polypeptide with CD73. In this regard,the variable region can comprise or be derived from any type of mammalthat can be induced to mount a humoral response and generateimmunoglobulins against the desired tumor associated antigen. As such,the variable region of the modified anti-CD73 antibodies orantigen-binding fragments thereof can be, for example, of human, murine,non-human primate (e.g., cynomolgus monkeys, macaques, etc.) or lupineorigin. In some aspects both the variable and constant regions of themodified anti-CD73 antibodies or antigen-binding fragments thereof arehuman. In other aspects the variable regions of compatible antibodies(usually derived from a non-human source) can be engineered orspecifically tailored to improve the binding properties or reduce theimmunogenicity of the molecule. In this respect, variable regions can behumanized or otherwise altered through the inclusion of imported aminoacid sequences.

In certain aspects, the variable domains in both the heavy and lightchains of an anti-CD73 antibody (for example, a clone 10.3 antibody or aclone 2C5 antibody) or antigen-binding fragment thereof are altered byat least partial replacement of one or more CDRs and, if necessary, bypartial framework region replacement and sequence changing. Although theCDRs can be derived from an antibody of the same class or even subclassas the antibody from which the framework regions are derived, it isenvisaged that the CDRs will be derived from an antibody of differentclass and in certain aspects from an antibody from a different species.It is not necessary to replace all of the CDRs with the complete CDRsfrom the donor variable region to transfer the antigen binding capacityof one variable domain to another. Rather, it is only necessary totransfer those residues that are necessary to maintain the activity ofthe antigen binding site. Given the explanations set forth in U.S. Pat.Nos. 5,585,089, 5,693,761 and 5,693,762, it will be well within thecompetence of those skilled in the art, either by carrying out routineexperimentation or by trial and error testing to obtain a functionalantibody with reduced immunogenicity.

Alterations to the variable region notwithstanding, those skilled in theart will appreciate that the modified anti-CD73 antibodies (for example,a modified clone 10.3 antibody or a modified clone 2C5 antibody) orantigen-binding fragments thereof will comprise antibodies (e.g.,full-length antibodies or immunoreactive fragments thereof) in which atleast a fraction of one or more of the constant region domains has beendeleted or otherwise altered so as to provide desired biochemicalcharacteristics such as increased tumor localization or reduced serumhalf-life when compared with an antibody of approximately the sameimmunogenicity comprising a native or unaltered constant region. In someaspects, the constant region of the modified antibodies will comprise ahuman constant region. Modifications to the constant region compatiblewith this the anti-CD73 molecules disclosed herein comprise additions,deletions or substitutions of one or more amino acids in one or moredomains. That is, the modified antibodies disclosed herein can comprisealterations or modifications to one or more of the three heavy chainconstant domains (CH1, CH2 or CH3) and/or to the light chain constantdomain (CL). In some aspects, modified constant regions wherein one ormore domains are partially or entirely deleted are contemplated. In someaspects, the modified antibodies will comprise domain deleted constructsor variants wherein the entire CH2 domain has been removed (ΔCH2constructs). In some aspects, the omitted constant region domain will bereplaced by a short amino acid spacer (e.g., 10 residues) that providessome of the molecular flexibility typically imparted by the absentconstant region.

Besides their configuration, it is known in the art that the constantregion mediates several effector functions. For example, binding of theC1 component of complement to antibodies activates the complementsystem. Activation of complement is important in the opsonisation andlysis of cell pathogens. The activation of complement also stimulatesthe inflammatory response and can also be involved in autoimmunehypersensitivity. Further, antibodies bind to cells via the Fc region,with a Fc receptor site on the antibody Fc region binding to a Fcreceptor (FcR) on a cell. There are a number of Fc receptors which arespecific for different classes of antibody, including IgG (gammareceptors), IgE (eta receptors), IgA (alpha receptors) and IgM (mureceptors). Binding of antibody to Fc receptors on cell surfacestriggers a number of important and diverse biological responsesincluding engulfment and destruction of antibody-coated particles,clearance of immune complexes, lysis of antibody-coated target cells bykiller cells (called antibody-dependent cell-mediated cytotoxicity, orADCC), release of inflammatory mediators, placental transfer and controlof immunoglobulin production.

In certain aspects, the anti-CD73 antibody (for example, a clone 10.3antibody or a clone 2C5 antibody) or an antigen-binding fragment thereofprovides for altered effector functions that, in turn, affect thebiological profile of the administered antibody or antigen-bindingfragment thereof. For example, the deletion or inactivation (throughpoint mutations or other means) of a constant region domain can reduceFc receptor binding of the circulating modified antibody therebyincreasing tumor localization. In other cases it can be that constantregion modifications, consistent with this disclosure, moderatecomplement binding and thus reduce the serum half-life and nonspecificassociation of a conjugated cytotoxin. Yet other modifications of theconstant region can be used to eliminate disulfide linkages oroligosaccharide moieties that allow for enhanced localization due toincreased antigen specificity or antibody flexibility. Similarly,modifications to the constant region in accordance with this disclosurecan easily be made using well known biochemical or molecular engineeringtechniques well within the purview of the skilled artisan.

In certain aspects, a CD73-binding molecule disclosed herein that is anantibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) orantigen-binding fragment thereof does not have one or more effectorfunctions. For instance, in some aspects, the antibody orantigen-binding fragment thereof has no antibody-dependent cellularcytotoxicity (ADCC) activity and/or no complement-dependent cytotoxicity(CDC) activity. In certain aspects, the anti-CD73 antibody or antigenbinding fragment thereof does not bind to an Fc receptor and/orcomplement factors. In certain aspects, the antibody or antigen-bindingfragment thereof has no effector function.

It will be noted that in certain aspects, the anti-CD73 modifiedantibodies or antigen-binding fragments thereof can be engineered tofuse the CH3 domain directly to the hinge region of the respectivemodified antibodies or fragments thereof. In other constructs it can bedesirable to provide a peptide spacer between the hinge region and themodified CH2 and/or CH3 domains. For example, compatible constructscould be expressed wherein the CH2 domain has been deleted and theremaining CH3 domain (modified or unmodified) is joined to the hingeregion with a 5-20 amino acid spacer. Such a spacer can be added, forinstance, to ensure that the regulatory elements of the constant domainremain free and accessible or that the hinge region remains flexible.However, it should be noted that amino acid spacers can, in some cases,prove to be immunogenic and elicit an unwanted immune response againstthe construct. Accordingly, in certain aspects, any spacer added to theconstruct will be relatively non-immunogenic, or even omittedaltogether, so as to maintain the desired biochemical qualities of themodified antibodies.

Besides the deletion of whole constant region domains, it will beappreciated that the anti-CD73 antibodies and antigen-binding fragmentsthereof of the present disclosure can be provided by the partialdeletion or substitution of a few or even a single amino acid. Forexample, the mutation of a single amino acid in selected areas of theCH2 domain can be enough to substantially reduce Fc binding and therebyincrease tumor localization. Similarly, it can be desirable to simplydelete that part of one or more constant region domains that control theeffector function (e.g., complement C1Q binding) to be modulated. Suchpartial deletions of the constant regions can improve selectedcharacteristics of the antibody or antigen-binding fragment thereof(e.g., serum half-life) while leaving other desirable functionsassociated with the subject constant region domain intact. Moreover, asalluded to above, the constant regions of the disclosed anti-CD73antibodies and antigen-binding fragments thereof can be modified throughthe mutation or substitution of one or more amino acids that enhancesthe profile of the resulting construct. In this respect it is possibleto disrupt the activity provided by a conserved binding site (e.g., Fcbinding) while substantially maintaining the configuration andimmunogenic profile of the modified antibody or antigen-binding fragmentthereof. Certain aspects can comprise the addition of one or more aminoacids to the constant region to enhance desirable characteristics suchas decreasing or increasing effector function or provide for morecytotoxin or carbohydrate attachment. In such aspects it can bedesirable to insert or replicate specific sequences derived fromselected constant region domains.

The present disclosure also provides variants and equivalents which aresubstantially homologous to the chimeric, humanized and human anti-CD73antibodies, or antigen-binding fragments thereof, set forth herein.These can contain, for example, conservative substitution mutations,i.e., the substitution of one or more amino acids by similar aminoacids. For example, conservative substitution refers to the substitutionof an amino acid with another within the same general class such as, forexample, one acidic amino acid with another acidic amino acid, one basicamino acid with another basic amino acid or one neutral amino acid byanother neutral amino acid. What is intended by a conservative aminoacid substitution is well known in the art.

An anti-CD73 antibody or antigen-binding fragment thereof can be furthermodified to contain additional chemical moieties not normally part ofthe protein. Those derivatized moieties can improve the solubility, thebiological half-life or absorption of the protein. The moieties can alsoreduce or eliminate any desirable side effects of the proteins and thelike. An overview for those moieties can be found in Remington’sPharmaceutical Sciences, 20th ed., Mack Publishing Co., Easton, PA(2000).

VI. Polynucleotides Encoding CD73-Binding Molecules

In certain aspects, the present disclosure encompasses polynucleotidescomprising nucleic acid sequences that encode a polypeptide thatspecifically binds CD73 or an antigen-binding fragment thereof. Forexample, the present disclosure provides a polynucleotide comprising anucleic acid sequence that encodes an anti-CD73 antibody (e.g., a clone10.3 antibody or a clone 2C5 antibody) or encodes an antigen-bindingfragment of such an antibody. The polynucleotides of the presentdisclosure can be in the form of RNA or in the form of DNA. DNA includescDNA, genomic DNA, and synthetic DNA; and can be double-stranded orsingle-stranded, and if single stranded can be the coding strand ornon-coding (anti-sense) strand.

In certain aspects, the polynucleotides are isolated. In certainaspects, the polynucleotides are substantially pure. In certain aspectsthe polynucleotides comprise the coding sequence for the maturepolypeptide fused in the same reading frame to a polynucleotide whichaids, for example, in expression and secretion of a polypeptide from ahost cell (e.g., a leader sequence which functions as a secretorysequence for controlling transport of a polypeptide from the cell). Thepolypeptide having a leader sequence is a preprotein and can have theleader sequence cleaved by the host cell to form the mature form of thepolypeptide. The polynucleotides can also encode for a CD73-bindingproprotein which is the mature protein plus additional 5′ amino acidresidues.

In certain aspects the polynucleotides comprise the coding sequence forthe mature CD73-binding polypeptide, e.g., an anti-CD73 antibody (e.g.,a clone 10.3 antibody or a clone 2C5 antibody) or an antigen-bindingfragment thereof fused in the same reading frame to a marker sequencethat allows, for example, for purification of the encoded polypeptide.For example, the marker sequence can be a hexa-histidine tag (SEQ ID NO:164) supplied by a pQE-9 vector to provide for purification of themature polypeptide fused to the marker in the case of a bacterial host,or the marker sequence can be a hemagglutinin (HA) tag derived from theinfluenza hemagglutinin protein when a mammalian host (e.g., COS-7cells) is used.

The present disclosure also provides variants of the describedpolynucleotides encoding, for example, CD73-binding fragments, analogs,and derivatives of the CD73-binding molecules disclosed herein (e.g., aclone 10.3 antibody or a clone 2C5 antibody).

The polynucleotide variants can contain alterations in the codingregions, non-coding regions, or both. In some aspects the polynucleotidevariants contain alterations which produce silent substitutions,additions, or deletions, but do not alter the properties or activitiesof the encoded polypeptide. In some aspects, nucleotide variants areproduced by silent substitutions due to the degeneracy of the geneticcode. Polynucleotide variants can be produced for a variety of reasons,e.g., to optimize codon expression for a particular host (change codonsin the human mRNA to those preferred by a bacterial host such as E.coli). Vectors and cells comprising the polynucleotides described hereinare also provided.

In some aspects a DNA sequence encoding a CD73-binding molecule, e.g.,an anti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5antibody) or an antigen-binding fragment thereof can be constructed bychemical synthesis using an oligonucleotide synthesizer. Sucholigonucleotides can be designed based on the amino acid sequence of thedesired polypeptide and selecting those codons that are favored in thehost cell in which the recombinant polypeptide of interest will beproduced. Standard methods can be applied to synthesize an isolatedpolynucleotide sequence encoding an isolated polypeptide of interest.For example, a complete amino acid sequence can be used to construct aback-translated gene. Further, a DNA oligomer containing a nucleotidesequence coding for the particular isolated polypeptide can besynthesized. For example, several small oligonucleotides coding forportions of the desired polypeptide can be synthesized and then ligated.The individual oligonucleotides typically contain 5′ or 3′ overhangs forcomplementary assembly.

Once assembled (by synthesis, site-directed mutagenesis or anothermethod), the polynucleotide sequences encoding a particular isolatedpolypeptide of interest will be inserted into an expression vector andoperatively linked to an expression control sequence appropriate forexpression of the protein in a desired host. Proper assembly can beconfirmed by nucleotide sequencing, restriction mapping, and expressionof a biologically active polypeptide in a suitable host. As is wellknown in the art, in order to obtain high expression levels of atransfected gene in a host, the gene must be operatively linked totranscriptional and translational expression control sequences that arefunctional in the chosen expression host.

In certain aspects, recombinant expression vectors are used to amplifyand express DNA encoding anti-CD73 antibodies (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen-binding fragments thereof.Recombinant expression vectors are replicable DNA constructs which havesynthetic or cDNA-derived DNA fragments encoding a polypeptide chain ofan anti-CD73 antibody or and antigen-binding fragment thereof,operatively linked to suitable transcriptional or translationalregulatory elements derived from mammalian, microbial, viral or insectgenes.

A transcriptional unit generally comprises an assembly of (1) a geneticelement or elements having a regulatory role in gene expression, forexample, transcriptional promoters or enhancers, (2) a structural orcoding sequence which is transcribed into mRNA and translated intoprotein, and (3) appropriate transcription and translation initiationand termination sequences, as described in detail below. Such regulatoryelements can include an operator sequence to control transcription. Theability to replicate in a host, usually conferred by an origin ofreplication, and a selection gene to facilitate recognition oftransformants can additionally be incorporated. DNA regions areoperatively linked when they are functionally related to each other. Forexample, DNA for a signal peptide (secretory leader) is operativelylinked to DNA for a polypeptide if it is expressed as a precursor whichparticipates in the secretion of the polypeptide; a promoter isoperatively linked to a coding sequence if it controls the transcriptionof the sequence; or a ribosome binding site is operatively linked to acoding sequence if it is positioned so as to permit translation.Structural elements intended for use in yeast expression systems includea leader sequence enabling extracellular secretion of translated proteinby a host cell. Alternatively, where recombinant protein is expressedwithout a leader or transport sequence, it can include an N-terminalmethionine residue. This residue can optionally be subsequently cleavedfrom the expressed recombinant protein to provide a final product.

The choice of expression control sequence and expression vector willdepend upon the choice of host. A wide variety of expression host/vectorcombinations can be employed. Useful expression vectors for eukaryotichosts, include, for example, vectors comprising expression controlsequences from SV40, bovine papilloma virus, adenovirus andcytomegalovirus. Useful expression vectors for bacterial hosts includeknown bacterial plasmids, such as plasmids from E. coli, including pCR1, pBR322, pMB9 and their derivatives, wider host range plasmids, suchas M13 and filamentous single-stranded DNA phages.

Suitable host cells for expression of a CD73-binding molecule, e.g., ananti-CD73 antibody (e.g., a clone 10.3 antibody or a clone 2C5 antibody)or antigen-binding fragment thereof include prokaryotes, yeast, insector higher eukaryotic cells under the control of appropriate promoters.Prokaryotes include gram negative or gram positive organisms, forexample E. coli or bacilli. Higher eukaryotic cells include establishedcell lines of mammalian origin as described below. Cell-free translationsystems could also be employed. Appropriate cloning and expressionvectors for use with bacterial, fungal, yeast, and mammalian cellularhosts are described by Pouwels et al. (Cloning Vectors: A LaboratoryManual, Elsevier, N.Y., 1985), the relevant disclosure of which ishereby incorporated by reference. Additional information regardingmethods of protein production, including antibody production, can befound, e.g., in U.S. Pat. Publication No. 2008/0187954, U.S. Pat. Nos.6,413,746, 6,660,501, and 7,932,087, each of which is herebyincorporated by reference herein in its entirety.

Various mammalian or insect cell culture systems can also beadvantageously employed to express recombinant CD73-binding molecules,e.g., anti-CD73 antibodies (e.g., a clone 10.3 antibody or a clone 2C5antibody) or antigen-binding fragments thereof. Expression ofrecombinant proteins in mammalian cells can be performed because suchproteins are generally correctly folded, appropriately modified andcompletely functional.

Examples of suitable mammalian host cell lines include HEK-293 andHEK-293T, the COS-7 lines of monkey kidney cells, described by Gluzman(Cell 23:175, 1981), and other cell lines including, for example, Lcells, C127, 3T3, Chinese hamster ovary (CHO), NSO, HeLa and BHK celllines. Mammalian expression vectors can comprise nontranscribed elementssuch as an origin of replication, a suitable promoter and enhancerlinked to the gene to be expressed, and other 5′ or 3′ flankingnontranscribed sequences, and 5′ or 3′ nontranslated sequences, such asnecessary ribosome binding sites, a polyadenylation site, splice donorand acceptor sites, and transcriptional termination sequences.Baculovirus systems for production of heterologous proteins in insectcells are reviewed by Luckow and Summers, BioTechnology 6:47 (1988).

CD73-binding molecules, e.g., anti-CD73 antibodies (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen-binding fragments thereofproduced by a transformed host can be purified according to any suitablemethod. Such standard methods include chromatography (e.g., ionexchange, affinity and sizing column chromatography), centrifugation,differential solubility, or by any other standard technique for proteinpurification. Affinity tags such as hexahistidine (SEQ ID NO: 164),maltose binding domain, influenza coat sequence andglutathione-S-transferase can be attached to the protein to allow easypurification by passage over an appropriate affinity column. Isolatedproteins can also be physically characterized using such techniques asproteolysis, nuclear magnetic resonance and x-ray crystallography.

For example, supernatants from systems which secrete recombinant proteininto culture media can be first concentrated using a commerciallyavailable protein concentration filter, for example, an AMICON® orMillipore PELLICON® ultrafiltration unit. Following the concentrationstep, the concentrate can be applied to a suitable purification matrix.Alternatively, an anion exchange resin can be employed, for example, amatrix or substrate having pendant diethylaminoethyl (DEAE) groups. Thematrices can be acrylamide, agarose, dextran, cellulose or other typescommonly employed in protein purification. Alternatively, a cationexchange step can be employed. Suitable cation exchangers includevarious insoluble matrices comprising sulfopropyl or carboxymethylgroups. Finally, one or more reversed-phase high performance liquidchromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media,e.g., silica gel having pendant methyl or other aliphatic groups, can beemployed to further purify an CD73-binding molecule (e.g., a clone 10.3antibody or a clone 2C5 antibody). Some or all of the foregoingpurification steps, in various combinations, can also be employed toprovide a homogeneous recombinant protein.

A recombinant CD73-binding protein, e.g., an anti-CD73 antibody (e.g., aclone 10.3 antibody or a clone 2C5 antibody) or antigen-binding fragmentthereof produced in bacterial culture can be isolated, for example, byinitial extraction from cell pellets, followed by one or moreconcentration, salting-out, aqueous ion exchange or size exclusionchromatography steps. High performance liquid chromatography (HPLC) canbe employed for final purification steps. Microbial cells employed inexpression of a recombinant protein can be disrupted by any convenientmethod, including freeze-thaw cycling, sonication, mechanicaldisruption, or use of cell lysing agents.

Methods known in the art for purifying antibodies and other proteinsalso include, for example, those described in U.S. Pat. Publication Nos.2008/0312425, 2008/0177048, and 2009/0187005, each of which is herebyincorporated by reference herein in its entirety.

In certain aspects, the CD73-binding molecule is a polypeptide that isnot an antibody. A variety of methods for identifying and producingnon-antibody polypeptides that bind with high affinity to a proteintarget are known in the art. See, e.g., Skerra, Curr. Opin. Biotechnol.,18:295-304 (2007), Hosse et al., Protein Science, 15:14-27 (2006), Gillet al., Curr. Opin. Biotechnol., 17:653-658 (2006), Nygren, FEBS J.,275:2668-76 (2008), and Skerra, FEBS J., 275:2677-83 (2008), each ofwhich is incorporated by reference herein in its entirety. In certainaspects, phage display technology can been used to identify/produce anCD73-binding polypeptide. In certain aspects, the polypeptide comprisesa protein scaffold of a type selected from the group consisting ofprotein A, a lipocalin, a fibronectin domain (e.g., a fibronectin domainsuch as a Tenascin-3 Fn III domain), an ankyrin consensus repeat domain,and thioredoxin.

VI. Treatment Methods Using Therapeutic Anti-CD73 Antibodies

The present disclosure provides methods directed to the use of anti-CD73binding molecules, e.g., antibodies, including antigen-bindingfragments, variants, and derivatives thereof (for example, a clone 10.3antibody or a clone 2C5 antibody), to treat patients having a diseaseassociated with CD73 expression or CD73-expressing cells, e.g., cancer.In some specific aspects, such cancer is lung cancer, breast cancer,ovarian cancer, colorectal cancer, bladder cancer, pancreatic cancer,renal cancer, stomach cancer, prostate cancer, breast cancer, lungcoloncancer, and lymphoma.

By “CD73-expressing cell” is meant a cell expressing CD73. CD73 can bemembrane-bound via glycosyl phosphatidylinositol-anchoring and also bepresent as a soluble protein. Methods for detecting CD73 expression incells and other suitable samples are well known in the art and include,but are not limited to immunohistochemistry, flow cytometry, Westernblot, ELISA, and the like.

Though the following discussion refers to diagnostic methods andtreatment of various diseases and disorders with an CD73-bindingmolecule of the present disclosure (e.g., a clone 10.3 antibody or aclone 2C5 antibody), the methods described herein are also applicable toany other anti-CD73 antibodies, and the antigen-binding fragments,variants, and derivatives (e.g., fusion proteins or conjugates) of theseanti-CD73 antibodies that retain the desired properties of the anti-CD73antibodies disclosed herein, e.g., being capable of specifically bindingCD73 and neutralizing its 5′-nucleotidase activity. In some aspects,CD73-binding molecules are human or humanized antibodies that do notmediate human ADCC, or are anti-CD73 antibodies that are engineered suchthat they do not mediate ADCC.

In some aspects, the CD73-binding molecule is a CD730010 antibody orantigen-binding fragment thereof, a clone 10.3 antibody or anantigen-binding fragment thereof, a CD730002 antibody or antigen-bindingfragment thereof, a clone 2C5 antibody or an antigen-binding fragmentthereof, or a CD73004 antibody or antigen-binding fragment thereof. Inother aspects, the CD73-binding molecule is a clone 10.3 mutantantibody. In some aspects, the CD73-binding molecule is a clone 10.3monoclonal antibody. In some aspects, the CD73-binding molecule is aclone 10.3 monoclonal antibody engineered to extend serum half-life. Inother aspects, the CD73-binding molecule is a clone 10.3 YTE mutantantibody. In other aspects, the CD73-binding molecule is a clone 2C5mutant antibody. In some aspects, the CD73-binding molecule is a clone2C5 monoclonal antibody. In some aspects, the CD73-binding molecule is aclone 2C5 monoclonal antibody engineered to extend serum half-life. Inother aspects, the CD73-binding molecule is a clone 2C5 YTE mutantantibody.

In one aspect, treatment includes the application or administration ofan anti-CD73 binding molecule, e.g., an antibody (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen binding fragment, variant,or derivative thereof of the current disclosure to a subject or patient,or application or administration of the anti-CD73 binding molecule to anisolated tissue or cell line from a subject or patient, where thesubject or patient has a disease, a symptom of a disease, or apredisposition toward a disease. In another aspect, treatment is alsointended to include the application or administration of apharmaceutical composition comprising the anti-CD73 binding molecule,e.g., an antibody or antigen binding fragment, variant, or derivativethereof of the current disclosure to a subject or patient, orapplication or administration of a pharmaceutical composition comprisingthe anti-CD73 binding molecule to an isolated tissue or cell line from asubject or patient, who has a disease, a symptom of a disease, or apredisposition toward a disease.

The anti-CD73 binding molecules, e.g., antibodies (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen-binding fragments,variants, or derivatives thereof of the present disclosure are usefulfor the treatment of various cancers. In one aspect, the presentdisclosure provides anti-CD73 binding molecules, e.g., antibodies (e.g.,a clone 10.3 antibody or a clone 2C5 antibody) or antigen-bindingfragments, variants, or derivatives thereof for use as a medicament, inparticular for use in the treatment or prophylaxis of cancer (e.g.,colon cancer, melanoma, breast cancer, lymphoma, or non-small cell lungcarcinoma Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’slymphoma, ovarian cancer, breast cancer, head and neck cancers, andpancreatic cancer.. In some aspect, the cancer presents a prometastaticphenotype. In some aspects, the cancer presenting a prometastaticphenotype is melanoma or breast cancer. In some aspects, the cancer is ametastatic cancer. In some aspects, the anti-CD73 binding moleculesdisclosed herein can trigger adaptive anti-tumor activity and/or inhibitmetastasis. In some particular aspects, the anti-CD73 binding moleculesdisclosed herein can inhibit metastasis in breast cancer.

In accordance with the methods of the present disclosure, at least oneanti-CD73 binding molecule, e.g., an antibody (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen binding fragment, variant,or derivative thereof as defined elsewhere herein is used to promote apositive therapeutic response with respect to cancer. The term “positivetherapeutic response” with respect to cancer treatment refers to animprovement in the disease in association with the activity of theseanti-CD73 binding molecules, e.g., antibodies or antigen-bindingfragments, variants, or derivatives thereof, and/or an improvement inthe symptoms associated with the disease. Thus, for example, animprovement in the disease can be characterized as a complete response.By “complete response” is intended an absence of clinically detectabledisease with normalization of any previously test results.Alternatively, an improvement in the disease can be categorized as beinga partial response. A “positive therapeutic response” encompasses areduction or inhibition of the progression and/or duration of cancer,the reduction or amelioration of the severity of cancer, and/or theamelioration of one or more symptoms thereof resulting from theadministration of an anti-CD73 binding molecule disclosed herein.

In specific aspects, such terms refer to one, two or three or moreresults following the administration of anti-CD73 binding moleculesdisclosed herein: (1) a stabilization, reduction or elimination of thecancer cell population; (2) a stabilization or reduction in cancergrowth; (3) an impairment in the formation of cancer; (4) eradication,removal, or control of primary, regional and/or metastatic cancer; (5) areduction in mortality; (6) an increase in disease-free, relapse-free,progression-free, and/or overall survival, duration, or rate; (7) anincrease in the response rate, the durability of response, or number ofpatients who respond or are in remission; (8) a decrease inhospitalization rate, (9) a decrease in hospitalization lengths, (10)the size of the cancer is maintained and does not increase or increasesby less than 10%, preferably less than 5%, preferably less than 4%,preferably less than 2%, and (12) an increase in the number of patientsin remission.

Clinical response can be assessed using screening techniques such asmagnetic resonance imaging (MRI) scan, x-radiographic imaging, computedtomographic (CT) scan, flow cytometry or fluorescence-activated cellsorter (FACS) analysis, histology, gross pathology, and blood chemistry,including but not limited to changes detectable by ELISA, RIA,chromatography, and the like. In addition to these positive therapeuticresponses, the subject undergoing therapy with the anti-CD73 bindingmolecule, e.g., an antibody or antigen-binding fragment, variant, orderivative thereof, can experience the beneficial effect of animprovement in the symptoms associated with the disease.

The anti-CD73 binding molecules, e.g., antibodies (e.g., a clone 10.3antibody or a clone 2C5 antibody) or antigen-binding fragments,variants, or derivatives thereof disclosed herein can be used incombination with any known therapies for cancer, including any agent orcombination of agents that are known to be useful, or which have beenused or are currently in use, for treatment of cancer, e.g., coloncancer, melanoma, breast cancer, lymphoma, non-small cell lung carcinomaHodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’s lymphoma,ovarian cancer, breast cancer, head and neck cancers, and pancreaticcancer). The second agent or combination of agents of the pharmaceuticalcombination formulation or dosing regimen preferably has complementaryactivities to the antibody or polypeptide of the present disclosure suchthat they do not adversely affect each other.

Anticancer agents include drugs used to treat malignancies, such ascancerous growths. Drug therapy can be used alone, or in combinationwith other treatments such as surgery or radiation therapy. Severalclasses of drugs can be used in cancer treatment, depending on thenature of the organ involved. For example, breast cancers are commonlystimulated by estrogens, and can be treated with drugs which inactivethe sex hormones. Similarly, prostate cancer can be treated with drugsthat inactivate androgens, the male sex hormone. Anti-cancer agents foruse in certain methods of the present disclosure include, among others,antibodies (e.g., antibodies which bind IGF-1R, antibodies which bindEGFR, antibodies which bind Her2, or antibodies which bind cMET), smallmolecules targeting IGF1R, small molecules targeting EGFR, smallmolecules targeting Her2, antimetabolites, alkylating agents,topoisomerase inhibitors, microtubule targeting agents, kinaseinhibitors, protein synthesis inhibitors, immunotherapeutic agents,hormonal therapies, glucocorticoids, aromatase inhibitors, mTORinhibitors, chemotherapeutic agents, Protein Kinase B inhibitors,Phosphatidylinositol 3-Kinase (PI3K) inhibitors, Cyclin Dependent Kinase(CDK) inhibitors, RLr9, CD289, enzyme inhibitors, anti-TRAIL, MEKinhibitors, etc.

In specific aspects the CD73-binding molecules disclosed herein, e.g.,antibodies (e.g., a clone 10.3 antibody or a clone 2C5 antibody) orantigen-binding fragments thereof, can be administered in combinationwith antibodies or antibody fragments targeting, for example, PD-1(programmed death 1 protein), its two ligands PD-L1 (programmed deathligand 1) and/or PD-L2, or CTLA-4 (cytotoxic T lymphocyte antigen 4protein). See, e.g., Stagg et al. PNAS 107:1547-1552 (2010); Jin et al.Cancer Res. 70(6): (2010); Allard et al. Clin. Cancer Res. 19:5626(2013) which are herein incorporated by reference in their entireties.In some aspects, the anti-CTLA-4 antibody is ipilimumab or an antigenbinding fragment thereof. In other aspects, the anti-CTLA-4 antibody istremelimumab (ticilimumab, CP-675,206) or an antigen binding fragmentthereof. In some aspects, the anti-PD-1 antibody is pembrolizumab(KEYTRUDA®, formerly lambrolizumab, also known as MK-3475) or anantigen-binding fragment thereof. In some aspects, the anti-PD-1antibody is nivolumab (BMS-936558, MDX-1106, ONO-4538, OPDIVA®) or anantigen-binding fragment thereof. In some aspects, the anti-PD-L1antibody is BMS-936559 or an antigen binding fragment thereof. In otheraspects, the anti-PD-L1 antibody is MPDL3280A . In other aspects, theanti-PD-1 antibody is AMP-224 (anti-PD-1 Fc fusion protein) or anantigen binding fragment thereof. In various aspects, the anti-PD-L1antibody is MEDI4736 or an antigen binding fragment thereof.

In some aspects, the CD73-binding molecules disclosed herein (forexample, a clone 10.3 antibody or a clone 2C5 antibody) can beadministered in combination with an anti-PD-1 or anti-PD-1 antibody. Invarious embodiments, the anti-CD73 antibody is administered at aconcentration of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg,about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18mg/kg, about 19 mg/kg, or about 20 mg/kg. In some aspects, theCD73-binding molecules disclosed herein (for example, a clone 10.3antibody or a clone 2C5 antibody) can be administered in combinationwith an anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody, wherein theanti-PD-1, anti-PD-L1, or anti-CTLA4 antibody is administered at aconcentration of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg,about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18mg/kg, about 19 mg/kg, or about 20 mg/kg. In some aspects, the anti-CD73antibody and the anti-PD-1 antibody, anti-PD-L1, or anti-CTLA4 areadministered at a ratio of about 1:1, 1:2, 1:3 or 1:4. In some aspects,the anti-CD73 antibody and the anti-PD-1, anti-PD-L1, or anti-CTLA4antibody are administered at a ratio of about 1:2. In an specificaspects, the concentration of anti-CD73 antibody (for example, a clone10.3 antibody or a clone 2C5 antibody) is about 10 mg/kg, and theconcentration of the anti-PD-1 antibody is about 20 mg/kg.In someaspects, the CD73-binding molecules disclosed herein (for example, aclone 10.3 antibody or a clone 2C5 antibody) can be administered incombination with an anti-PD-1 antibody. In some aspects, theadministration of a combination treatment comprising an CD73-bindingmolecule disclosed herein (for example, MEDI9447, a clone 10.3 antibodyor a clone 2C5 antibody) in combination with an anti-PD-1, anti-PD-L1,or anti-CTLA4 antibody, can increase survival by about 10%, about 20%,about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about90%, or about 100% compared to untreated subjects or subjects treatedwith a monotherapy (e.g., an anti-PD-1, anti-PD-L1, or anti-CTLA4antibody without an anti-CD73 antibody). In some aspects, theadministration of a combination treatment comprising an CD73-bindingmolecule disclosed herein (for example, a clone 10.3 antibody or a clone2C5 antibody) in combination with an anti-PD-1, anti-PD-L1, oranti-CTLA4 antibody, can increase survival by about 2-fold, about3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about8-fold, about 9-fold, or about 10-fold compared to untreated subjects orsubjects treated with a monotherapy (e.g., an anti-PD-1, anti-PD-L1, oranti-CTLA4 antibody without an anti-CD73 antibody).

Where the combined therapies comprise administration of an anti-CD73binding molecule in combination with administration of anothertherapeutic agent (e.g., an anti-PD-1, anti-PD-L1, or anti-CTLA4antibody), the methods disclosed herein encompass co-administration,using separate formulations or a single pharmaceutical formulation, andconsecutive administration in either order. In some aspects, theanti-CD73 antibodies described herein (for example, a clone 10.3antibody or a clone 2C5 antibody) are administered in combination withother drugs, wherein the antibody or antigen binding fragment, variant,or derivative thereof and the therapeutic agent(s) can be administeredsequentially, in either order, or simultaneously (i.e., concurrently orwithin the same time frame).

The combination therapy can provide “synergy” and prove “synergistic”,i.e., the effect achieved when the active ingredients used together isgreater than the sum of the effects that results from using thecompounds separately. A synergistic effect can be attained when theactive ingredients are: (1) co-formulated and administered or deliveredsimultaneously in a combined, unit dosage formulation; (2) delivered byalternation or in parallel as separate formulations; or (3) by someother regimen. When delivered in alternation therapy, a synergisticeffect can be attained when the compounds are administered or deliveredsequentially, e.g., by different injections in separate syringes. Ingeneral, during alternation therapy, an effective dosage of each activeingredient is administered sequentially, i.e., serially, whereas incombination therapy, effective dosages of two or more active ingredientsare administered together.

In other aspects, the CD73-binding molecules disclosed herein (forexample, a clone 10.3 antibody or a clone 2C5 antibody) can beadministered in combination with tyrosine kinase inhibitors. In someother specific aspects, the CD73-binding molecules disclosed herein canbe administered in combination with inhibitors of the tyrosine kinaseactivity associated with EGFR and/or HER2/neu, e.g., lapatinib. In someaspects, the CD73-binding molecules disclosed herein can be administeredin combination with antimitotic agents. In some specific aspects, theCD73-binding molecules disclosed herein can be administered incombination with agents that stabilize the mitotic spindle microtubuleassembly, e.g, paclitaxel or docetaxel.A further aspect is the use ofanti-CD73 binding molecules, e.g., antibodies or antigen-bindingfragments, variants, or derivatives thereof (for example, a clone 10.3antibody or a clone 2C5 antibody), for diagnostic monitoring of proteinlevels in tissue as part of a clinical testing procedure, e.g., todetermine the efficacy of a given treatment regimen. For example,detection can be facilitated by coupling the antibody to a detectablesubstance.

Examples of detectable substances include various enzymes, prostheticgroups, fluorescent materials, luminescent materials, bioluminescentmaterials, and radioactive materials. Examples of suitable enzymesinclude horseradish peroxidase, alkaline phosphatase, β-galactosidase,or acetylcholinesterase; examples of suitable prosthetic group complexesinclude streptavidin/biotin and avidin/biotin; examples of suitablefluorescent materials include umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin; an example of a luminescent material includesluminol; examples of bioluminescent materials include luciferase,luciferin, and aequorin; and examples of suitable radioactive materialinclude ¹²⁵I, ¹³¹I, ³⁵S, or³H.

VIII. Anti-CD73 Antibody Therapeutic Combinations and Co-Therapy

The present disclosure provides methods directed to the use oftherapeutic combinations comprising anti-CD73 binding molecules, e.g.,antibodies, including antigen binding fragments, variants, andderivatives thereof (for example, a clone 10.3 antibody or a clone 2C5antibody), to treat patients having cancer (including colon cancer,melanoma, breast cancer, lymphoma, non-small cell lung carcinomaHodgkin’s lymphoma, non-Hodgkin’s lymphoma, Burkitt’s lymphoma, ovariancancer, breast cancer, head and neck cancers, and pancreatic cancer).

Though the following discussion refers to therapeutic combinationsfeaturing a CD73-binding molecule of the present disclosure (e.g., aclone 10.3 antibody or a clone 2C5 antibody), the methods describedherein are also applicable to any other anti-CD73 antibodies, and theantigen binding fragments, variants, and derivatives (e.g., fusionproteins or conjugates) of these anti-CD73 antibodies that retain thedesired properties of the anti-CD73 antibodies disclosed herein, e.g.,being capable of specifically binding CD73 and neutralizing its5′-nucleotidase activity. In some aspects, CD73-binding molecules arehuman or humanized antibodies that do not mediate human ADCC, or areanti-CD73 antibodies that are engineered such that they do not mediateADCC.

Treatment of a patient with a solid tumor using a combination of theinvention, such as an anti-CD73 antibody, or antigen binding fragmentthereof, in combination with an anti-PD-1, anti-PD-L1, or anti-CTLA4antibody, or antigen binding fragments thereof, can result in anadditive or synergistic effect. As used herein, the term “synergistic”refers to a combination of therapies (e.g., a combination of ananti-CD73 antibody (e.g., MEDI9447) and an anti-PD-1, anti-PD-L1, oranti-CTLA4 antibody, which is more effective than the additive effectsof the single therapies.

A synergistic effect of a combination of therapies (e.g., a combinationof an anti-CD73 antibody (e.g., MEDI9447) and an anti-PD-1, anti-PD-L1,or anti-CTLA4 antibody permits the use of lower dosages of one or moreof the therapeutic agents and/or less frequent administration of saidtherapeutic agents to a patient with a solid tumor. The ability toutilize lower dosages of therapeutic agents and/or to administer saidtherapies less frequently reduces the toxicity associated with theadministration of said therapies to a subject without reducing theefficacy of said therapies in the treatment of a solid tumor. Inaddition, a synergistic effect can result in improved efficacy oftherapeutic agents in the management, treatment, or amelioration of ansolid tumor. The synergistic effect of a combination of therapeuticagents can avoid or reduce adverse or unwanted side effects associatedwith the use of either single therapy.

In co-therapy, a combination of an anti-CD73 antibody (e.g., MEDI9447)or antigen binding fragment thereof and anti-PD-1, anti-PD-L1, oranti-CTLA4 antibody, or antigen binding fragments thereof, can beoptionally included in the same pharmaceutical composition, or may beincluded in a separate pharmaceutical composition. In this latter case,the pharmaceutical composition comprising an anti-CD73 antibody (e.g.,MEDI9447) or antigen binding fragment thereof is suitable foradministration prior to, simultaneously with, or followingadministration of the pharmaceutical composition comprising ananti-PD-1, anti-PD-L1, or anti-CTLA4 antibody, or antigen bindingfragment thereof. In certain instances, the anti-CD73 antibody (e.g.,MEDI9447) or antigen binding fragment thereof and an anti-PD-1,anti-PD-L1, or anti-CTLA4 antibody is administered at overlapping timesin a separate composition.

An anti-CD73 antibody (e.g., MEDI9447) or antigen binding fragmentthereof and an anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody, or antigenbinding fragment thereof, can be administered only once or infrequentlywhile still providing benefit to the patient. In further aspects thepatient is administered additional follow-on doses. Follow-on doses canbe administered at various time intervals depending on the patient’sage, weight, clinical assessment, tumor burden, and/or other factors,including the judgment of the attending physician.

The methods provided herein can decrease or retard tumor growth. In someaspects the reduction or retardation can be statistically significant. Areduction in tumor growth can be measured by comparison to the growth ofpatient’s tumor at baseline, against an expected tumor growth, againstan expected tumor growth based on a large patient population, or againstthe tumor growth of a control population. In other embodiments, themethods of the invention increase survival.

IX. Anti-PD-L1 Antibodies

Antibodies that specifically bind and inhibit PD-L1 activity (e.g.,binding to PD-1 and/or CD80) are useful for the treatment of tumors.B7-H1, also known as PD-L1, is a type I transmembrane protein ofapproximately 53 kDa in size. In humans B7-H1 is expressed on a numberof immune cell types including activated and anergic/exhausted T cells,on naïve and activated B cells, as well as on myeloid dendritic cells(DC), monocytes and mast cells. It is also expressed on non-immune cellsincluding islets of the pancreas, Kupffer cells of the liver, vascularendothelium and selected epithelia, for example airway epithelia andrenal tubule epithelia, where its expression is enhanced duringinflammatory episodes. B7-H1 expression is also found at increasedlevels on a number of tumors including, but not limited to breast,colon, colorectal, lung, renal, including renal cell carcinoma, gastric,bladder, non-small cell lung cancer (NSCLC), hepatocellular cancer(HCC), and pancreatic cancer, as well as melanoma.

B7-H1 is known to bind two alternative ligands, the first of these,PD-1, is a 50-55 kDa type I transmembrane receptor that was originallyidentified in a T cell line undergoing activation-induced apoptosis.PD-1 is expressed on activated T cells, B cells, and monocytes, as wellas other cells of the immune system and binds both B7-H1 (PD-L1) and therelated B7-DC (PD-L2). The second is the B7 family member B7-1, which isexpressed on activated T cells, B cells, monocytes and antigenpresenting cells.

Signaling via the PD-1/B7-H1 axis is believed to serve important,non-redundant functions within the immune system, by negativelyregulating T cell responses. B7-H1 expression on tumor cells is believedto aid tumors in evading detection and elimination by the immune system.B7-H1 functions in this respect via several alternative mechanismsincluding driving exhaustion and anergy of tumor infiltrating Tlymphocytes, stimulating secretion of immune repressive cytokines intothe tumor micro-environment, stimulating repressive regulatory T cellfunction and protecting B7-H1 expressing tumor cells from lysis by tumorcell specific cytotoxic T cells.

MEDI4736 is an exemplary anti-PD-L1 antibody that is selective for B7-H1and blocks the binding of B7-H1 to the PD-1 and CD80 receptors. MEDI4736can relieve B7-H1-mediated suppression of human T-cell activation invitro and inhibits tumor growth in a xenograft model via a T-celldependent mechanism. Other agents that could be used include agents thatinhibit PD-L1 and/or PD-1 (AB or other).

Information regarding MEDI4736 (or fragments thereof) for use in themethods provided herein can be found in US20130034559 / US 8779108 andUS20140356353, the disclosures of each of which are incorporated hereinby reference in their entireties. The fragment crystallizable (Fc)domain of MEDI4736 contains a triple mutation in the constant domain ofthe IgG1 heavy chain that reduces binding to the complement componentC1q and the Fcγ receptors responsible for mediating antibody-dependentcell-mediated cytotoxicity (ADCC).

MEDI4736 and antigen binding fragments thereof for use in the methodsprovided herein comprises a heavy chain and a light chain or a heavychain variable region and a light chain variable region. In a specificaspect, MEDI4736 or an antigen binding fragment thereof for use in themethods provided herein comprises a light chain variable regioncomprising the amino acid sequence of SEQ ID NO: 130 and a heavy chainvariable region comprising the amino acid sequence of SEQ ID NO: 131. Ina specific aspect, MEDI4736 or an antigen binding fragment thereof foruse in the methods provided herein comprises a heavy chain variableregion and a light chain variable region, wherein the heavy chainvariable region comprises the Kabat-defined CDR1, CDR2, and CDR3sequences of SEQ ID NOs: 132-134, and wherein the light chain variableregion comprises the Kabat-defined CDR1, CDR2, and CDR3 sequences of SEQID NOs:135-137. Those of ordinary skill in the art would easily be ableto identify Chothia-defined, Abm-defined or other CDR definitions knownto those of ordinary skill in the art. In a specific aspect, MEDI4736 oran antigen binding fragment thereof for use in the methods providedherein comprises the variable heavy chain and variable light chain CDRsequences of the 2.14H9OPT antibody as disclosed in US20130034559 / US8779108 and US20140356353, the disclosures of each of which areincorporated herein by reference in their entireties.

X. Anti-CTLA4 Antibodies

Accordingly, in one embodiment therapeutic combinations of the inventioncomprise a CTLA4 blocking antibody (e.g., Tremelimumab) and/orantibodies that reduce PD1/PD-L1 interactions. Two T cell modulatorypathways receiving significant attention to date signal throughcytotoxic T lymphocyte antigen-4 (CTLA4, CD152) and programmed deathligand 1 (PD-L1, also known as B7H-1 or CD274).

CTLA4 is expressed on activated T cells and serves as a co-inhibitor tokeep T cell responses in check following CD28-mediated T cellactivation. CTLA4 is believed to regulate the amplitude of the earlyactivation of naïve and memory T cells following TCR engagement and tobe part of a central inhibitory pathway that affects both antitumorimmunity and autoimmunity. CTLA4 is expressed primarily on T cells, andthe expression of its ligands CD80 (B71) and CD86 (B7.2), is largelyrestricted to antigen-presenting cells, T cells, and other immunemediating cells. Antagonistic anti-CTLA4 antibodies that block the CTLA4signaling pathway have been reported to enhance T cell activation. Onesuch antibody, ipilimumab, was approved by the FDA in 2011 for thetreatment of metastatic melanoma. Another anti-CTLA4 antibody,tremelimumab, was tested in phase III trials for the treatment ofadvanced melanoma but did not significantly increase the overallsurvival of patients compared to the standard of care (temozolomide ordacarbazine) at that time.

Information regarding tremelimumab (or antigen binding fragmentsthereof) for use in the methods provided herein can be found in US6,682,736 (where it is referred to as 11.2.1), the disclosure of whichis incorporated herein by reference in its entirety. Tremelimumab (alsoknown as CP-675,206, CP-675, CP-675206, and ticilimumab) is a human IgG2monoclonal antibody that is highly selective for CTLA4 and blocksbinding of CTLA4 to CD80 (B7.1) and CD86 (B7.2). It has been shown toresult in immune activation in vitro and some patients treated withtremelimumab have shown tumor regression.

Tremelimumab for use in the methods provided herein comprises a heavychain and a light chain or a heavy chain variable region and a lightchain variable region. In a specific aspect, tremelimumab or an antigenbinding fragment thereof for use in the methods provided hereincomprises a light chain variable region and a heavy chain variableregion. In a specific aspect, tremelimumab or an antigen bindingfragment thereof for use in the methods provided herein comprises aheavy chain variable region and a light chain variable region identifiedherein. Those of ordinary skill in the art would easily be able toidentify Chothia-defined, Abm-defined or other CDR definitions known tothose of ordinary skill in the art. In a specific aspect, tremelimumabor an antigen binding fragment thereof for use in the methods providedherein comprises the variable heavy chain and variable light chain CDRsequences of the 11.2.1 antibody as disclosed in US 6,682,736, which isherein incorporated by reference in its entirety.

XI. VII. Pharmaceutical Compositions and Methods of Administration

Methods of preparing and administering anti-CD73 binding molecules,e.g., antibodies, or antigen-binding fragments, variants, or derivativesthereof (e.g., a clone 10.3 antibody or a clone 2C5 antibody) to asubject in need thereof are well known to or are readily determined bythose skilled in the art. The route of administration of the anti-CD73binding molecule, e.g., an antibody, or antigen-binding fragment,variant, or derivative thereof can be, for example, oral, parenteral, byinhalation or topical. The term parenteral as used herein includes,e.g., intravenous, intraarterial, intraperitoneal, intramuscular,subcutaneous, rectal, or vaginal administration. However, in othermethods compatible with the teachings herein, anti-CD73 bindingmolecules, e.g., antibodies, or antigen-binding fragments, variants, orderivatives thereof, of the present disclosure can be delivered directlyto the site of the adverse cellular population thereby increasing theexposure of the diseased tissue to the therapeutic agent.

As discussed herein, anti-CD73 binding molecules, e.g., antibodies, orantigen-binding fragments, variants, or derivatives thereof of thepresent disclosure (for example, a clone 10.3 antibody or a clone 2C5antibody) can be administered in a pharmaceutically effective amount forthe in vivo treatment of CD73-expressing cell-mediated diseases such ascertain types of cancers.

Methods of preparing and administering therapeutic combinationscomprising anti-CD73 binding molecules, e.g., antibodies, or antigenbinding fragments, variants, or derivatives thereof (e.g., a clone 10.3antibody or a clone 2C5 antibody) in combination with an anti-PD-1,anti-PD-L1, and/or anti-CTLA4 antibody, or antigen binding fragmentsthereof to a subject in need thereof are well known to or are readilydetermined by those skilled in the art. The route of administration ofthe combination thereof can be, for example, oral, parenteral, byinhalation or topical. The term parenteral as used herein includes,e.g., intravenous, intraarterial, intraperitoneal, intramuscular,subcutaneous, rectal, or vaginal administration. However, in othermethods compatible with the teachings herein, a combination of thepresent disclosure can be delivered directly to the site of the adversecellular population thereby increasing the exposure of the diseasedtissue to the therapeutic agent. As discussed herein, a combination ofan anti-CD73 antibody (e.g., MEDI9447) and an anti-PD-1, anti-PD-L1,and/or anti-CTLA4 antibody can be administered in a pharmaceuticallyeffective amount for the in vivo treatment of CD73-expressingcell-mediated diseases such as certain types of cancers.

The pharmaceutical compositions used in this disclosure can comprisepharmaceutically acceptable carriers, including, e.g., water, ionexchangers, proteins, buffer substances, and salts. Preservatives andother additives can also be present. The carrier can be a solvent ordispersion medium. Suitable formulations for use in therapeutic methodsdisclosed herein are described in Remington’s Pharmaceutical Sciences(Mack Publishing Co.) 16th ed. (1980).

In any case, sterile injectable solutions can be prepared byincorporating a therapeutic combination of the invention an activecompound (e.g., an anti-CD73 antibody, or antigen-binding fragment,variant, or derivative thereof, for example a clone 10.3 antibody or aclone 2C5 antibody, by itself or in combination with other activeagents) in the required amount in an appropriate solvent followed byfiltered sterilization. Further, the preparations can be packaged andsold in the form of a kit. Such articles of manufacture can have labelsor package inserts indicating that the associated compositions areuseful for treating a subject suffering from, or predisposed to adisease or disorder.

Parenteral formulations can be a single bolus dose, an infusion or aloading bolus dose followed with a maintenance dose. These compositionscan be administered at specific fixed or variable intervals, e.g., oncea day, or on an “as needed” basis.

The composition can be administered as a single dose, multiple doses orover an established period of time in an infusion. Dosage regimens alsocan be adjusted to provide the optimum desired response (e.g., atherapeutic or prophylactic response).

Therapeutically effective doses of the compositions of the presentdisclosure, for treatment of CD73-expressing cell-mediated diseases,such as certain types of cancers including e.g., colon cancer, melanoma,breast cancer, lymphoma, non-small cell lung carcinoma Hodgkin’slymphoma, non-Hodgkin’s lymphoma, and Burkitt’s lymphoma, ovariancancer, breast cancer, head and neck cancers, and pancreatic cancer,vary depending upon many different factors, including means ofadministration, target site, physiological state of the patient, whetherthe patient is human or an animal, other medications administered, andwhether treatment is prophylactic or therapeutic. Usually, the patientis a human, but non-human mammals including transgenic mammals can alsobe treated. Treatment dosages can be titrated using routine methodsknown to those of skill in the art to optimize safety and efficacy.

The amount of at least one anti-CD73 binding molecule, e.g., antibody orbinding fragment, variant, or derivative thereof (for example, a clone10.3 antibody or a clone 2C5 antibody) or therapeutic combination of theinvention to be administered is readily determined by one of ordinaryskill in the art without undue experimentation given the disclosure ofthe present disclosure. Factors influencing the mode of administrationand the respective amount of at least one anti-CD73 binding molecule,e.g., antibody, antigen binding fragment, variant or derivative thereof,or therapeutic combination of the invention, include, but are notlimited to, the severity of the disease, the history of the disease, andthe age, height, weight, health, and physical condition of theindividual undergoing therapy. Similarly, the amount of anti-CD73binding molecule, e.g., antibody, or fragment, variant, or derivativethereof, or therapeutic combination of the invention, to be administeredwill be dependent upon the mode of administration and whether thesubject will undergo a single dose or multiple doses of this agent.

The present disclosure also provides for the use of an anti-CD73 bindingmolecule, e.g., an antibody or antigen binding fragment, variant, orderivative thereof (for example, a clone 10.3 antibody or a clone 2C5antibody), or therapeutic combination of the invention, in themanufacture of a medicament for treating a type of cancer, including,e.g., colon cancer, melanoma, breast cancer, lymphoma, non-small celllung carcinoma Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Burkitt’slymphoma, ovarian cancer, breast cancer, head and neck cancers, andpancreatic cancer.

The disclosure also provides for the use of an anti-CD73 bindingmolecule, e.g., antibody, or antigen-binding fragment, variant, orderivative thereof (for example, a clone 10.3 antibody or a clone 2C5antibody), in the manufacture of a medicament for treating a subject fortreating a type of cancer. In certain aspects, the medicament is used ina subject that has been pretreated with at least one other therapy.

By “pretreated” or “pretreatment” is intended the subject has receivedone or more other therapies (e.g., been treated with at least one otheranti-cancer therapy) prior to receiving the medicament comprising theanti-CD73 binding molecule, e.g., antibody or antigen-binding fragment,variant, or derivative thereof (for example, a clone 10.3 antibody or aclone 2C5 antibody). It is not necessary that the subject was aresponder to pretreatment with the prior therapy or therapies. Thus, thesubject that receives the medicament comprising the anti-CD73 bindingmolecule, e.g., an antibody or antigen-binding fragment, variant, orderivative thereof could have responded, or could have failed to respondto pretreatment with the prior therapy, or to one or more of the priortherapies where pretreatment comprised multiple therapies.

The present disclosure also provides for the co-administration of ananti-CD73 binding molecule, e.g., antibody, or antigen-binding fragment,variant, or derivative thereof (for example, a clone 10.3 antibody or aclone 2C5 antibody) and at least one other therapy. The anti-CD73antibody and the at least one other therapy can be co-administeredtogether in a single composition or can be co-administered together atthe same time or overlapping times in separate compositions. In someaspects, the anti-CD73 antibody can be co-administered with, forexample, an antibody that targets PD-1 (programmed death 1 protein Thepresent disclosure also provides for the use of an anti-CD73 bindingmolecule, e.g., antibody, or antigen-binding fragment, variant, orderivative thereof (for example, a clone 10.3 antibody or a clone 2C5antibody), in the manufacture of a medicament for treating a subject fortreating cancer, wherein the anti-CD73 binding molecule is administeredbefore a subject has been treated with at least one other therapy.

VIII. Diagnostics

The present disclosure further provides diagnostic methods useful duringdiagnosis of CD73-expressing cell-mediated diseases such as certaintypes of cancer, which involves measuring the expression level of CD73protein in tissue or other cells or body fluid from an individual andcomparing the measured expression level with a standard CD73 expressionlevel in normal tissue or body fluid, whereby an increase in theexpression level compared to the standard is indicative of a disorder.

The anti-CD73 antibodies disclosed herein and antigen-binding fragments,variants, and derivatives thereof (e.g., a clone 10.3 antibody or aclone 2C5 antibody), can be used to assay CD73 protein levels in abiological sample using classical immunohistological methods known tothose of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol.101:976-985 (1985); Jalkanen et al., J. Cell Biol. 105:3087-3096(1987)). Other antibody-based methods useful for detecting CD73 proteinexpression include immunoassays, such as the enzyme linked immunosorbentassay (ELISA), immunoprecipitation, or Western blotting. Suitable assaysare described in more detail elsewhere herein.

By “assaying the expression level of CD73 polypeptide” is intendedqualitatively or quantitatively measuring or estimating the level ofCD73 polypeptide in a first biological sample either directly (e.g., bydetermining or estimating absolute protein level) or relatively (e.g.,by comparing to the disease associated polypeptide level in a secondbiological sample). CD73 polypeptide expression level in the firstbiological sample can be measured or estimated and compared to astandard CD73 polypeptide level, the standard being taken from a secondbiological sample obtained from an individual not having the disorder orbeing determined by averaging levels from a population of individualsnot having the disorder. As will be appreciated in the art, once the“standard” CD73 polypeptide level is known, it can be used repeatedly asa standard for comparison.

By “biological sample” is intended any biological sample obtained froman individual, cell line, tissue culture, or other source of cellspotentially expressing CD73. Methods for obtaining tissue biopsies andbody fluids from mammals are well known in the art.

IX. Kits Comprising CD73-Binding Molecules

The present disclosure also provides kits that comprise at least one ofthe CD73-binding molecules described herein, e.g., anti-CD73 antibodiesor antigen-binding fragment thereof, variants, or derivatives of themolecules disclosed herein (e.g., a clone 10.3 antibody or a clone 2C5antibody), that can be used to perform the methods described herein. Incertain aspects, a kit comprises at least one purified anti-CD73antibody or an antigen-binding fragment thereof in one or morecontainers. In some aspects, the kits contain all of the componentsnecessary and/or sufficient to perform a detection assay, including allcontrols, directions for performing assays, and any necessary softwarefor analysis and presentation of results. One skilled in the art willreadily recognize that the disclosed CD73-binding molecule, e.g., ananti-CD73 antibody or antigen binding fragment thereof of the presentdisclosure (e.g., a clone 10.3 antibody or a clone 2C5 antibody) can bereadily incorporated into one of the established kit formats which arewell known in the art.

X. Immunoassays

Anti-CD73 binding molecules disclosed herein, e.g., anti-CD73 antibodiesor antigen-binding fragments thereof, variants, or derivatives of themolecules disclosed herein (e.g., a clone 10.3 antibody or a clone 2C5antibody), can be assayed for immunospecific binding by any method knownin the art. The immunoassays that can be used include but are notlimited to competitive and non-competitive assay systems usingtechniques such as Western blots, radioimmunoassays, ELISA (enzymelinked immunosorbent assay), “sandwich” immunoassays,immunoprecipitation assays, precipitin reactions, gel diffusionprecipitin reactions, immunodiffusion assays, agglutination assays,complement-fixation assays, immunoradiometric assays, fluorescentimmunoassays, protein A immunoassays, to name but a few. Such assays areroutine and well known in the art (see, e.g., Ausubel et al., eds,(1994) Current Protocols in Molecular Biology (John Wiley & Sons, Inc.,NY) Vol. 1, which is incorporated by reference herein in its entirety).

CD73-binding molecules, e.g., anti-CD73 antibodies or antigen-bindingfragments thereof, and their variants or derivatives (for example, aclone 10.3 antibody or a clone 2C5 antibody), can be employedhistologically, as in immunofluorescence, immunoelectron microscopy ornon-immunological assays, for in situ detection of CD73 or conservedvariants or peptide fragments thereof. In situ detection can beaccomplished by removing a histological specimen from a patient, andapplying thereto a labeled CD73-binding molecule, e.g., an anti-CD73antibody or antigen-binding fragment thereof, variant, or derivativethereof, preferably applied by overlaying the labeled CD73-bindingmolecule (e.g., and antibody or fragment) onto a biological sample.Through the use of such a procedure, it is possible to determine notonly the presence of CD73, or conserved variants or peptide fragments,but also its distribution in the examined tissue. Using the presentdisclosure, those of ordinary skill will readily perceive that any of awide variety of histological methods (such as staining procedures) canbe modified in order to achieve such in situ detection.

The binding activity of a given lot of CD73-binding molecule, e.g.,anti-CD73 antibody (for example, a clone 10.3 antibody or a clone 2C5antibody) or antigen-binding fragment thereof, variant, or derivativethereof can be determined according to well-known methods. Those skilledin the art will be able to determine operative and optimal assayconditions for each determination by employing routine experimentation.

Methods and reagents suitable for determination of bindingcharacteristics of an isolated CD73-binding molecule, e.g., anti-CD73antibody (for example, a clone 10.3 antibody or a clone 2C5 antibody) orantigen-binding fragment thereof, variant, or an altered/mutantderivative thereof, are known in the art and/or are commerciallyavailable. Equipment and software designed for such kinetic analyses arecommercially available (e.g., BIAcore, BIAevaluation software,GEHealthcare; KinExa Software, Sapidyne Instruments).

The practice of the present disclosure will employ, unless otherwiseindicated, conventional techniques of cell biology, cell culture,molecular biology, transgenic biology, microbiology, recombinant DNA,and immunology, which are within the skill of the art. Such techniquesare explained fully in the literature. See, for example, Sambrook etal., ed. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; ColdSpring Harbor Laboratory Press); Sambrook et al., ed. (1992) MolecularCloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); D.N. Glover ed., (1985) DNA Cloning, Volumes I and II; Gait, ed. (1984)Oligonucleotide Synthesis; Mullis et al. U.S. Pat. No. 4,683,195; Hamesand Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins,eds. (1984) Transcription And Translation; Freshney (1987) Culture OfAnimal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRLPress) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; thetreatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Miller andCalos eds. (1987) Gene Transfer Vectors For Mammalian Cells, (ColdSpring Harbor Laboratory); Wu et al., eds., Methods In Enzymology, Vols.154 and 155; Mayer and Walker, eds. (1987) Immunochemical Methods InCell And Molecular Biology (Academic Press, London); Weir and Blackwell,eds., (1986) Handbook Of Experimental Immunology, Volumes I-IV;Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, ColdSpring Harbor, N.Y., (1986); and in Ausubel et al. (1989) CurrentProtocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.).

General principles of antibody engineering are set forth in Borrebaeck,ed. (1995) Antibody Engineering (2nd ed.; Oxford Univ. Press). Generalprinciples of protein engineering are set forth in Rickwood et al., eds.(1995) Protein Engineering, A Practical Approach (IRL Press at OxfordUniv. Press, Oxford, Eng.). General principles of antibodies andantibody-hapten binding are set forth in: Nisonoff (1984) MolecularImmunology (2nd ed.; Sinauer Associates, Sunderland, Mass.); and Steward(1984) Antibodies, Their Structure and Function (Chapman and Hall, NewYork, N.Y.). Additionally, standard methods in immunology known in theart and not specifically described are generally followed as in CurrentProtocols in Immunology, John Wiley & Sons, New York; Stites et al.,eds. (1994) Basic and Clinical Immunology (8th ed; Appleton & Lange,Norwalk, Conn.) and Mishell and Shiigi (eds) (1980) Selected Methods inCellular Immunology (W.H. Freeman and Co., NY).

Standard reference works setting forth general principles of immunologyinclude Current Protocols in Immunology, John Wiley & Sons, New York;Klein (1982) J., Immunology: The Science of Self-Nonself Discrimination(John Wiley & Sons, NY); Kennett et al., eds. (1980) MonoclonalAntibodies, Hybridoma: A New Dimension in Biological Analyses (PlenumPress, NY); Campbell (1984) “Monoclonal Antibody Technology” inLaboratory Techniques in Biochemistry and Molecular Biology, ed. Burdenet al., (Elsevere, Amsterdam); Goldsby et al., eds. (2000) KubyImmunnology (4th ed.; H. Freemand & Co.); Roitt et al. (2001) Immunology(6th ed.; London: Mosby); Abbas et al. (2005) Cellular and MolecularImmunology (5th ed.; Elsevier Health Sciences Division); Kontermann andDubel (2001) Antibody Engineering (Springer Verlan); Sambrook andRussell (2001) Molecular Cloning: A Laboratory Manual (Cold SpringHarbor Press); Lewin (2003) Genes VIII (Prentice Hall2003); Harlow andLane (1988) Antibodies: A Laboratory Manual (Cold Spring Harbor Press);Dieffenbach and Dveksler (2003) PCR Primer (Cold Spring Harbor Press).

All of the references cited above, as well as all references citedherein, are incorporated herein by reference in their entireties.

The following examples are offered by way of illustration and not by wayof limitation.

EXAMPLES

Aspects of the present disclosure can be further defined by reference tothe following non-limiting examples, which describe in detailpreparation of certain antibodies of the present disclosure and methodsfor using antibodies of the present disclosure. It will be apparent tothose skilled in the art that many modifications, both to materials andmethods, can be practiced without departing from the scope of thepresent disclosure.

CD73 (Cluster of Differentiation 73), also known as ecto-5′-nucleotidase(NT5E), is a transmembrane receptor found on tumor cells as well as innormal stromal cells such as endothelial cells and certain leukocytes.CD73 catalyzes adenosine monophosphate to adenosine and organicphosphate. Binding of the extracellular portion of adenosine receptorssignals through cyclic AMP to inhibit T-cell receptor activation(reviewed by Linden and Cekic, 2012). CD73 is believed to play a role inmediating the inhibitory function of regulatory B and T lymphocytes(Saze et al, 2013), as well as in maintaining endothelial integrity(reviewed by Jalkanen and Salmi, 2008).

In addition to its role in normal biology, CD73 and adenosine affecttumor biology. The presence of extracellular adenosine within the tumormicroenvironment has been described as an immunosuppressive “halo”(Antonioli et al, 2013). Consistent with this role for adenosine,knockout mice lacking adenosine receptors have been shown to rejecttumors more readily than normal mice (Ohta et al, 2006). The primarysource of extracellular adenosine within tumors is believed to be CD73(Augusto et al, 2013). Consistent with this hypothesis as well asstudies with A2A deficient mice, knockout mice lacking CD73 haveincreased anti-tumor immunity (Stagg et al, 2011) and show decreasedcarcinogenesis (Stagg et al, 2012) when compared normal mice.Specifically, extracellular adenosine is believed to mediate theimmunosuppressive effects of both regulatory T cells and myeloid-derivedsuppressor cells (MDSCs), among others (reviewed by Antonioli et al,2013). Taken together with other studies showing that molecularinhibition of CD73 with small molecules or antibodies can inhibit tumorformation, growth, and metastasis (reviewed by Young et al, 2014), it ishypothesized that tumors use CD73 to generate adenosine and, thereby, tosuppress anti-tumor immunity. Accordingly, anti-CD73 antibodies thatselectively bind to and inhibit the ectonucleotidase activity of CD73are likely to be useful for enhancing an anti-tumor immune response.

Example 1: Isolation and Identification of Anti-CD73 Antibodies

Human scFv phage display libraries were panned with biotinylated CD73extracellular domain (ECD) to isolate antibodies binding to human,cynomolgus, and murine CD73. The lead antibody, CD730010, was shown tobind specifically to human, murine, and cynomolgus CD73-expressing cells(by flow cytometry), and to inhibit the activity of recombinant solubleCD73 ECD as well as native CD73 displayed on cells. Affinity maturationof CD730010 was initiated to enhance binding affinity of CD730010 tohuman CD73.

Prior to affinity optimization, it was attempted to revert as manyframework residues of CD730010 to the closest human germline sequences(based on IMGT repertoire) without impairing affinity. This was done tominimize the potential immunogenicity of the final antibody drug inhumans. All framework residues of the VL domain and all except oneframework residue of the VH domain could be reverted to match the aminosequence of human germlines IGLV1-44, IGLJ3, IGHV3-23, and IGHJ2. Lysinein position 94 (Kabat numbering; Kabat, 1991) of the VH domain ofCD730010 could not be reverted without loss of affinity.

The affinity and potency of germlined CD730010 antibody was optimized bygenerating libraries of CDR variants and testing the variants forimproved binding to CD73. Several mutations with the best improvement inaffinity were combined to generate the candidate drug MEDI9447. Thenucleotide and deduced amino acid sequences of MEDI9447 are shown inFIGS. 1A-1D.

CD73-specific scFv antibodies were isolated from the human scFv phagedisplay library in a series of repeated alternate selection cycles onbiotinylated human and murine CD73 extracellular domain (ECD) producedin-house from mammalian cells essentially as described previously inLloyd et al., PEDS 22:159-68 (2009). ScFv genes from rounds 2 and 3 ofthe selection outputs were converted in batch into bacterial scFv-Fc orFab expression vectors. Bacterial culture supernatants carrying solublescFv-Fc or Fab were screened for their binding to human, murine, andcynomolgus CD73 ECD by ELISA or homogeneous time resolved fluorescence(HTRF). The top hits showing cross reactivity were selected, subjectedto DNA sequencing, and converted to whole immunoglobulin G1 triplemutant antibody format (“IgG-TM”, IgG1 Fc sequence incorporatingmutations L234F, L235E and P331S). IgG1 TM antibodies were expressed inmammalian cells, purified by affinity chromatography and ranked based ontheir characteristics in binding and functional assays.

Example 2: Epitope Binning of Anti-CD73 Antibodies

The ability of anti-CD73 antibodies to compete with each other forbinding to human CD73 ECD was assessed on an Octet instrumentessentially as described (Abdiche YN et al., Anal Biochem 386: 172-80(2009). CD73 ECD protein and first anti-CD73 antibody were preincubatedand added to a biotinylated second anti-CD73 antibody captured on aStreptavidin sensor. If the first anti-CD73 antibody blocked binding ofCD73 ECD to the second anti-CD73 antibody, both antibodies were placedin same or overlapping epitope bins. If both antibodies could bindsimultaneously to CD73 ECD, they were placed in non-overlapping epitopebins. Pairwise testing of the anti-CD73 antibodies demonstrated thatthey belong to 3 non-overlapping epitope bins (Table 2).

TABLE 2 Epitope bins of anti-CD73 antibodies Epitope bin Antibodies ACD730002, CD730004, CD730008, CD730011 B CD730003, CD730010, CD730021,CD730042, CD730046, CD730047 C CD730068, CD730069

Example 3: Binding of Anti-CD73 Antibodies to CD73

The binding affinity and specificity of anti-CD73 antibodies wasdetermined by Surface Plasmon Resonance (SPR) and flow cytometry.

A ProteOn XPR36 instrument was used to characterize binding of MEDI9447to human, murine, and cynomolgus CD73 ECD. MEDI9447 wasaffinity-captured using an anti-human Fc antibody. CD73 ECD was in themobile phase. The association and dissociation of CD73 to MEDI9447 couldbe accurately described with the Langmuir 1: 1 model. The results shownin Table 3 demonstrate that the affinity of MEDI9447 to CD73 ECD fromthe three species is comparable and in the low picomolar range.

TABLE 3 Affinity of MEDI9447 to CD73 ECD Determined by Surface PlasmonResonance Analyte k_(a) (M⁻¹s⁻¹) k_(d) (s⁻¹) K_(D) (M) Human CD73 ECD2.57 × 10⁶ 1.06 × 10⁻⁵ 4.1 × 10⁻¹² Murine CD73 ECD 2.41 × 10⁶ 2.32 ×10⁻⁶ 0.9 × 10⁻¹² Cynomolgus CD73 ECD 2.71 × 10⁶ 1.76 × 10⁻⁵ 6.5 × 10⁻¹²k_(a) Association rate constant; k_(d) Dissociation rate constant; K_(D)Dissocation constant

Binding of MEDI9447 to native CD73 expressed on human, murine, andcynomolgus monkey cell lines was characterized by flow cytometry. Thecells were incubated with various concentrations of MEDI9447 andantibody binding was monitored with and fluorophore-labeled anti-humanFc antibody. A plot of the median fluorescence intensity as a functionof the MEDI9447 concentration was fitted nonlinearly using a one-sitebinding isotherm model to calculate the equilibrium dissociationconstant. The analysis by flow cytometry confirms the binding ofMEDI9447 to human, murine, and cynomolgus CD73 with comparableaffinities (Table 4), although the K_(D) values are 13 - 126-foldgreater than those determined by SPR, probably because of conformationaldifferences between recombinant and native CD73.

TABLE 4 Affinity of MEDI9447 to Native CD73 Determined by Flow CytometryAnalyte K_(D) (M) MDA-MB-231 cells (human) 154 × 10⁻¹² 4T1 cells(murine) 113 × 10⁻¹² MK-1 cells (cynomolgus) 84 × 10⁻¹²

To determine the specificity of MEDI9447 for human CD73 by flowcytometry, cell lines were developed. MDA-MB-231 cells, which are humanbreast cancer cells derived from a pleural effusion, were transfectedwith human CD73 short hairpin RNA (shRNA) to knock down the cell-surfaceexpression of CD73. Jurkat cells, a line of T cells derived from Burkittlymphoma cells, were transfected with a plasmid expressing human CD73mRNA to knock in cell-surface expression of CD73. Jurkat cells expresslittle endogenous CD73.

Specificity of MEDI9447 for human CD73 was determined by the ratio ofMEDI9447 binding to a high CD73-expressing cell line (MDA-MB-231) to lowexpressing cell line (MDA-MB-231, CD73-shRNA). Specificity of MEDI9447for human CD73 was also determined by the ratio of high CD73 expressingcell line (Jurkat -CD73 knock-in) to lower expressing cell line Jurkat.

Specificity of MEDI9447 for murine CD73 (mCD73) was determined by flowcytometry comparing the mouse cell line 4T1 (high mCD73 expression) tothe knocked-down cell line (4T1 mCD73 -shRNA). In addition, specificityof MEDI9447 for Jurkat cells with murine CD73 knock-in was compared withwild-type Jurkat cells (no murine CD73).

TABLE 5 Specificity of MEDI9447 for Human and Mouse CD73 Specificity ofMEDI9447 Cell Line Relationship Mean Fluorescence Intensity Ratio (MFIR)human MDA-MB-231 / MDA-MB-231(CD73-shRNA) 3.5 human Jurkat (CD73knock-in) / Jurkat 7.9 Mouse 4T1 / 4T1(mCD73 -shRNA) 3.9 Mouse Jurkat(mCD73 knock-in) / Jurkat 57.1

Example 4: Internalization of CD73 by Anti-CD73 Antibody MEDI9447

Antibody-mediated internalization or shedding of CD73 was assessed byflow cytometry. MDA-MB-231 cells were incubated in presence of 100 nMMEDI9447 or negative control antibody R347 in growth medium at 37° C.for 0 - 4 hours. Cells were washed and resuspended in ice-cold PBS. Thepresence of CD73 on the cell surface was detected by adding 10 nMDyLight488-labeled detection antibody. Cells were incubated for 15minutes, washed and analyzed by flow cytometry. The detection antibodybinds to an epitope of CD73 that is different from the MEDI9447 epitopeand both antibodies simultaneously bind to CD73 without interference.Cell surface expression of CD73 dropped to 73% of its original valueafter 4 hours incubation with MEDI9447, suggesting that 27% of CD73 waseither internalized or shed upon MEDI9447 binding (Table 3.5-1)

TABLE 6 Percentage of CD73 remaining on the cell surface of MDA-MB-231cells after incubation with test antibody Time [h] R347 MEDI9447 0 100%100% 0.25 107% 90% 0.5 104% 90% 1 102% 87% 2 104% 80% 4 102% 73%

Internalization of MEDI9447 into cell lines MDA-MB-231 (human mammarycarcinoma) and 4T1 (murine mammary carcinoma) was assessed using a humanAntibody Internalization Kit that is sold commercially as the FabZAPassay (Advanced Targeting Systems, San Diego CA). Serial dilutions ofMEDI9447 or negative control antibody R347 were preincubated with 40 nMFabZAP reagent (Fab fragment of a polyclonal anti-human IgG antibodyconjugated to the cytotoxic protein saporin) and then added to the celllines. After 3 days in culture, cell proliferation was measured using aluminescent cell viability assay sold commercially as the CellTiter-Gloassay (Promega, Madison WI). This assay was used to calculate EC₅₀values and maximum toxicity. The FabZAP reagent cannot internalize intocells on its own. It binds to a test antibody (e.g., MEDI9447) and iscytotoxic only upon internalization of the test antibody. MEDI9447caused internalization of FabZAP and inhibited cell proliferation in adose-dependent manner.

TABLE 7 Antibody-mediated Internalization of Cytotoxic FabZAP Reagentinto MDA-MB-231 Cells and 4T1 Cells MDA-MB-231 4T1 EC₅₀ [pM] maximumtoxicity EC₅₀ [pM] maximum toxicity MEDI9447 3.5 97% 18.5 97%

Cell proliferation of MDA-MB-231 cells and 4T1 cells treated with serialdilutions of test antibody and FabZAP reagent was measured byCellTiter-Glo assay (FIG. 2 ). The signal from the negative controlantibody R347 in the CellTiter-Glo assay was subtracted from the signalof MEDI9447 and the EC50 value and maximum toxicity were calculated byfitting the dose-response curve using non-linear regression analysis.

Example 5: Inhibition of 5′Ectonucleotidase Activity by Anti-CD73Antibody MEDI9447

In this study, the functional activity of MEDI9447 was determined in anin vitro assay that measured the CD73-catalyzed hydrolysis of AMP usinga human non-small cell carcinoma cell line, NCI-H322. Formulation ofMEDI9447 was prepared by diluting its stock solution in serum-free RPMImedium to a final concentration of 1 µM. Formulation of R347 wasprepared by diluting its stock solution in RPMI to a final concentrationof 1 µM.

NCI-H322 cells were centrifuged for 5 minutes at 1500 rpm. Thesupernatant was removed and replaced with serum-free RPMI medium. Thecell suspension was counted using the ViCell (Beckman, Coulter) cellcounter. The cells were plated into 96-well plates at a cell density of10,000 cells per 100 µLs per well. 50 µL of 4X concentrated AMP (200 µM)was added. The plates were then incubated at 37° C., 5%CO₂ for 24 hours.Plates were centrifuged and 50µL of the culture supernatant wastransferred well-to-well to 96-well opaque round bottom plates. 2X ATPwas then added. CellTiterGlo® (Promega) was added according to themanufacturer’s instructions. Cellular enzyme inhibition of 5′ectonucleotidase was measured on a multilabel reader, the Perkin-ElmerEnvision Workstation. The samples were analyzed using Prism Software.

MEDI9447 specifically inhibited dephosphorylation of adenosinemonophosphate (AMP) in a human in vitro system In a cell-based assay ofsurface-expressed CD73, conversion of adenosine monophosphate toadenosine was reduced in a dose-dependent manner by MEDI9447, but not byan irrelevant isotype control antibody (FIG. 3 ). The results depictedin FIG. 3 were obtained using CD73-expressing NSCLC cells that wereplated into 96-well non-tissue culture treated plates (Falcon 3788) at10,000 cells per well in 100 µL of RPMI medium without additives.Antibodies were added in duplicate along with AMP (200 µM finalconcentration) and plates were incubated at 37° C., 5% CO₂ for 24 hours.Plates were then centrifuged for 3 minutes at 1500 rpm. Supernatantswere collected into a new 96 well plate (Costar #3605) and ATP was addedto a final concentration of 100 µM. CellTiter-Glo® reagent (Promega) wasadded 1: 1 and cellular CD73 enzyme AMP phosphorylase activity wasdetermined by measuring ATP levels using the Envision luminescence platereader (Perkin Elmer). Buffer containing only ATP and AMP was used as anegative control. The assay was repeated and the results shown at FIG. 3are representative of two similar experiments using other human cancercell lines.

These results indicate that MEDI9447 inhibited the production ofadenosine by cancer cells. Adenosine is believed to mediate the tumor’simmunosuppressive effects within the tumor microenvironment.

Example 6: Reduction in Tumor-Infiltrating Myeloid-Derived SuppressorCells by MEDI9447

CT26 cells, which are derived from a murine colon cancer, wereestablished by subcutaneous (SC) injection of 5×10⁵ cells suspended in0.1 mL of PBS into the right flanks of 4-to-6-week-old female mice. Themice were treated with MEDI9447 or with a control antibody.

10 mice per group were used in this study. Animals were randomlyassigned into groups. Animals in Group 1 were untreated and Group 2 wasadministered an isotype control. MEDI9447 was administered to Group 3.Test articles were administered intraperitoneally twice weekly startingon Day 3. On Day 16, 5 animals from each group were necropsied andtumors were isolated.

Group designation and dose levels are presented in Table 8.

TABLE 8 Group Designation and Dose Levels Group Number of animals(female) Treatment Days of dosing Dose level (mg/kg) ^(a) ROA 1 5untreated N/A N/A N/A 2 5 isotype 2X weekly 20 mg/kg IP 3 5 MEDI9447 2Xweekly 10 mg/kg IP N/A = not applicable; ROA = route of administration.

Tumors were measured on Days 1, 7, 9, 12, 14, and 16 by caliper, and thevolumes of tumors were calculated as follows:

-   (1) (tumor volume length (mm) × (tumor volume width)² (mm)) / 2

The anticancer effects of MEDI9447 were expressed as percent tumorgrowth inhibition, which was calculated as follows:

-   (2) (Average tumor volume for MEDI9447/Average tumor volume for    R347-TM)×100

Tumors were isolated for flow cytometry. Tumors were dissected from CT26tumor-bearing mice on study Day 16. Tumors were cut into small piecesand were digested with collagenase. After a 30-minute incubation, thedigested sample was passed through a 70-micron filter. Dissociated cellswere pelleted at 1000 rpm for 5 minutes at 4° C. and were re-suspendedin fluorescence-activated cell sorting (FACS) buffer. Cells were countedon Vi-Cell using the default setting. 1×10⁶ cells were plated per well.Cells were stained with anti-CD45 (to detect all leukocytes) anti-GR1(to detect MDSCs) and anti-Ly6g (Gran MDSC). Data were acquired on theLSRII flow cytometer. Significant p-values, if any, obtained from theMDSC analyses are presented in FIG. 4 adjacent to the descriptivestatistics (ie, mean and standard deviation).

MEDI9447 inhibited tumor growth in murine CT26 syngeneic Balb/C tumormodel (FIG. 4 ).

MEDI9447 reduced the proportion of tumor-infiltrating MDSCs in themurine CT26 syngeneic Balb/C tumor model (FIG. 5 ).

MEDI9447 inhibited the growth of CT26 murine syngeneic tumors. Inaddition, myeloid-derived suppressor cells were decreased in syngeneicCT26 colon carcinoma tumors following treatment with MEDI9447.Intra-tumoral MDSCs have an immunosuppressive effect on the tumormicroenvironment, allowing for enhanced tumor growth. The observedreduction in intra-tumoral MDSCs following treatment with MEDI9447demonstrates a mechanism by which treatment with MEDI9447 reduces tumorimmune suppression.

Example 7: A Combination of MEDI9447 mIgG1 and an Anti-PD-1 AntibodyReduced Tumor Growth and Increased Survival

Syngeneic tumors were established by subcutaneous (SC) injection of 0.1ml of 5×10⁶ CT26 cells/ml suspended in HBSS into the right flanks of 8-to 10-week-old animals. Tumors were measured by caliper and the volumesof tumors (TV) were calculated using the following formula:

$\begin{matrix}{\text{TV} = {\left( {\text{L} \times \text{W}^{2}} \right)/2}} & \text{­­­(1)}\end{matrix}$

where L is tumor length in millimeters and W is tumor width is inmillimeters

Mice were randomized into groups based on bodyweight. There were noanimal substitutions. 60 female Balb/c mice were used in this study.

Animals were randomly assigned into 6 groups. Animals were administeredMEDI9447(mIgG1). Test articles were administered by intraperitoneal (IP)injection twice weekly starting on Day 3. Group designation and doselevels are presented in Table 9.

TABLE 9 Group Designation and Dose Levels Group Number of animals(Female) Treatment Schedule of dosing (2× weeky) Dose level (mg/kg) ^(a)ROA 1 10 Untreated NA NA NA 2 10 Isotype mIgG1 4 doses 10 ip 3 10Isotype rIgG2a 4 doses 10 ip 4 10 MEDI9447 mIgG1 4 doses 10 ip 6 10Anti-PD1 4 doses 0.5 ip 7 10 PD1 + MEDI9447 4 doses 0.5 + 10 ip F =female; IV = intravenous; M = Male; ROA = route of administration.

(A) Results of in Vivo Tumor Inhibition Study

CT26 murine colon carcinoma were implanted into syngeneic Balb/C miceand treated with anti-CD73 (MEDI9447 mIgG1), anti-PD1 or thecombination. The combination treatment significantly inhibited tumorgrowth when compared to anti-CD73 alone (p = 0.015, ANOVA)Tumor volumeseach group of animals were plotted for individual animals out to studyday 40. No control group mice were tumor free by the end of the 40 daystudy period. Anti-CD73 treatment alone resulted in 10% tumor freeanimals at the end of study. Anti-PD1 treatment alone also resulted in10% tumor free animals at the end of study. Remarkably, the combinationof anti-CD73 and anti-PD treatment resulted in 60% tumor free mice. Noneof the control group mice were tumor free by the end of the study. CT26tumors were measured in mice treated with anti-CD73 (MEDI9447 mIgG1),anti-PD1 or the combination of anti-CD73 and anti-PD1. Mice weremeasured until study day 40, and humanely sacrificed once tumors reached2000 mm³. The combination of anti-CD73 and anti-PD1 treatment togetherresulted in a statistically significant increase in survival whencompared to anti-CD73 or anti-PD1 treatment alone (p value = 0.005 and p= 0.038, respectively, Log Rank Test)(FIG. 7 ). Median survivalincreased from 25 and 33 days (anti-CD73 and anti-PD1, respectively)compared to “undefined” at day 40 for the combination (Table 10).

TABLE 10 Outcome at Study Day 40 Treatment Tumor free mice (%) Survival(%) untreated 0 0 Isotype mIgG1 0 0 Isotype rIgG2a 0 0 Anti-CD73 10 10Anti-PD1 10 20 Anti-CD73 + Anti-PD1 60 70

In summary, anti-CD73 antibody, MEDI9447 mIgG1, showed enhancedanti-tumor activity when combined with an anti-PD-1 antibody in a murinesyngeneic CT26 colon carcinoma model. In addition, the combination ofanti-CD73 and anti-PD treatment resulted in 60% tumor free mice. Thecombination of anti-CD73 and anti-PD1 treatment together also resultedin a statistically significant increase in survival when compared toanti-CD73 or anti-PD1 treatment alone.

EXAMPLE 8: Anti-PD-1 induced a CD73-rich tumor microenvironment asmeasured by CD73 expression on tumor cells (FIG. 9 ) myeloid-derivedsuppressor cells (MDSC) and tumor infiltrating CD4+, FoxP3+ lymphocytes(FIG. 15 ).

Syngeneic tumors were established by subcutaneous (SC) injection ofsyngeneic B16F10 melanoma cells or syngeneic EG7-OVA lymphoma cells.Mice were treated twice weekly with MEDI9447 (10 mg/kg), anti-PD-L1antibody (10 mg/kg), or a combination of MEDI9447 (10 mg/kg) andanti-PD-L1 antibody (10 mg/kg). Tumor volume was measured twice weekly.Administering MEDI9447 and anti-PD-L1 in combination significantlyenhanced tumor growth inhibition in melanoma tumors (FIG. 12 ) andlymphoma tumors (FIG. 13 ).

To understand the effect of anti-PD-L 1 on tumor microenvironment, CD73expression on lymphocytes was studied. Mice (n=4) were injectedsubcutaneously with syngeneic CT26 colorectal cells and treated twiceweekly with 10 mg per kg of anti-PD-L1 or an irrelevant isotype controlantibody. One day after the first treatment cells were isolated fromdraining lymph nodes and analyzed for surface phenotype by flowcytometry. Three days after the first treatment tumors were isolated,cells dissociated and analyzed for surface phenotype by flow cytometry.Anti-PD-L1 induced a CD73-rich tumor microenvironment as measured bysurface expression of CD73 on draining lymph node B lymphocytes (FIG. 14) and on tumor infiltrating CD4+, FoxP3+ lymphocytes (FIG. 15 ).

Mice bearing colorectal CT26 syngeneic tumors were treated twice weeklywith MEDI9447 (30 mg/kg) or anti-PD-L1 (30 mg/kg) or a combination ofMEDI9447 (30 mg/kg) and anti-PD-L1 (30 mg/kg). On Day 16, tumors andperipheral whole blood cells were harvested and analyzed for surfaceCD73 expression by flow cytometry and enzyme activity. MEDI9447 alone orin combination with anti-PD-L1 reduced CD73 expression on peripheralwhole blood cells (FIG. 16 ), tumor infiltrating CD4+, FoxP3+lymphocytes (FIG. 17 ) and tumor infiltrating CD8+ lymphocytes (FIG. 18). MEDI9447 alone or in combination with anti-PD-L1 also reduced CD73

expression on tumor cells (FIG. 19 ).

MEDI9447 and antibodies or fusion proteins specific for CTLA4, OX40,PD-1, and PD-L1 were incubated for 72 hrs. with primary human peripheralblood mononuclear cells in a mixed leukocyte reaction. The indicatedcytokines in duplicate supernatants were quantified by ELISA. Data shownrepresent optimal dose combinations of anti-CD73 antibody with the 4different partner agents. The anti-PD-1 and anti-CD73 combination showedsignificant (p<0.05) synergy (FIG. 20 ) as determined by the Blisssurface response method (Zhao et al.). The cytokine profile indicatesthat both myeloid and lymphoid lineages were impacted. Greater than 50donor pairs have been tested

In summary, anti-PD-1 and anti-PD-L1 antibodies created a CD73 richtumor microenvironment detectable in the periphery and reversible bytreatment with anti-CD73 antibody, MEDI9447 mIgG1. Specifically, levelsof CD73 cell surface expression and enzyme activity increaseddramatically on murine CT26 tumors when mice bearing these tumors weretreated with an anti-PD-1 or anti-PD-L1 antibody. Furthermore,expression and activity levels were reduced by treatment with anti-CD73antibody MEDI9447 alone or in combination with the anti-PD-L1 antibody.These changes were observed in both tumors as well as in circulatingperipheral whole blood cells. Thus, CD73 expression and activity mayserve as a pharmacodynamic marker of both anti-PDL1 and anti-CD73treatment or as a predictive biomarker for segmentation of patientstreated with anti-PD-1 or anti-PD-L1 whose tumors have “escaped” byunregulating CD73 expression and activity. Importantly, anti-CD73antibody, MEDI9447, in combination with anti-PD1 or anti-PD-L1, MEDI4736, showed enhanced anti-tumor activity.

Taken together these results confirm, by various measures, thatanti-PD-1 and anti-PD-L1 antibodies induce a “CD73 rich” tumormicroenvironment and provide a strong rationale for combining MEDI9447with therapies that target the PD-1/PD-L1 axis.

Example 9: Anti-CD730010 Antibody and Antibody Variants

TABLE 11 Affinity of parental anti-CD730010 antibody and antibodyvariants with germlined amino acids. antibody variant amino acid in VLposition amino acid in VH position EC50 [nM] 1 2 11 37 39 94 CD730010 LP V K V R 69 CD730010 GL9 Q S A Q L R 64 CD730010 GL10 L P V K V K 205CD730010 GL18 Q S A Q L K 132

For CD730002, the closest germline genes were IGHV3-23 and IGHJ3 for theVH domain, and IGLV3-1 and IGLJ3 for the VL domain. Four non-germlineresidues outside the CDR regions were identified: R94 in VH, and T20,R57, L81 and F87 in VL (Kabat numbering) (Table 11). Nucleotides in theCD730002 IgG1-TM expression vector were back-mutated by standardmolecular biology techniques, so that the resulting expression vectorsencoded germline amino acids in these positions (K94 in VH, and S20,G57, M81, and Y87 in VL). The CD730002 IgG1-TM protein variants wereexpressed, purified and tested for binding to recombinant human andmurine CD73 by flow cytrometry. All 4 non-germline amino acids in VLcould be changed to their germline residues without impairing binding.However, R94 in VH is important for binding and changing it to K impairsbinding. Variant CD730002 SGMY (non-germlined V, fully germlined VL) wasused as a template for generating affinity-optimized antibody variants.

Example 10: Affinity-Optimization of Anti-CD73 Antibodies CD730010GL9

CD730010GL9 IgG1-TM was optimized by screening Fab libraries comprisingvariant CDR sequences with single amino acid mutations. Each of the 61positions in the six CDRs was individually randomized to 19 amino acids(all natural amino acids except Cysteine), generating a library with atheoretical diversity of 1159 unique clones (19 amino acids per positiontimes 61 positions). Bacterial Fab fragments were produced from 4224clones of the library and screened for binding to human and murine CD73protein by capture ELISA (Assay 2). 180 clones with increased bindingsignal compared to parental CD730010 GL9 IgG1-TM were selected and themutations in the VH or VL domain were identified by DNA sequencing. TheFab concentration in the bacterial supernatants was normalized and thebinding of the normalized supernatants to human and murine CD73 proteinwas evaluated by direct ELISA (Assay 1). Table 12 lists selectedbeneficial single amino acid substitutions and their effect on bindingto recombinant CD73 protein.

TABLE 12 Single amino acid variants of CD730010 GL9 with improvedaffinity. CDR Amino acid change ELISA signal, fold improvement overparental antibody huCD73 muCD73 L1 P32E 27.7 6.7 L1 P32D 11.7 6.5 H3Y102K 9.9 7.4 L2 N51D 8.9 4.5 H2 G54N 8.9 7.1 H2 S52W 8.9 4.4 H3 Y102M7.9 6.3 H3 Y102L 7.3 5.8 L2 S56G 7.1 5.6 L2 N51A 6.7 2.5 H3 Y102A 6.65.0 L1 P32G 6.1 5.8 L1 P32A 6.0 5.5 L2 Q53L 6.0 3.8 L2 Q53Y 5.8 2.3 L2P55L 5.7 4.3 H2 S56R 5.6 4.9 L2 N51Q 4.2 2.3 H2 G54W 4.2 3.7 H2 A50L 4.23.0 L2 Q53F 4.1 2.7 H1 M34Y 3.9 2.9 L2 P55I 3.7 3.2 H3 Y102Q 3.6 3.0 L2Q53W 3.1 2.7 L2 Q53H 2.4 1.9 L2 L50F 2.2 1.4 H1 S35H 1.8 1.1 H1 M34I 1.51.1

To further improve the affinity of the anti-CD73 antibody, severalsingle amino acid changes which improved binding when compared toparental CD730010 GL9 were combined to create a combinatorial Fablibrary (Assay 4). Fab fragments of 4224 clones of the combinatoriallibrary were produced in E.coli and screened for binding to human andmurine CD73 protein by capture ELISA. The top 20 clones from eachscreening assay were selected for further characterization. The Fabconcentration in the supernatants was normalized and serial dilutions ofnormalized supernatants were tested for binding to human and murine CD73by capture ELISA and direct ELISA. Clones C1, C2, D3 and G10 showedstrong binding to human and murine CD73 and were selected for furthercharacterization.

Antigen binding of CD730010 GL9 was also optimized using affinity-basedphage selections. Large scFv libraries derived from the lead CD730010GL9 sequence were created by oligonucleotide-directed mutagenesis of thevariable heavy (VH) complementarity determining region 3 (CDR3) orvariable light (VL) chain CDR3 using standard molecular biologytechniques as described (Finch et al., JMB 411, 791-807 (2011)). Thelibraries were panned in a series of repeated alternate selection cycleswith biotinylated human and murine CD73 extracellular domain protein.ScFv genes from round 3 of the selection output were batch-convertedinto a bacterial IgG expression vector. Bacterial culture supernatantscontaining soluble IgG were screened for their binding to human andmurine CD73. IgG variants with significantly improved binding to CD73compared to parental CD730010 GL9 were subjected to DNA sequencing. Twovariants, GRVE and HPT, were selected for further characterization.

To generate further affinity improvements, beneficial mutationsidentified from the combinatorial Fab library and from theaffinity-based phage selection were combined creating variants 73combo1to 73combo6.

Example 11: Affinity-Optimization of Anti-CD73 Antibodies CD730002SGMY

CD730002SGMY IgG1-TM was optimized by screening Fab libraries comprisingvariant CDR sequences with single amino acid mutations as described forCD730010GL9. Five amino acid mutations in the VH domain and four aminoacid mutations in the VL domain were identified that resulted inincreased binding signal to recombinant CD73. Table 13 lists beneficialsingle amino acid substitutions and their effect on binding torecombinant CD73.

TABLE 13 Single amino acid variants of CD730002SGMY with improvedaffinity. CDR Amino acid change FACS signal, fold improvement overparental antibody MDA-MB-231 cells H1 Y32V 1.2 H1 M34R 1.1 H2 T57P 1.5H2 A60G 1.3 H2 G65R 1.3 L2 T52S 1.5 L2 R54Y 1.2 L2 P55L 1.9 L2 P55H 1.5

To further improve the affinity of the anti-CD73 antibody CD730002SGMY,IgG variants were prepared that harbored one beneficial amino acidchange in the VH domain and one beneficial amino acid change in the VLdomain. Antibody variants were prepared by transient transfection of293F cells and were screened for binding to MDA-MB-231 cells by flowcytometry. Clone 2C5 had a 3-fold lower EC50 value than parentalCD730002SGMY.

Example 12: Affinity of Optimized Anti-CD73 Antibodies

The affinity of optimized anti-CD73 antibodies (in IgG1-TM format) tohuman, murine, and cynomolgus CD73 was determined by flow cytometry andsurface plasmon resonsance (SPR) (Table 14). The optimized antibodieshad pM affinity to cellular and recombinant CD73 from the three species.

TABLE 14 Affinity of anti-CD73 antibodies to human, murine, andcynomolgus CD73 KD [pM] flow cytometry SPR (Proteon) MB-MDA-231 (human)4T1 (murine) MK-1 (cyno) human CD73 murine CD73 cyno CD73 CD730010 80006100 ND 3580 2470 1920 CD730010GL9 8949 16365 16460 1640 ND ND P32E 178145 110 63 35 27 C1 179 95 160 29 6 12 C2 158 67 105 23 G10 354 259 2589 HPT 739 5812 1138 548 GRVE 125 88 101 29 73combo1 (C1+GRVE+HPT) 157150 90 7 2 8 73combo2 (C2+GRVE+HPT) 166 64 74 5 73combo3(D3+GRVE+HPT)154 113 84 4 1 7 73combo5 (G10+GRVE+HPT) 169 205 78 7 73combo6(GRVE+HPT)166 82 107 15 CD730002 52 50 52 7 40 15 CD730002 2C5 84 55 63 9 22 9

Example 13: Internalization of Anti-CD73 Antibodies

Internalization of anti-CD73 antibodies into cell lines MDA-MB-231 and4T1 was assessed using the FabZAP assay (Advanced Targeting Systems, SanDiego CA). Cell lines were incubated in the presence of anti-CD73antibodies and FabZAP reagent. After 3 days, cell proliferation wasmeasured to calculate EC50 values and maximum toxicity (Table 15). FACSdata shows that the internalization rate of affinity-optimizedantibodies is low.

TABLE 15 73combol 3.8 97% 33.1 97% 73combo3 3.5 97% 18.5 97% CD7300027.1 95% 205.6 83% CD730002 2C5 9.1 98% 172.6 82% Phen0203 92.5 91% ND ND

In another experiment, internalization of antibodies into cell lines wasassessed by analyzing the cytotoxic effect of anti-CD73 antibody/saporinconjugates on CD73-positive cell lines (Table 15). Anti-CD73 antibodieswere directly conjugated to saporin toxin using S-HyNic and 4FBchemistries (Solulink, San Diego CA) and the antibody/saporin conjugateconcentration required for inhibiting cell growth by 50% was determined.

TABLE 15 Characterization of anti-CD73 antibodies. Antibody 1/EC₅₀ (nM)Binding Enzyme Inhibition Internaliza tion Human Mouse Cyno rCD73MDA-MB-231 MDA-MB-231 CD730002 1.0E-001 2.4E-002 2.0E-001 2.10E-021.20E+01 2.10E-02 CD730003 1.8E-004 2.3E-004 4.8E-005 2.00E-03 7.00E-032.00E-03 CD730004 2.3E-005 2.3E-004 2.0E-006 0.00E+0 0 6.00E-02 0.00E+00CD730008 1.1E-003 5.8E-004 1.1E-003 0.00E+0 0 1.10E-01 0.00E+00 CD7300103.4E-003 2.4E-003 3.3E-003 6.20E-03 3.30E-01 6.20E-03 CD730011 2.1E-0031.5E-003 2.7E-003 0.00E+0 0 6.80E-04 0.00E+00 CD730021 8.5E-004 5.7E-0041.2E-003 1.10E-03 9.50E-03 1.10E-03 CD730042 1.7E-003 0.0E+000 1.4E-0030.00E+0 0 3.20E-03 0.00E+00 CD730046 4.1E-003 5.2E-003 1.0E-002 0.00E+00 8.10E-02 0.00E+00 CD730047 0.0E+000 0.0E+000 0.0E+000 1.00E-032.70E-02 1.00E-03 CD730068 ND ND ND 0.00E+0 0 0.00E+00 0.00E+00 CD730069ND ND ND 3.80E-02 1.30E-03 3.80E-02

Example 14: The Anti-Human CD73 Antibody, Phen0203 hIgG1, InhibitedAMP-Mediated Suppression of CD4+CD25- T Cell Proliferation in Vitro, ina Concentration Dependent-Manner

A study was conducted to determine the ability of an anti-CD73 antibody(Phen0203) to relieve AMP-mediated T-cell suppression in vitro. In thisin vitro study, the ability of an anti-human CD73 antibody (Phen0203hIgG1) to inhibit the catalysis of adenosine monophosphate to adenosineand organic phosphate by CD73 and the subsequent impact on T-cellfunction was examined. Phen0203 hIgG1 has similar functional propertiesto MEDI9447, including the ability to inhibit the cellular andbiochemical enzymatic activity of CD73 in vitro).

Phen0203 hIgG1 antibody is a human IgG1 mAb with no engineering in theheavy chain constant region. Similar to MEDI9447, it also selectivelybinds to and inhibits production of immunosuppressive adenosine by theectonucleotidase activity of human CD73. However, Phen0203 lackscross-reactivity against mouse CD73.

In an assay for AMP-mediated T-cell suppression, primary human CD4⁺ Tcells depleted of CD25⁺ cells were isolated from the content ofleukocyte cones and used as effector cells; each cone was processedseparately. Briefly, the content from a leukocyte cone was diluted inPBS, then layered over Ficoll-Paque Plus (GE Healthcare, Chalfont StGiles, UK) and centrifuged at 400×g for 40 minutes with brakes turnedoff. Peripheral blood mononuclear cells (PBMC) were then isolated fromthe interface and washed with PBS by centrifugation at 200×g for 10minutes. Supernatant was discarded and cells were suspended in PBS.Viable cells were determined, then pelleted at 350×g for 5 minutes andsuspended in Robosep buffer (Stem Cell, Grenoble, France) at aconcentration of 5 × 10⁷ per mL. CD4⁺ T cells were isolated from PBMCsby negative selection using the EasySep human CD4⁺ T cell enrichment kit(Stem Cell, Grenoble, France) and the RoboSep (Stem Cell, Grenoble,France). Purified CD4⁺ T cells were pelleted and resuspended at 1.5 ×10⁷ per mL in Robosep buffer. Dynabeads CD25 (a component of DynabeadsRegulatory CD4⁺CD25⁺ T cell kit; Life Technologies, Paisley, UK) wereadded at 200 µL per 1.5 × 10⁷ cells and incubated for 25 minutes at 4°C. with continuous mixing. Cells were then placed into a DynaMag-15magnet (Life Technologies, Paisley, UK) for 1 minute and the supernatantcontaining the CD4⁺CD25⁻ effector cells were transferred into a newtube.

Isolated effector cells were labeled with CFSE probe (3 µM) using theCellTrace CFSE cell proliferation kit (Life Technologies, Paisley, UK)at a cell density of 1 × 10⁶ cells per mL in PBS containing 0.1% BSAwith an incubation period of 15 minutes at 37° C. Cells were washedtwice with warm X-Vivo 15 media and suspended at 5 × 10⁵ cells per mL inthe same media. Labeled effector cells were activated for 1 hour at 37°C. by adding 25 µL of anti-CD3 and anti-CD28 coated microbeads(Dynabeads human T-activator CD3/CD28; Life Technologies, Paisley, UK)per 1 × 10⁶ cells and 60 IU/mL of rhIL-2. Thereafter, activatedCD4+CD25- cells (approximately 50,000 in 100 µL) were added to wells ofsterile roundbottom 96-well plates. Serial dilutions of the followingreagents were performed in X-Vivo 15 media (Lonza, Slough, UK): the testarticle Phen0203 hIgG1 and R347 control antibody,

To the cells in the plate, 50 µL of diluted reagents were added followedby 50 µL of X-Vivo 15 (Lonza, Slough, UK) containing 400 µM or 800 µM ofAMP (Sigma-Aldrich, Gillingham, UK). The following control wells werealso included: activated CFSE-labeled CD4⁺CD25⁻ cells with no AMP(activated control); CFSE-labeled CD4⁺CD25⁻ cells with AMP but notest/control articles (untreated control); and un-activated (restingcontrol) CFSE-labeled CD4⁺CD25⁻ cells with no AMP. Cells in the assaywere gently pelleted by centrifugation, at 100×g for 2 minutes, andplaced in a 37° C. humidified tissue culture incubator with 5% CO₂ for72 hours.

After 72 hours of incubation, cells were pelleted by centrifugation at380 g for 4 minutes, washed once with 100 µL of FACS buffer(eBioscience, Hatfield, UK) and finally suspended in 100 µL of PBScontaining 3.7% of formaldehyde for flow cytometry analysis on a BDFACSCanto II (BD Biosciences, Oxford, UK). Resting CFSE⁺ CD4⁺CD25⁻ cellswith no AMP well was used to identify cells that have undergone cellulardivision (divided cells).

CD73 was found to be expressed on a subset of CD4⁺ T cells. In thepresence of extracellular AMP, CD73⁺ T cells have the potential toenable paracrine/autocrine pathways which involves the metabolism of AMPto adenosine by CD73, followed by the activation of the adenosinereceptors and the subsequent regulation of T cell function. ThisCD73/adenosine pathway was modeled in vitro by using purified CD4⁺CD25⁻primary human T cells activated by TCR-signaling and rhIL-2. T-cellproliferation was suppressed in the presence of 100 or 200 µM ofextracellular AMP.

Phen0203 hIgG1, an anti-human CD73 antibody, was capable of inhibitingAMP-mediated suppression of CD4⁺CD25⁻ T cell proliferation in vitro, ina concentration dependent-manner. The data provide a scientificrationale for an anti-CD73 antibody approach targeting theimmunosuppressive effects of the AMP/CD73/adenosine pathway.

Example 15: MEDI9447 Epitope and Paratope Mapping

In order to identify the binding interface of MEDI9447 and CD73,hydrogen deuterium exchange MS (HDX-MS) analysis was performed withMEDI9447 Fab and recombinant soluble CD73 (sCD73) either alone or incomplex (FIGS. 19A, 19B, and 20A-20E). In recent years, hydrogendeuterium exchange MS (HDX-MS) has proven to be a powerful tool to mapsites of protein-protein interaction and characterize protein structureand conformational dynamics. By exploiting differential labeling ofprotein regions in a manner mediated by solvent accessibility, antibodyepitopes have been successfully mapped using HDX-MS. Comparing thekinetics of hydrogen exchange between free and complexed CD73 revealedtwo regions located within the N-terminal domain of sCD73 (amino acids(aa) 132-143 and 182-187) that exhibit decreased deuterium uptake whenbound to Fab (FIGS. 19A, 20A and 20B). Region 132-143 (HDX_E1) showed asignificant change in uptake only at the shortest exposure time points.At the longer exposure times there was no difference in exchange.Without being bound to a particular theory, this indicates that the siteis only partially protected from solvent. In contrast, the degree ofdifferential uptake of deuterium in region 182-187 (HDX_E2) increasedwith exposure time. Without being bound to a particular theory, this isconsistent with a high affinity protein-protein interaction that reducessolvent accessibility (FIG. 19A). Analysis of the Fab showed thatcomplementary determining region (CDR) 1 and 3 of the heavy chain, andCDR1 and CDR2 of the light chain displayed the greatest decrease inexchange when in complex with CD73, indicating that these regions arethe primary constituents of the paratope (FIGS. 20C and 20D). AlthoughCD73 aa 132-143 (HDX_E1) and 182-187 (HDX_E2) are discontinuous insequence space, they are adjacent when mapped onto the folded structureof CD73 (FIG. 19B). Differences in hydrogen exchange were observed atother regions within CD73. However, the majority of mass changes,including those of peptides containing known substrate-binding andactive site residues, were not statistically significant (FIGS. 19A and20E).

As HDX reports on context-dependent changes in polypeptide backbonesolvent exposure, validation is required to distinguish betweendifferences in hydrogen exchange due to backbone masking within theepitope-paratope interface versus conformational alterations indirectlyor allosterically induced by antibody binding. To determine whetherHDX_E1 and HDX_E2 constituted the MEDI9447 epitope, antibody binding todomain-swapped chimeric CD73 mutants was evaluated (FIGS. 21A-21H andTable 16).

TABLE 16 Binding of MEDI9447 to CD73 variants CD73 Construct KOSwap/Mutation Position KD (M) ka (1/Ms) kd (1/s) Wild Type human CD73 WThuCD73 4.20E-12 4.63E+06 1.94E-05 KO_Nterm+Cterm KO_1-291+311-523 NoBinding KO_Nterm KO_1-291 No Binding KO_Linker KO_292-310 4.14E-125.7E+06 2.31E-05 KO_Cterm KO_311-523 1.70E-12 4.75E+06 8.10E-06 HDX_E1KO_132-143 9.90E-12 2.15E+06 2.12E-05 HDX_E2 KO_182-187* 2.83E-095.73E+06 1.62E-02 HDX_E1+E2 KO_132-143+182-187* 4.43E-09 4.76E+062.11E-02 V144K V144K 8.14E-11 1.13E+06 9.18E-05 K180A K180A 4.35E-113.45E+06 1.54E-04 N185G N185G* 2.69E-11 9.11E+06 2.45E-04 V144K+K180AV144K+K180A 2.68E-09 1.58E+06 4.25E-03 V144K+N185G V144K+N185G NoBinding K180A+N185G K180A+N185G No Binding *Kinetics values derived from2:1 fit.

Domain swapping is a technique whereby a homolog of the target protein(i.e., human CD73) that does not bind the antibody of interest is usedto generate chimeras that reveal those residues composing the epitope.As opposed to introducing deletions, exchanging sequence betweenhomologs minimizes the likelihood of globally disrupting proteinstructure or preventing protein expression. Gallus gallus (chicken) CD73shares ~65% sequence identity with mature human CD73 (FIG. 22 ). Whenhuman CD73 N-terminal domain (KO_1-291) or both N- and C-terminaldomains (KO_1-291+311-523) were knocked out by replacement with thecorresponding chicken sequence, binding of the swapped chimeras toMEDI9447 was lost (FIGS. 21A-21H and Table 16). Knocking out only theC-terminal domain (aa 311-523) or the alpha helix linker region (aa292-310) did not affect binding compared to the wild-type (WT) protein(FIGS. 21A, 21D, 21E and Table 16). These results are consistent with anepitope location within the N-terminal domain of CD73. Next, each HDXinterface region was knocked out separately and in combination. Bindingof MEDI9447 to KO_HDX_E1 was comparable to WT CD73, though there was aminor decrease in the association rate k_(a) (FIG. 21F and Table 16). Incontrast, the binding affinity to KO_HDX_E2 was significantly weakerthan WT CD73, driven by faster dissociation (FIG. 21F and Table 16).Knocking out both regions (KO_HDX_E1+E2) resulted in only a smalldecrease in binding as compared to region E2 alone (FIG. 21G and Table16). These findings indicate that although region 182-187, and to alesser extent 132-143, contain residues important for antibody binding,additional residues outside the HDX-identified interface compose theepitope.

To fully define the MEDI9447 epitope, a panel of sequence swappedchimeras was generated replacing ~70 aa stretches of the N-terminaldomain of human CD73 with the corresponding chicken sequence (FIGS. 22,23A and 23B). Knocking out either region 2 (DS2) or 3 (DS3) alonedecreased binding and swapping both regions together (DS2_3) knocked outbinding (FIGS. 23A and 23B). Knocking out region 4 (DS4) or a portion ofregion 1 (DS1a) (swapping the full region prevented expression) did notaffect binding (FIGS. 23A and 23B). Binding analysis with chimerascontaining ~20-30 aa swapped regions revealed that sub-region DS2d (aa135-152) and DS3b (aa 171-188) contain residues that impact MEDI9447binding (FIGS. 23A and 23B). When a portion of sub-regions 2d (DS2dmod)was swapped with region 3b (DS2dmod_3b), binding was lost (FIGS. 23A and23B). Notably, these two sub-regions encompass the interface identifiedby the HDX study (FIG. 22 ). The observation that swapping both HDXregions together did not ablate binding indicates that the additionalresidues mediating binding are located within sub-regions 2d and 3b, butnot within the HDX-identified sites. To map these additional epitoperesidues, antibody binding to a panel of CD73 chimeras containing eithersingle point mutations, or a combination of point mutations and regionswap was evaluated. Alanine mutagenesis was also performed on residueswithin and spatially proximal to the HDX interface that are conservedbetween chicken and human CD73 (FIGS. 22, 23A and 23B). These analysesrevealed that V144, K180, and N185 are the primary epitope residues,with N185 being the most important (FIGS. 23A, 23B, and 24 ). Combininga N185G mutation with either K180A or V144K ablated binding whereasmutating K180 and V144 together resulted in a reduction in binding(FIGS. 23A and 23B). In addition to K180, it was found that three otherconserved residues, Y135, K136, and N187 effected binding, but to alesser extent (FIGS. 23A, 23B, and 24A). The impact of these latterthree residues was revealed by mutating them to alanine in the contextof a domain-swapped KO background; as exclusive point mutations they hadminimal or no impact on affinity (FIGS. 23A and 23B). To validate V144,K180, and N185 as important constituents of the epitope, chicken CD73was replaced with V144 and N185 (K180 is conserved). The presence ofthese three residues conferred binding by MEDI9947 at sub-nanomolaraffinity (K_(D) = 79 pM) (FIGS. 23A, 23B, and 24B). Without being boundto a particular theory, this indicates that binding of MEDI9447 to CD73is primarily mediated by these three amino acid positions. Notably,although HDX analysis identified the general location of the bindinginterface, two of the three important epitope residues were notcontained within peptides exhibiting change in hydrogen exchange (FIGS.20A and 20B).

Overlaying the identified epitope onto the structure of CD73 shows thatthe binding site is located at the apical, lateral surface of the openconformation of CD73 (FIGS. 24C-24E). N185 is positioned near theN-terminal domain apex in a loop region extending outward from helix G,which contains K180 (FIG. 24C). Located on β-strand 6, and adjacent toK180, are Y135 and K136. V144 is positioned within β-strand 7, in closecontact to N187 (FIG. 24C). Collectively, the side chains of theseresidues form a near contiguous binding surface (FIG. 24D). When viewedin the CD73 monomer open structure, it is evident that the epitope isboth on the opposing face and spatially distant from the substratebinding site (FIG. 24F). Additionally, the binding site does notencompass any active site residues, including those that coordinateinteraction with Zn²⁺ co-factor (FIG. 24F). Without being bound to aparticular theory, it was predicted that MEDI9447 does not compete forAMP binding but instead inhibits CD73 enzymatic activity through apotential allosteric mechanism, based on the position of the epitope.

Example 14: MEDI9447inhibited CD73 Enyzme Activity

To characterize the MEDI9447 mode of inhibition, first the kinetics ofsCD73 hydrolysis of AMP was examined in the presence of either MEDI9447or the non-hydrolyzable inhibitor of CD73, APCP. MEDI9447non-competitively inhibited sCD73, as was evidenced by decreased V_(max)(4.59±0.26 vs 1.21±0.03), regardless of substrate concentration (FIG.25A). In contrast, APCP increased the Michaelis constant K_(m)(75.85±3.36 vs 26.03±3.87), but did not decrease V_(max) (3.35±0.04 vs3.50±0.11), in agreement with previous findings that APCP is acompetitive inhibitor of CD73 (FIG. 25B). These results show thatMEDI9447 blocked the ability of sCD73 to hydrolyze AMP. Additionally,they indicate that MEDI9447 does not block binding of AMP substrate,which is consistent with the position of the epitope.

Next, inhibition of sCD73 was tested as a function of increasingconcentration of MEDI9447 in either an IgG or Fab format. MEDI9447 IgGinhibited sCD73 activity in a dose-response manner, with maximalinhibition achieved a molar ratio of ~1:1 between the IgG and sCD73dimer (FIG. 25C). However, when IgG was in stoichiometric excessrelative to sCD73, a loss of inhibition was observed (FIG. 25C). Thisso-called “hook effect” has been observed in other immunoassays and canresult from monovalent antibody binding driven by Fab arms on the sameIgG molecule competing for limiting binding sites on the target antigen.Consistent with this observation, the Fab format of MEDI9447 did notinhibit sCD73 activity (FIG. 25C). Together these results indicate thatbivalent interaction of MEDI9447 is required to inhibit sCD73 function.

Example 15: MEDI9447 Prevented the Conformational Transition of CD73 tothe Closed State

Previous structural studies of CD73 revealed that the enzymatic activityof CD73 requires transition between an “open” and “closed” conformation.In the open state, the enzyme is inactive, whereas in the closed statethe active site is formed, enabling substrate hydrolysis. Thedetermination of the crystal structure of human CD73 showed thattransition between open and closed conformers requires extensive bendingand rotation of the alpha-helix linker region to allow the N-terminaldomain to reposition against the C-terminal domain to form the activesite. It was hypothesized that engagement of each Fab arm of MEDI9447 ontwo CD73 N-terminal domains could form a bridge that restricts thetransition of CD73 from the inactive, open state, to the catalyticallyactive, closed state. In order to test whether MEDI9447 inhibits CD73conformational transition, an antibody, mAb A, was utilized which wasdeveloped as a reporter of CD73 conformation. Mapping the bindinginterface of mAb A showed that it interacts with both the N- andC-terminal domain of CD73 (FIGS. 26A-26C). Considering the location ofthe binding region, it was postulated that the epitope would be presentin the CD73 open conformer, but disrupted in the closed conformer (FIG.26B). To test this, binding of mAb A to open, substrate-free, sCD73 andclosed sCD73 were measured (FIGS. 27A-27C). To induce the closedconformation, sCD73 was pre-incubated with Zn²⁺ and APCP; this co-factorand non-hydrolyzable substrate were previously used to generate thecrystal structure of the closed conformer of human CD73. Bindinganalysis showed that mAb A binds to open sCD73, but binding is abolishedwhen CD73 is pre-incubated with Zn²⁺ and APCP (FIG. 27A). Without beingbound to a particular theory, this finding is consistent with the mAb Aepitope being present in only the open structure of CD73. In contrast,MEDI9447 binding was not sensitive to the state of CD73, indicating thatit can bind to either substrate-free or bound CD73 (FIG. 27A). The lossof binding by mAb A was dependent on both Zn²⁺ and APCP (FIG. 28A).Having established that mAb A binding reports on the conformationalstate of CD73, the effect of MEDI9447 on the Zn²⁺/APCP-inducedstructural transition of CD73 was next tested. mAb A bound to sCD73 thatwas pre-incubated with MEDI9447, indicating that the two antibodies bindto distinct epitopes (FIG. 27B). Importantly, when the sCD73-MEDI9447complex was subsequently incubated with Zn²⁺ and APCP, binding by mAb Awas maintained (FIG. 27B). In contrast, a control IgG and a Fab formatof MEDI9447 did not restore mAb A binding when pre-complexed with sCD73prior to Zn²⁺ and APCP addition (FIG. 28B). These results support thehypothesis that bivalent MEDI9447 binding prevents the transition ofsCD73 from the open state to the fully closed, hydrolytically activeconformation. The observation that mAb A binding is only partiallymaintained when MEDI9447 is bound indicates that Zn²⁺ and APCP mayinduce CD73 to adopt a catalytically inactive intermediate that bindswith lower affinity to the reporter antibody (FIG. 27C).

Example 16: sCD73 and MEDI9447 Formed Inter-Dimer Bridged Complexes

The observed inhibitory activity of MEDI9447 could occur throughN-terminal domain, inter-dimer bridging of a single CD73 molecule, orthrough intra-dimer bridging of separate CD73 molecules. To discriminatebetween these scenarios, the size of the complexes formed in solutionwas characterized. Based on the measured mass of unbound MEDI9447 andCD73 (145 and 125 kilodaltons (kD), respectively), the predicted size ofan inter-dimer bridged 1:1 complex of antibody to CD73 would be ~270 kD(FIG. 29A). When MEDI9447 and sCD73 were bound at a 1:1 molar ratio, twocomplexes were formed. The predominant species had a weight averagemolar mass (Mw) of ~1.74 megadaltons and the less abundant species had aMw of ~0.66 kD (FIG. 30A). The Mw of the largest complex is consistentwith an oligomer containing seven CD73 dimers and six IgGs (7 × 125 kD +6 × 150 kD = 1.745 megadaltons). When MEDI9447 is limiting (0.5:1,0.1:1), complexes of comparable Mw are formed, but the relativedifference in abundance of each species is less pronounced (FIG. 30A).The complexes with MEDI9447 were compared to those formed with adifferent anti-CD73 antibody, mAb B. Binding analysis of mAb B to apanel of domain swapped CD73 chimeras showed that it binds to a regionwithin the N-terminal domain of CD73 that, in contrast to MEDI9447, isproximal to the groove formed between the CD73 monomers (FIGS. 29B and19B). It was postulated that binding at this internally positionedsurface may preclude the Fab arms of mAb B from bridging across CD73dimers. Indeed, the SEC-MALS showed that mAb B forms complexes of~270-295 kD, a Mw close to that predicted for a 1:1 interaction (FIG.30C). Collectively, the findings indicate that the MEDI9447 formsinter-dimer bridges between multiple sCD73 dimers and that generation ofthese oligomers is conferred by the epitope.

Example 17: MEDI9447 Inhibited Anchored CD73 via Monovalent Interaction

Although CD73 is shed from the cell surface in vivo and retainsenzymatic activity in its soluble form, the majority of native CD73exists in a GPI anchored format. In light of this and the fact that thepreceding studies were performed with a soluble form of CD73, it wasnecessary to characterize MEDI9447 activity with CD73 in an immobilizedstate. Capturing recombinant CD73 via a C-terminal six histidine tag onnickel-coated microtiter plates allowed us to assay enzyme activity ofimmobilized CD73 that is spatially oriented in a manner resembling thatof GPI anchored CD73 on the cell surface. Similar to our previousresults, MEDI9447 IgG inhibited AMP hydrolysis in a dose-dependentmanner (FIG. 31A). However, when the antibody was in molar excessrelative to CD73 dimer, no loss of inhibition, or hook effect, wasobserved (FIGS. 31A and 32 ). Unexpectedly, MEDI9447 Fab also inhibitedCD73 activity but with a lower maximal inhibition compared to MEDI9447IgG (FIGS. 31A and 32 ). These results indicate that unlike solubleCD73, anchored CD73 can be inhibited via monovalent antibodyinteraction. The difference in inhibition between the IgG and Fabsuggested that the size of the antibody molecule may dictate potency. Toinvestigate this, MEDI9447 Fab was pre-incubated with an anti-Fdantibody (xFd) under conditions such that one Fab arm of the xFdantibody binds a MEDI9447 Fab and other arm binds a non-specific,polyclonal Fab (pFab) (FIG. 31B). Formation of this complex effectivelyincreased the size of MEDI9447 Fab while maintaining monovalency toCD73. This xFd-bound Fab inhibited CD73 activity to an equivalent degreeas MEDI9447 IgG (FIG. 31A). To validate this observation, antibodyinhibition of endogenously expressed CD73 was measured in the humanepithelial breast cancer cell line MBA-MD-231. Similar to immobilizedrecombinant CD73, GPI-anchored CD73 was inhibited robustly by MEDI9447IgG, modestly by MEDI9447 Fab, and pre-binding Fab to the xFd antibodyincreased maximal inhibition to a level equivalent to IgG (FIG. 31C).Lastly, inhibition of sCD73 by MEDI9447 Fab bound to either one or botharms of the xFd antibody was tested. Unlike surface bound CD73, sCD73was not inhibited by MEDI9447 Fab bound to a single xFd arm (FIG. 31D).However, conferring bivalency by binding MEDI9447 Fab to both xFd armsresulted in sCD73 inhibition comparable with MEDI9447 IgG (FIGS. 31B and31D). These findings show that surface anchored CD73 can be inhibited bymonovalent antibody binding and that potency is mediated by the size ofthe antibody. This is in direct contrast to sCD73, which is onlyinhibited by MEDI9447 through bivalent interaction.

Example 18: MEDI9447 Inhibits CD73 Conformational Change and AMPHydrolysis by a Dual, Non-Competitive Mechanism of Action

As described herein, the epitope and mechanism of action of atherapeutic monoclonal antibody that inhibits the enzymatic activity ofCD73 were determined. The results of this study revealed a binding sitewithin the CD73 N-terminal domain that enabled inhibition through twodistinct mechanisms. Importantly, this feature confers MEDI9447 theability to block both soluble and cell surface anchored CD73 in anon-competitive manner.

Using HDX-MS, the binding interface between CD73 and MEDI9447 Fab wasidentified. Due to the relatively large peptides derived from pepsindigestion, the interaction site identified by the exchange analysis wasrelatively broad, spanning a total of eighteen amino acids across twodiscontinuous peptides. Domain swapping and mutagenesis experimentsshowed that only a subset of these residues were influential in antibodybinding and two of the three most impactful amino acids (V144 and K180)were contained within peptides that did not exhibit differentialhydrogen exchange. One explanation for this discrepancy is that whilethe V144 and K180 side chains may be occluded due to contact withantibody CDR residues, the associated polypeptide backbone amidehydrogen atoms that undergo exchange with deuterium may be relativelyexposed to solvent. The HDX-MS results also showed that the regioncomposed of aa 132-143 only exhibited significant change in exchangekinetics at the shortest exposure time points. Without being bound to aparticular theory, this indicated that binding at this region isrelatively weak. Indeed, the two residues found to impact binding withinthis region (Y135 and K136) had only a minor effect on MEDI9947 affinity(FIGS. 23A and 23B). In contrast, the region with the most significantdifferential exchange, aa 182-187, contained the most important residuefor binding (N185). Absent a co-crystal structure, the possibilitycannot be formally excluded that some residues which were discounted asinteractors with MEDI9447 do indeed form contacts with the paratope.However, the extensive mutant binding analysis indicates that thesepotential residues would contribute minimally to the thermodynamics ofbinding. As heavy chain CDR3 is important in forming antigen contactsites, this CDR exhibited the greatest degree of differential exchange.The HDX results also indicated that the light chain is important toantigen binding, particularly CDR1 and 2 (FIGS. 20C and 20D).Collectively, these results highlight both the utility of HDX-MS inepitope mapping as well as the importance of validating the predictedbinding interface by an orthogonal technique such mutagenesis.

The location of the epitope at a position within the N-terminal domainthat is distant from CD73 substrate binding and active site residues isconsistent with results showing that MEDI9447 has a non-competitive modeof inhibition. Based on the footprint of the epitope alone, one mighthypothesize that the antibody acts as a classic allosteric inhibitor,inducing a long-range conformational change in CD73 that distorts activesite residues in a manner that prevents hydrolytic activity. However,HDX-MS data did not reveal significant alterations in CD73 structure inregions outside the binding interface that would support this form ofallostery. Alternatively, the epitope could suggest that MEDI9447binding restricts movement of loops, β-strands, or α helices within theN-terminal domain that is required for catalytic activity. Contrary tothis, little to no difference in secondary or tertiary structure withinthe N-terminal domain was reported between the open and closedstructures of CD73. The local, inter-domain conformational changes thatdo occur are restricted to the linker and C-terminal domain.

As an alternative to inducing a structural change, it was consideredthat the location of the epitope would be well-positioned to enableantibody bridging or cross-linking of CD73 dimers that would restrict anecessary change in conformation. This bridging concept is supported bydata showing that IgG was required to inhibit a soluble form of CD73 andthat MEDI9447 forms complexes containing multiple CD73 dimers. Thislatter result was in contrast to mAb B, which did not form inter-dimerbridges, highlighting the importance of the MEDI9447 epitope inconferring this cross-linking activity. Rationally, if two CD73N-terminal domains are bound by Fab domains of the same IgG, this couldphysically restrict the movement of the N-terminal domain and linkerregion that is required for the enzyme to adopt its closed, activestructure. Through the use of mAb A, which acts as a conformationalprobe of CD73 state, it was demonstrated that binding of MEDI9447inhibits CD73 from adopting the fully closed conformer, as induced byZn²⁺ and APCP. The intermediate level of binding by the reporter mAb Awhen MEDI9447 was pre-complexed with CD73 indicates that some degree ofconformational transition is still induced by Zn²⁺ and APCP. Thediminished mAb A binding may reflect that its epitope is partiallydistorted in this intermediate state, but still sufficient to yieldbinding. Given the high degree of flexibility of the hinge region, it isnot surprising that even when MEDI9447 is bridging CD73 dimers, therewould still be some CD73 structural alteration due to substrate binding.Without being bound to a particular theory, it is difficult to envisionthat the bound IgG would trap CD73 in a completely rigid conformation.

A surprising result of this work is that in addition to bridging viabivalent interaction, MEDI9447 can also inhibit CD73 when it is surfacebound through a monovalent binding mechanism. Although initiallyperplexing, a second, steric-mediated blocking mechanism of anchoredCD73 activity is consistent with the observations described herein. Theformation of catalytically active, GPI anchored CD73 requires that theN-terminal domain rotate downwards, to a position proximal to the cellsurface. The native CD73 dimer is ~130 kDa. Compared to size of an IgGor Fab (~150 kD and ~50 kD, respectively), it is reasonable thatantibody bound to the N-terminal domain could sterically block CD73 fromfully rotating to adopt the closed conformation. This mechanism issupported by two observations. Firstly, the fact that Fab exhibits lowermaximal inhibition compared to the IgG agrees with a size-dependentsteric effect. The disparity between Fab and IgG is unlikely to be dueto differences in binding as the Fab affinity is still sub-nanomolar(K_(D)= 327 pM, data not shown). Further, the elevated potency conferredby increasing the effective size of the Fab through conjugation with anxFd antibody also strongly supports a size, and not valency oravidity-dependent steric mechanism. The second observation that supportsthis mode of inhibition is that a hook effect, or loss of inhibition,was not observed by MEDI9447 IgG when CD73 was surface bound.Presumably, this is because the antibody can block anchored CD73hydrolysis of AMP through either bi- or monovalent interaction (FIG. 33). In contrast, a hook effect is observed when CD73 is soluble due tothe absence of a solid-phase required for monovalently bound IgG or Fabto sterically block N-terminal domain rotation.

Thus, a model is proposed whereby MEDI9447 antagonizes soluble andGPI-anchored CD73 function through a dual mechanism of inhibition thatis integrally linked to its epitope (FIG. 33 ). Although the studiesdescribed herein show that MEDI9447 can block both soluble and boundCD73, in vivo it is unknown whether GPI anchored CD73 would be inhibitedthrough one or both mechanisms. Presumably, the density, orientation,and inter-dimer distance of CD73 on the cell surface would dictate thedominant mode of inhibition. Given that most cancer cells overexpressCD73, which would increase the likelihood of the dimers being in closeproximity, it is expected that MEDI9447 would engage in both bi- andmonovalent interactions. On normal, non-tumor tissue, where CD73expression would be at relatively lower surface density, MEDI9447 mightinhibit AMP hydrolysis primarily through the steric blocking mode.

From a mechanistic perspective, blocking CD73 is an immuno-oncologystrategy distinct from that of comparable targets such as PD-1 andCTLA-4, for which there are already approved drugs. From a therapeuticstandpoint, the activity of MEDI9447 is advantageous. Itnon-competitively inhibits CD73 and, therefore, does not have to competewith endogenous nucleotide binding by blocking the active site. Thisavoids potential cross-reactivity towards other nucleotide/side bindingproteins with structurally conserved active sites. Further, MEDI9447 caninhibit both soluble and membrane-bound CD73 through either mono- orbivalent engagement. Both of these features would be expected tocontribute to in vivo efficacy. This therapeutic mAb hasimmune-modulating potential for the treatment of cancer both alone andin combination with existing chemotherapeutic agents that targetcomplementary immune modulating pathways.

The results described above were carried out using the followingmaterials and methods.

Assay 1: Direct ELISA

384-well ELISA plates were coated with about 1.5 ng/well recombinantCD73 protein, blocked with 1% BSA/0.1%Tween20/PBS and incubating withantibody samples for 90 minutes at room temperature. This was followedby incubation with goat-anti-Iglambda-horseradish peroxidase (HRP)conjugate for 30 min at room temperature. HRP activity was detected withtetra methyl benzidine (TMB) substrate and the reaction was stopped with1 M HCl. Plates were read at 450 nm.

Assay 2: Capture ELISA

384-well ELISA plates were coated with about 3 ng/well sheep-anti-humanFd antibody (for screening antibodies in Fab format), blocked with 1%BSA/0.1%Tween20/PBS and incubating with samples for 90 minutes at roomtemperature. Biotinylated CD73 protein was then added for 1 h at roomtemperature. This was followed by incubation withstreptavidin-horseradish peroxidase (HRP) conjugate for 30 min at roomtemperature. HRP activity was detected with tetra methyl benzidine (TMB)substrate and the reaction was stopped with 1 M HCl. Plates were read at450 nm.

About 50 ng/well biotinylated recombinant CD73 was used to screen cloneswith single amino acid mutations. For the screening of clones from thecombinatorial library, 10 ng/well biotinylated recombinant CD73 wereused.

Assay 3: Flow Cytometry Binding Assay

All flow cytometry expreriments were run at 4C and reagents wereprepared in PBS/1% FBS buffer. 10,000 cells were incubated with testantibody in 50 uL volume for 4 hours. Cells were washed twice andincubated in 50 uL goat anti-human IgGFc-AlexaFluor647 conjugate for 15minutes. Cells were washed, resuspended in buffer supplemented withDapi, and analyzed on a flow cytometer. Dead cells, identified by highDapi staining, were excluded from the analysis. For the determination ofKD values, a plot of the median fluorescence intensity as a function oftest antibody concentration was fitted nonlinearly using a one sitebinding isotherm model.

Assay 4: Generation of the Antibody Library With Single Amino AcidChanges

Site-directed mutagenesis of the CDR codons of CD730010 or CD730002 wasperformed using a QuikChange Lightning Multi Site-Directed MutagenesisKit (Agilent) and primers. Each codon was mutagenized with a primerwhich replaced the wild-type codon with codon NNS. Mutagenized VH and VLgenes were cloned into a Fab vector for bacterial expression. E.colistrain BL21(DE3) was transformed with the antibody library, individualcolonies were picked and cultured in Magic Media (Invitrogen) for 24hours at room temperature to produce bacterial Fab fragments. Bacterialsupernatant was prepared and used to screen the antibody library inELISA binding assays.

Assay 5: Generation of the Antibody Library With Combinatorial AminoAcid Changes

CD730010GL9 VH and VL genes were cloned into a vector for bacterial Fabexpression. Site-directed mutagenesis of the CDR codons of CD730010GL9was performed using either QuikChange Lightning Multi Site-DirectedMutagenesis Kit (Agilent) or overlapping PCR and degenerate primers. Thedegenerate primers were designed to encode selected amino acid changesas well as the parental amino acid at the same position. E.coli strainBL21(DE3) was transformed with the Fab library, individual colonies werecultured in Magic Media (Invitrogen) for 24 hours at room temperature toproduce bacterial Fab fragments. Bacterial supernatants were used toscreen the antibody library in ELISA binding assays.

Assay 6: FabZAP Assay

1,000 cells/well were cultured in 96 well plates in RPMI/10%FBS. Serialdilutions of anti-CD73 antibodies starting at 5 nM were mixed withFabZAP reagent (Advanced Targeting Systems, San Diego CA) and added tothe cells. After 3 days incubation at 37C, the cell proliferation wasmeasured using the CellTiter-Glo assay (Promega, Madison WI).

The following assays (Assays 7-11) were performed using the followingCD73 and antibody reagents.

A mammalian expression vector plasmid encoding recombinant mature humanCD73 (amino acid positions 1-526) was constructed (MedImmune). In orderto achieve expression of a soluble, secreted form of CD73, the GPIanchor signal peptide was removed and replaced with a C-terminal6x-histidine tag (SEQ ID NO: 164). CD73 sequence numbering is based onthe mature protein without the signal peptide (human NT5E, NCBIreference sequence NP_002517.1). Plasmids encoding the recombinanthuman/chicken chimeric domain swapped “knock-out” (KO) mutants weregenerated using synthetic DNA gBlocks (IDT, Inc.) encoding codonoptimized chicken CD73 DNA sequence (chicken NT5E, NCBI referencesequence XP_004940453.1). Based on alignment with human CD73 proteinsequence, amino acid coding position 1 of constructs containing achicken N-terminal domain corresponds to position 20 of immature chickenCD73 containing the predicted signal peptide. Full-length KO DNAconstructs were made by single overlap extension PCR of gBlocks and PCRamplicons of human CD73. All constructs contained a C-terminal 6xhistidine tag (SEQ ID NO: 164). Single and multiple point mutations inhuman and chimeric constructs were made by site-directed mutagenesisusing the Quick Change Lightning Multi Site-Directed Mutagenesis Kit(Stratagene). All CD73 constructs were expressed in suspension HEK293cells. Histidine-tagged wild-type human CD73 (lacking the GPI anchorsignal sequence) was purified using a HisTrap nickel affinity column (GEHealthcare Life Sciences) by the MedImmune Protein Sciences group. Theprotein was confirmed to be a dimer in solution, with a molar mass of~125 kDa (see FIGS. 18A and 18B). All mutant CD73 constructs wereexpressed by transiently transfecting suspension HEK293 cells using293Fectin (Life Technologies). Cells were grown and transfected inserum-free 293Freestyle media (Life Technologies) in 24-well deep-wellblocks. Crude cell supernatants were harvested six dayspost-transfection and filtered through a 0.45 µm filter to remove celldebris before use. Supernatant concentrations of CD73 variants weredetermined by measuring binding of the histidine tagged proteins to HIS2biosensors (FortéBio/Pall Life Sciences) on an Octet QK384 bio-layerinterferometry (BLI) instrument (FortéBio/Pall Life Sciences).Concentrations were calculated using the Octet data analysis software bycomparing binding signal to a standard curve generated from dilutions ofpurified, recombinant 6x-histidine tagged (SEQ ID NO: 164) human CD73 ofknown concentration. MEDI9447 (human IgG1 and mouse IgG1 formats), mAb A(human IgG1), and mAb B (human IgG1) and MEDI9447 Fab (human IgG1) wereexpressed and purified by the MedImmune Protein Sciences and Expressiongroups. IgGs were expressed in mammalian cells and purified by Protein Aand size-exclusion chromatography. To generate MEDI9447 Fab, 10 mg ofIgG were digested for 5 hr at 37° C. with immobilized papain (ThermoScientific/Life Technologies) and the Fab was purified using a HiTrap Qcolumn (GE Healthcare Life Sciences).

Assay 7: HDX-MS Analysis

Recombinant human CD73 and MEDI9447 Fab samples were prepared at aconcentration of 2 mg /mL. The CD73 + Fab complex was formed bypre-incubation at a concentration ratio of 1:1. The entire HDXexperiments were carried out using Waters HDX Technology (WatersCorporation) equipped with a Leap automation robot. Briefly, 1.25 µLprotein samples were diluted twenty times with either H₂O or D₂O buffer(10 mM phosphate, pH 7.0) at 20° C. After different incubation time (0second for undeuterated experiments or 0.5, 1, 5, 10, 30, 60, and 120minutes for deuterated experiments), the labeled samples were quenchedby adding an equal volume of an ice-cold solution of 4.0 M guanidine HCl(Pierce Biotechnology), 500 mM Tris(2-carboxyethyl)phosphinehydrochloride (TCEP) (Pierce Biotechnology), pH 2.4. Immediatelythereafter, samples were digested using a Poroszyme Immobilized Pepsincartridge (Applied Biosystems) at 20° C. The peptic fragments werecollected and desalted using a ACQUITY BEH C18 VanGuard Pre-column(2.1×5 mm, Waters), and eluted into an ACQUITY BEH C18 column (1.7 µm,1.0 × 100 mm, Waters) at 0° C. Peptides separated on the column wereanalyzed by a SYNAPT G2 mass spectrometer (Waters). For data analysis,peptides were identified using ProteinLynx Global Server software(Waters), and the deuterium incorporation levels for each peptic peptidefrom each labeling time were calculated using DynamX (Waters). For eachprotein, four undeuterated experiments and three complete HDXexperiments were performed. The significant difference values (±1.6daltons) were calculated using the experimental uncertainty and a 98%confidence interval as previously described, except that a pooledvariance of standard deviations was used instead of the mean ofindividual standard deviations . The relative fractional uptakes betweenthe CD73 + Fab complex and CD73 were generated by DynamX software(Waters) and exported to PyMOL (Shrödinger, Inc.) for structuralmodeling. All structure figures of human CD73 were generated using PyMoland the reported crystal structures of the open and closed conformationsof CD73 (PDB reference numbers 4H2F and 4H2I, respectively).

Assay 8: SPR and BLI Binding Analysis

Binding of MEDI9447 to wild-type and mutant CD73 proteins was measuredby surface plasmon resonance (SPR) using a ProteOn instrument (BioRad).CD73 crude cell supernatant protein samples were diluted to 3 µg/ml inPBS, 0.005% Tween-20, pH 7.4 (BioRad) and immobilized to ~400 RU on aHTG tris-NTA sensor chip (BioRad) pre-activated with 10 mM NiSO₄, 10 mMMES, pH 6.0 (BioRad). An equivalently diluted crude cell supernatantsample from non-transfected cells was included as a reference channelcontrol. Sensorgrams were recorded by flowing two-fold dilutions ofMEDI9447 prepared in PBS, 0.005% Tween-20, pH 7.4, ranging from 5 nM to0.31 nM. In some cases, for CD73 variants that bound weakly to MEDI9447,antibody dilutions ranged from 20 nM to 1.25 nM. Antibody binding wasmeasured at a flow rate of 100 µL/min with a 3 min association phase and20 min dissociation phase. The sensor chip surface was regeneratedbetween each run by an 800 s injection of 300 mM EDTA, pH 8.5 (BioRad)at a flow rate of 30 µL/min. Binding kinetics were analyzed using theProteOn data analysis software. Double referencing was performed and,unless noted otherwise, a 1:1 Langmuir binding model was utilized to fitthe data. Some CD73 variants containing mutations within the amino acidregion 171-188 fit poorly to a 1:1 model (i.e., Chi² values >10% ofRmax). Where noted, these variants were fit with a heterogenous antigen(2:1) model. Due to high affinity of MEDI9447 (~4 pM) and sensitivitylimitations of ProteOn, only changes of >2-fold in measured kineticswere considered meaningful when comparing MEDI9447 binding to the CD73variants. Due to the assay format (antigen immobilized) and the dimericstate of CD73, K_(D) values may be exaggerated due to avidity effects.However, it is not anticipated that this impacts ranking of MEDI9447binding to the different CD73 variants.

Mapping the hot spots of binding of anti-CD73 antibodies mAb A and mAb Bwas performed by BLI using an Octet QK384 instrument. All proteins wereprepared in 1x Kinetics Buffer (FortéBio/Pall Life Sciences).C-terminally histidine tagged CD73 variants from crude cell supernatantswere diluted to 6 µg/ml and immobilized on HIS2 biosensors to a bindingresponse threshold of 0.8 nm. After a 300 sec baseline step, sensorswere dipped into 30 nM antibody. Association and dissociation times were600 sec. A non-transfected cell supernatant reference control wasincluded for background binding subtraction during data analysis. Datawas processed and graphs prepared using the FortéBio Data Analysissoftware.

Assay 9: CD73 Enzyme Activity Assays

CD73-catalyzed hydrolysis of AMP to adenosine and inorganic phosphatewas analyzed by either quantifying inorganic phosphate (Malachite Greenassay; R&D Systems) or measuring the ATP-dependent oxidation ofluciferin which is inhibited by AMP (CellTiterGlo assay; Promega) . Datagraphs and enzyme kinetics measurements (Michaelis-Menten nonlinearregression) were generated using Prism software (Graphpad). Experimentswere performed in either duplicate or triplicate.

For measurements of soluble recombinant CD73 using the CellTiterGloassay, 400 pM recombinant CD73 and various concentrations of anti-CD73antibodies were incubated in assay buffer (25 mM Tris pH7.5, 5 mM MgCl₂,0.005% Tween-20) for 1 hour at 37° C. before adding an equal volume of200 µM AMP/600 µM ATP (in assay buffer). After 1 hour incubation at 37°C., the AMP concentration in the sample was determined using theCellTiterGlo assay following the manufacturer’s instructions.

For measurements of soluble recombinant CD73 using the Malachite Greenassay, 1 nM recombinant CD73 and either 1 nM antibody or 40 µM adenosine5′-(α,β-methylene)diphosphate (APCP; Sigma-Aldrich) were incubated inassay buffer (25 mM Tris pH 7.5, 5 mM MgCl₂, 0.005% Tween-20) for 1 hourat room temperature. An equal volume of 400 µM AMP (for anti-CD73antibodies) or 3 mM AMP (for APCP) in assay buffer was added and sampleswere incubated for 15 minutes at room temperature. The concentration ofinorganic phosphate was determined using the Malachite Green assayfollowing the manufacturer’s instructions.

For measurements of immobilized recombinant CD73, 50 µL CD73 at 100ng/mL in assay buffer (25 mM Tris pH 7.5, 5 mM MgCl₂, 0.005% Tween-20)supplemented with 100 µg/mL BSA was immobilized on nickel-coated plates(Life Technologies). Unbound CD73 was washed away and 50 µL of anti-CD73antibody (in assay buffer) was added. After incubating for 1 hour atroom temperature, plates were again washed, 100 µL of 500 µM AMP (inassay buffer) was added, and samples were incubated for 15 minutes atroom temperature. The concentration of inorganic phosphate wasdetermined using the Malachite Green assay following the manufacturer’sinstructions. In some experiments with both immobilized and solubleCD73, anti-CD73 antibody (IgG and Fab) was pre-incubated for at least 2hours with 10-fold molar excess polyclonal human Fab fragment (BethylLaboratories) and 100-fold molar excess sheep-anti-human IgG(Fd)(Meridian Life Sciences) before addition to CD73.

For measurements of endogenous CD73 activity in cultured cells, 20,000MDA-MB-231 cells per well were plated in RPMI/10% FBS (LifeTechnologies) in a 96-well plate. After an overnight incubation, wellswere washed 3 times with serum-free RPMI and 50 µL of antibodies (inserum-free RPMI) were added. After incubating for 30 minutes at 37° C.,25 µL of 1.2 mM AMP (in serum-free RPMI) were added per well. Plateswere incubated for 3 hours at 37° C. 25 µL of cell supernatant and 25 µLof 100 mM ATP were mixed and the AMP concentration in the sample wasdetermined using the CellTiterGlo assay following the manufacturer’sinstructions.

Assay 10: mAb A Reporter Assay of CD73 Conformational Transition

Binding of MEDI9447 and mAb A to purified recombinant human CD73 wasperformed on an Octet QK384 instrument. To compare binding of mAb A andMEDI9447, CD73 was diluted to 6 µg/mL in PBS, pH 7.4 (Life Technologies)plus 0.5% bovine serum albumin (PBSB; Sigma-Aldrich) and loaded ontoHIS2 biosensors to a binding signal threshold of 1.0 nm. The biosensorswere then transferred into either PBSB alone or PBSB with 10 µM ZnCl₂(Sigma-Aldrich), APCP, and/or 2 mM ethylenediaminetetraacetic acid(EDTA) (Life Technologies) and incubated for 15 min. Next, biosensorswere transferred to PBSB containing MEDI9447 or mAb A diluted to 30 nMin PBSB and antibody association was measured for 10 min.

To test the effect of MEDI9447 on CD73 conformational transition in thepresence of ZnCl₂ and APCP, mAb A diluted to 10 µg/mL in PBS, pH 7.4 wasimmobilized on an anti-human Fc AHC biosensor (FortéBio/Pall LifeSciences). Following the 400 s immobilization step, biosensors wereblocked for 10 min in non-specific polyclonal human IgG (JacksonImmunoResearch Laboratories) at 50 µg/mL in PBS, pH 7.4. After a 4 minbaseline step mAb A binding was measured by incubating the biosensorsfor 600 sec in wells containing CD73 diluted to 250 nM (based onmolecular weight of dimer) in PBS alone, or PBS containing 10 µM ZnCl₂and/or 0.5 mM APCP. For samples containing MEDI9447 bound to CD73, amouse IgG1 version of MEDI9447 (used in order to avoid binding to theanti-human Fc biosensor) diluted to 250 nM in PBS was pre-incubated withthe CD73 for 15 min at room temperature before incubation with ZnCl₂ andAPCP. MEDI9447 Fab and a mouse isotype-matched control IgG1 (generatedat MedImmune) were tested at 500 nM. Shake speed for all assay steps was1000 rpm. Binding analysis and data graphs were generated using theFortéBio Data Analysis software.

Assay 11: SEC-MALS Analysis

For experiments analyzing complexes formed with CD73 and MEDI9447 or mAbB, 900 pmoles of CD73 were incubated with 900, 450, 90, or 0 pmoles ofantibody, diluted into PBS, pH 7.4. A separate sample of 900 pmoles ofantibody only was also prepared. Samples were incubated for 30 min atroom temperature and then 100 µL of each sample was separated on a HP1100 HPLC (Agilent) using a TSKgel G3000W×L 5 µm, 7.88 mm × 30 cm column(Tosoh Bioscience, LLC) at a flow rate of 1 mL/min for 20 min. Samplerunning buffer was 0.1 M NaPi, 0.1 M NaSO₄, pH 6.8. Following HPLCseparation, all samples were analyzed using a Dawn Heleos II MALSdetector and Optilab T-rEx refractive index detector (Wyatt). Data wereanalyzed using Astra software (Wyatt).

The preceding description of the specific aspects will so fully revealthe general nature of the invention that others can, by applyingknowledge within the skill of the art, readily modify and/or adapt forvarious applications such specific aspects, without undueexperimentation, without departing from the general concept of thepresent invention. Therefore, such adaptations and modifications areintended to be within the meaning and range of equivalents of thedisclosed aspects, based on the teaching and guidance presented herein.It is to be understood that the phraseology or terminology herein is forthe purpose of description and not of limitation, such that theterminology or phraseology of the present specification is to beinterpreted by the skilled artisan in light of the teachings andguidance.

SEQUENCE LISTING

>SEQ ID NO: 1 CD730002 VL

QSVLTQPPSVSVSPGQTATITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKRPSRIPERFSGSNSGNTATLTISGTQALDEADYFCQAWDTSFWVFGGG TKLTVL

>SEQ ID NO:2 CD730002 VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:3 CD730010 VL

LPVLTQPPSVSGTPGQRVTISCSGSLSNIGRNPVNWYKQVPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWL FGGGTKLTVL

>SEQ ID NO:4 CD730010 VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDYWGRGTLVTVSS

>SEQ ID NO:5 CD730011 VL

NFMLTQPHSVSESPGKTVTISCTRSSGSIASKYVQWYQQRPGSSPMAVIYKDNQRSSGVPDRFSGSIDSSSNSASLTISGLKPEDEADYYCQSYDASNYY VFGTGTKVTVL

>SEQ ID NO:6 CD730011 VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRG HGLYFDLWGQGTTVTVSS

>SEQ ID NO:7 CD730021 VL

QSVLTQPPSASGTPGQRVTISCSGSRPNIGGNTVNWYQQLPGAAPKLLIYSNSQRPSGVPDRFSGSKYGTSASLAISGLQSDDEADYYCGTWDDSLNGPV FGRGTKLTVL

>SEQ ID NO:8 CD730021 VH

QVQLQESGPGLVRPSETLSLTCTVSGGSISSSSYYWAWVRQSPGKGLEWIGNIYYRGSTYYNPSLKSRVTMSVDMSKHQFSLKLSSLNAADTAVYYCASL YSGTYVFDYWGRGTLVTVSS

>SEQ ID NO:9 CD730042 VL

QSVLTQPASVSGSPGQSITISCAGTSSDVGGYNYVSWYQQHPGKAPKLMIYEGSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTR-STR VFGGGTKLTVL

>SEQ ID NO:10 CD730042 VH

GVQLVQSGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSIKYYADSVKGRFTISRDDSKNALYLQMNSLRAEDTAVYYCSTLS GSYGYFDYWGRGTLVTVSS

>SEQ ID NO:11 CD730046 VL

QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVSWYQHLPGTAPQLLIYTNNHRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLSGYV FGTGTKVTVL

>SEQ ID NO:12 CD730046 VH

QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSIKYYADSVKGRFTISRDNSKNSLFLQMNSLRDDDTATYYCARGHLLRIGDIFYYSLDVWGQGTLVTVSS

>SEQ ID NO: 13 CD730047 VL

QSVLTQPPSASGAPGQRVTISCSGSSSNIGSNTVNWYQRLPGAAPQLLIYNNDQRPSGIPDRFSGSKSGTSGSLVISGLQSEDEADYYCAAWDDSLSGNV FGTGTKVTVL

>SEQ ID NO:14 CD730047 VH

EVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSIKYYADSVKGRFAISRDNAKNTLYLQMNSLRREDTAMYYCASGL TGVAGALGVWGRGTLVTVSS

>SEQ ID NO:15 CD730058 VL

QSVLTQPPSVSVSPGQTATITCSGDRLRNEFVSWYQQRPGQSPVVVIYQDIYRPSGIPDRFSGSKSGNTATLTISGPQTVDEADYYCQAWDSNTVVFGGG TKLTVL

>SEQ ID NO:16 CD730058 VH

QLQLQESGSGLVKPSQTLSLICAVSGGSITSGGNAWNWIRQSPGAGLEWIGYIFSNGATYYNPSLESRVTISADTSKNQFSLTLTSVTAADTAVYYCARGDFWTGKGVFDPWGQGTLVTVSS

>SEQ ID NO:17 10.3AA_HC

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGYGRVDEWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

>SEQ ID NO:18 10.3Nt_HC

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCTATAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGAACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGATTAGGGTATGGGCGGGTGGACGAGTGGGGCAGGGGAACCCTGGTCACCGTCTCGAGTGCGTCGACCAAGGGCCCATCCGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCcTGGAACTCAGGCGCtCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATgcCCacCGTGCCCAGCACCTGAATTCGAGGGGGGAcCGTCAGTCTTCCTCTTCCCCCCAAAACCCaaGgACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTcTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA

>SEQ ID NO:19 10.3AA_LC

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWTFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVT HEGSTVEKTVAPTECS

>SEQ ID NO:20 10.3Nt-LC

CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGAAGCCTCTCCAACATCGGAAGGAATCCTGTTAACTGGTATCAGCAGCTCCCAGGGACGGCCCCCAAACTCCTCATCTATCTTGATAATCTACGGCTAAGTGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGAACCTCAGCCTCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGTGCAACATGGGATGACAGCCACCCCGGGTGGACGTTCGGCGGAGGGACCAAGCTGACCGTCCTAGGTCAGCCCAAGGCGGCGCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCA

>SEQ ID NO:21 10.3AA_VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:22 10.3Nt_VH

GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCAGCTATGCCTATAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGGTAGTGGTGGTAGAACATACTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTGTATTACTGTGCGAGATTAGGGTATGGGCGGGTGGACGAGTGGGGCAGGGGAACCCTGGTCACCGTCTCGAG T

>SEQ ID NO:23 10.3AA_VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:24 10.3Nt-VL

CAGTCTGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGAAGCCTCTCCAACATCGGAAGGAATCCTGTTAACTGGTATCAGCAGCTCCCAGGGACGGCCCCCAAACTCCTCATCTATCTTGATAATCTACGGCTAAGTGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGAACCTCAGCCTCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGTGCAACATGGGATGACAGCCACCCCGGGTGGACGTTCGGCGGAGGGACCAAGCTGACCGTCCTA

>SEQ ID NO:25 CD7300010 parent FW1-VL

LPVLTQPPSVSGTPGQRVTISC

>SEQ ID NO:26 CD7300010 GL FW1-VL

QSVLTQPPSASGTPGQRVTISC1

>SEQ ID NO:27 CD7300010 parent FW2-VL

WYKQVPGTAPKLLIY

>SEQ ID NO:28 CD7300010 GL FW2-VL

WYQQLPGTAPKLLIY

>SEQ ID NO:29 CD7300010 parent/GL FW3-VL

GVPDRFSGSKSGTSASLAISGLQSEDEADYYC

>SEQ ID NO:30 CD7300010 parent/GL FW4-VL (also CD370002 and 2C5)

FGGGTKLTVL

>SEQ ID NO:31 CD7300010 parent/GL FW1-VH (also CD370002 and 2C5)

EVQLLESGGGLVQPGGSLRLSCAASGFTFS

>SEQ ID NO:32 CD7300010 parent/GL FW2-VH (also CD370002 and 2C5)

WVRQAPGKGLEWVS

>SEQ ID NO:33 CD7300010 parent/GL FW3-VH (also CD370002 and 2C5)

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR

>SEQ ID NO:34 CD7300010 parent/GL FW4-VH

WGRGTLVTVSS

>SEQ ID NO:35 CD7300010 CDR1-VH (also CD370002 and 2C5)

SYAMS

>SEQ ID NO:36 CD7300010 CDR1-VH

SYAYS

>SEQ ID NO:37 CDR2-VH (also CD370002)

AISGSGGSTYYADSVKG

>SEQ ID NO:38 CDR2-VH

LIWGSWGSTYYADSVKG

>SEQ ID NO:39 CDR2-VH

AISGSGGRTYYADSVKG

>SEQ ID NO:40 CDR2-VH

AISGSWGRTYYADSVKG

>SEQ ID NO:41 CDR3-VH

LGYSTIDY

>SEQ ID NO:42 CDR3-VH

LGYSTIDK

>SEQ ID NO:43 CDR3-VH

LGYSTIDM

>SEQ ID NO:44 CDR3-VH

LGYSTIDL

>SEQ ID NO:45 CDR3-VH

LGYGRVDE

>SEQ ID NO:46 CDR1-VL

SGSLSNIGRNPVN

>SEQ ID NO:47 CDR1-VL

SGSLSNIGRNEVN

>SEQ ID NO:48 CDR1-VL

SGSLSNIGRNDVN

>SEQ ID NO:49 CDR2-VL

LNNQRPS

>SEQ ID NO:50 CDR2-VL

LDNLRLG

>SEQ ID NO:51 CDR2-VL

DNLRLS

>SEQ ID NO:52 CDR2-VL

LNNQRLG

>SEQ ID NO:53 CDR3-VL

ATWDDSLNGWL

>SEQ ID NO:54 CDR3-VL

ATWDDSLKGWL

>SEQ ID NO:55 CDR3-VL

ATWDDSLIGWL

>SEQ ID NO:56 CDR3-VL

ATWDDSHPGWT

>SEQ ID NO:57 CD730010-VL

LPVLTQPPSVSGTPGQRVTISCSGSLSNIGRNPVNWYKQVPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWL FGGGTKLTVL

>SEQ ID NO:58 CD730010GL9-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWL FGGGTKLTVL

>SEQ ID NO:59 P32E-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNEVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWL FGGGTKLTVL

>SEQ ID NO:60 C1-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNEVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLKGWL FGGGTKLTVL

>SEQ ID NO:61 C2-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLGGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLKGWL FGGGTKLTVL

>SEQ ID NO:62 D3-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLIGWL FGGGTKLTVL

>SEQ ID NO:63 G10-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNDVNWYQQLPGTAPKLLIYLNNQRLGGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLKGWL FGGGTKLTVL

>SEQ ID NO:64 HPT-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:65 GRVE-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGWL FGGGTKLTVL

>SEQ ID NO:66 73combo1 (C1+GRVE+HPT)-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNEVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:67 73combo2 (C2+GRVE+HPT)-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLGGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:68 73combo3(D3+GRVE+HPT)-VL [10.3]

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLDNLRLSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:69 73combo5 (G10+GRVE+HPT)-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNDVNWYQQLPGTAPKLLIYLNNQRLGGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:70 73combo6(GRVE+HPT)-VL

QSVLTQPPSASGTPGQRVTISCSGSLSNIGRNPVNWYQQLPGTAPKLLIYLNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSHPGWT FGGGTKLTVL

>SEQ ID NO:71 CD730010-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDYWGRGTLVTVSS

>SEQ ID NO:72 CD730010GL9-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDYWGRGTLVTVSS

>SEQ ID NO:73 P32E-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDYWGRGTLVTVSS

>SEQ ID NO:74 C1-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDKWGRGTLVTVSS

>SEQ ID NO:75 C2-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSLIWGSWGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDMWGRGTLVTVSS

>SEQ ID NO:76 D3-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDLWGRGTLVTVSS

>SEQ ID NO:77 G10-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSWGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDLWGRGTLVTVSS

>SEQ ID NO:78 HPT-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YSTIDYWGRGTLVTVSS

>SEQ ID NO:79 GRVE-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:80 73combo1 (C1+GRVE+HPT)-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:81 73combo2 (C2+GRVE+HPT)-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSLIWGSWGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:82 73combo3(D3+GRVE+HPT)-VH [10.3]

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSGGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:83 73combo5 (G10+GRVE+HPT)-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAYSWVRQAPGKGLEWVSAISGSWGRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:84 73combo6(GRVE+HPT)-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLG YGRVDEWGRGTLVTVSS

>SEQ ID NO:85 CD730002VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:86 CD730002VL

QSVLTQPPSVSVSPGQTATITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKRPSRIPERFSGSNSGNTATLTISGTQALDEADYFCQAWDTSFWVFGGG TKLTVL

>SEQ ID NO:87 2C5VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKRRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:88 2C5VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKRLSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGG TKLTVL

>SEQ ID NO:89 CD730002 parent/2C5 FW4-VH

WGQGTMVTVSS

>SEQ ID NO:90 CD730002 parent FW1-VL

QSVLTQPPSVSVSPGQTATITC

>SEQ ID NO:91 CD7300002 2C5 FW1-VL

QSVLTQPPSVSVSPGQTASITC

>SEQ ID NO:92 CD730002 parent/2C5 FW2-VL

WYQQKPGQSPVLVIY

>SEQ ID NO:93 CD730002 parent FW3-VL

RIPERFSGSNSGNTATLTISGTQALDEADYFC

>SEQ ID NO:94 CD730002/2C5 FW3-VL

GIPERFSGSNSGNTATLTISGTQAMDEADYYC

>SEQ ID NO:95 CD730002/2C5 CDR2-VH

AISGSGGSTYYADSVKR

>SEQ ID NO:96 CD730002 parent/2C5 CDR3-VH

DKGYYWYMDV

>SEQ ID NO:97 CD730002 parent/2C5 CDR1-VL

SGDKVGDKYAS

>SEQ ID NO:98 CD730002 parent CDR2-VL

EDTKRPS

>SEQ ID NO:99 CD730002 2C5 CDR2-VL

EDTKRLS

>SEQ ID NO:100 CD730002 parent/2C5 CDR3-VL

QAWDTSFWV

>SEQ ID NO:101 Phen0203-VH

EVQLVQSGGGVVQPGRSLRLSCAASGFRFSDFAMHWVRQAPGKGLEWVAGISYDGGNKYYADSVKGRFTISRDNSNNTLYLQMNSLRAEDTAVYYCAKDHGYSGYYGHLDYWGRGTLVTVSS

>SEQ ID NO:102 Phen0203-VL

QSVVTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGRV FGTGTKLTVL

>SEQ ID NO:103 CD730004-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRPNYYGASGSYYKQGGDHWGQGTMVTVSS

>SEQ ID NO:104 CD730004-VL

NFMLTQPHSVSESPGQTVTISCTRSSGSIASKYVQWYQKRPGSSPTTVIYEDTQRPSGVPDRFSGSIDISSNSASLTISGLRTEDEADYYCQSYDSTNWV FGGGTKVTVL

>SEQ ID NO:105 CD730008-VH

EVQLLETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGN YGNLDHWGKGTLVTVSS

>SEQ ID NO:106 CD730008-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYQDRKRPSGIPERFSGSNSGNTATLTISGTQPMDEADYYCQAWDSSHWVFGGG TKLTVL

>SEQ ID NO:107 CD730068-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYIMGWVRQAPGKGLEWVSSISSSGGATIYADSVKGRFTISRDNSKNTLYLQMNSLRAEDMAVYYCAKDH LGGHGMDVWGQGTTVTVSS

>SEQ ID NO:108 CD730068-VL

DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIFAASSLESGVPSKFSGSGSGTDFTLTISSLQPEDSATYYCQQYNSYPLTFGG GTKVEIK

>SEQ ID NO:109 CD730069-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSEYQMGWVRQAPGKGLEWVSYIRSSGGQTIYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRT YSSGWHIDYWGQGTLVTVSS

>SEQ ID NO:110 CD730069-VL

DIQMTQSPDSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFSLTISSLQLEDFATYYCQQSYRTPLTFGG GTKVEIQ

>SEQ ID NO:111 Clone 2 SGMY-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:112 Clone 2 SGMY-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGG TKLTVL

>SEQ ID NO:113 CDRH1 Y32V-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSVAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:114 CDRH1 M34R-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYARSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:115 CDRH2 T57P-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSPYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:116 CDRH2 A60G -VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:117 CDRH2 G65R-VH

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKRRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDK GYYWYMDVWGQGTMVTVSS

>SEQ ID NO:118 CDRL2 T52S-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYEDSKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGG TKLTVLL

>SEQ ID NO:119 CDRL2 R54Y-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKYPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGG TKLTVLVL

>SEQ ID NO:120 CDRL2 P55H-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSVLVIYEDTKRHSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGGT KLTVLVL

>SEQ ID NO:121 CDRL2 P55L-VL

QSVLTQPPSVSVSPGQTASITCSGDKVGDKYASWYQQKPGQSPVLVIYEDTKRLSGIPERFSGSNRGNTATLTISGTQAMDEADYYCQAWDTSFWVFGGG TKLTVLVL

>SEQ ID NO:122 2SGMY FW3-VL

GIPERFSGSNRGNTATLTISGTQAMDEADYYC

>SEQ ID NO:123 CDRH1 Y32V CDR1-VH

SVAMS

>SEQ ID NO:124 CDRH1 M34R CDR1-VH

SYARS

>SEQ ID NO:125 CDRH2 T57P CDR2-VH

AISGSGGSPYYADSVKG

>SEQ ID NO:126 CDRH2 A60G CDR2-VH

AISGSGGSTYYGDSVKG

>SEQ ID NO:127 CDRL2 T52S CDR2-VL

EDSKRPS

>SEQ ID NO:128 CDRL2 R54H CDR2-VL

EDTKYPS

>SEQ ID NO:129 CDRL2 P55H CDR2-VL

EDTKRLS

>SEQ ID NO:130 Tremelimumab VL from U.S. 6,682,736

PSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV

>SEQ ID NO:131 Tremelimumab VH from U.S. 6,682,736

GVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFP EPVTVSWNSGALTSGVH

>SEQ ID NO:132 Tremelimumab VH CDR1 from U.S. 6,682,736

GFTFSSYGMH

>SEQ ID NO:133 Tremelimumab VH CDR2 from U.S. 6,682,736

VIWYDGSNKYYADSV

>SEQ ID NO:134 Tremelimumab VH CDR3 from U.S. 6,682,736

DPRGATLYYYYYGMDV

>SEQ ID NO:135 Tremelimumab VL CDR1 from U.S. 6,682,736

RASQSINSYLD

>SEQ ID NO:136 Tremelimumab VL CDR2 from U.S. 6,682,736

AASSLQS

>SEQ ID NO:137 Tremelimumab VL CDR3 from U.S. 6,682,736

QQYYSTPFT

>SEQ ID NO:138 US 20130034559_77 Sequence 77 from US 20130034559Organism: Homo sapiens

EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFG QGTKVEIK

>SEQ ID NO:139 US 20130034559_72 Sequence 72 from US 20130034559Organism: Homo sapiens

EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREG GWFGELAFDYWGQGTLVTVSS

>SEQ ID NO:140 - VH CDR1 US 20130034559_73 Sequence 73 from US20130034559 Organism: Homo sapiens

RYWMS

>SEQ ID NO:141 - VH CDR2 US 20130034559_74 Sequence 74 from US20130034559 Organism: Homo sapiens

NIKQDGSEKYYVDSVKG

>SEQ ID NO:142 - VH CDR3 US 20130034559_75 Sequence 75 from US20130034559 Organism: Homo sapiens

EGGWFGELAFDY

>SEQ ID NO:143 - VL CDR1 US 20130034559_78 Sequence 78 from US20130034559 Organism: Homo sapiens

RASQRVSSSYLA

>SEQ ID NO:144 - VL CDR2 US 20130034559_79 Sequence 79 from US20130034559 Organism: Homo sapiens

DASSRAT

>SEQ ID NO:145 - VL CDR3 US 20130034559_80 Sequence 80 from US20130034559 Organism: Homo sapiens

QQYGSLPWT

What is claimed is: 1-46. (canceled)
 47. An isolated binding moleculewhich specifically binds to CD73 selected from: (a) an antibody V_(H)CDR1 of SEQ ID NO: 35, V_(H) CDR2 of SEQ ID NO: 95, V_(H) CDR3 of SEQ IDNO: 96, and V_(L) CDR1 of SEQ ID NO: 97, V_(L) CDR2 of SEQ ID NO: 99,V_(L) CDR3 of SEQ ID NO: 100; (b) an antibody V_(H) comprising SEQ IDNO: 87 and V_(L) comprising SEQ ID NO: 88; (c) an antibody V_(H) CDR1 ofSEQ ID NO: 35, V_(H) CDR2 of SEQ ID NO: 95, V_(H) CDR3 of SEQ ID NO: 96,and V_(L) CDR1 of SEQ ID NO: 97, V_(L) CDR2 of SEQ ID NO: 99, V_(L) CDR3of SEQ ID NO: 100, wherein the variable heavy domain comprises asequence 95%, 96%, 97%, 98%, or 99% similar to the VH of SEQ ID NO: 87,and wherein the variable light domain comprises a sequence 95%, 96%,97%, 98%, or 99% similar to the VL of SEQ ID NO: 88; or (d) an antibodyV_(H) comprising a sequence 95%, 96%, 97%, 98%, or 99% similar to theV_(H) of SEQ ID NO: 87, and the V_(L) comprising a sequence 95%, 96%,97%, 98%, or 99% similar to the V_(L) of SEQ ID NO: 88.